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Abstract 
PANcreatic DERived factor (PANDER, FAM3B) is a member of a 
superfamily of FAM3 proteins that are uniquely structured and 
strongly expressed from the endocrine pancreas and co-secreted 
with insulin. Unique animal models available to our lab have 
indicated that PANDER can induce a selective hepatic insulin 
resistant (SHIR) phenotype whereby insulin signaling is blunted 
yet lipogenesis is increased. The complexity of the biological 
networks involved with this process warranted the logical 
approach of employing quantitative mass spectrometry based 
proteomic analysis using stable isotope labeling of amino acids 
in cell culture (SILAC) to identify the global proteome 
differences between the PANDER transgenic (TG) overexpressing 
murine model to matched wild-type mice under three metabolic 
states (fasted, fed and insulin stimulated). Additionally, this 
technique was used to compare the hepatic proteome of mice on a 
high fat diet to elucidate early and late mechanisms of disease 
progression. The “spike-in” process was employed by equal 
addition of lysate obtained from livers of heavy L-Lysine (13C6, 
97%) fed mice to the mice liver protein lysate (PANTG and WT) 
for relative quantitative analysis. Upon acquisition of the 
x 
 
dataset by use of liquid chromatography tandem mass spectrometry 
(LC-MS/MS, LTQ Orbitrap), geometric means and Uniprot Protein 
identification numbers were uploaded to Ingenuity Pathway 
Analysis (IPA) to reveal the effect of PANDER on hepatic 
signaling. IPA identified lipid metabolism and fatty acid 
synthesis as top cellular functions differentially altered in 
all metabolic states. Several molecules with a role in lipid 
metabolism were identified and include FASN, ApoA1, ApoA4, SCD1, 
CD36, CYP7A1 and ACC. Furthermore, central to the differentially 
expressed proteins was the revealed activation of the liver X 
receptor (LXR) pathway. In summary, our SILAC proteomic approach 
has elucidated numerous previously unidentified PANDER induced 
molecules and pathways resulting in increased hepatic 
lipogenesis. In addition, we have demonstrated strong utility of 
this approach in comprehensively phenotyping animal models of 
hepatic insulin resistance. PANDER may potentially propagate 
pro-hepatic lipogenic effects by LXR activation in contrast to 
increased LXRα expression. This can be evaluated through the use 
of LXR agonists (T0901317) antagonists (GSK 2033). LXR activity 
can be measured by luciferase assays using an LXRE response 
plasmid. Our central hypothesis is that PANDER induces 
activation of LXR and is measured and predicted in our line of 
experiments. In general, PANDER induced LXR activation will be 
xi 
 
enhanced by T0901317 and diminish effects of GSK 2033 along with 
direct correlation of downstream metabolic effects such as 
increased hepatic lipogenesis and fatty acid metabolism. Taken 
together, PANDER strongly impacts hepatic lipid metabolism and 
may induce a SHIR phenotype via the LXR pathway. Additionally, 
phosphoproteomic analysis uncovered large-scale differences in 
protein phosphorylation states as PANDER impacts insulin 
signaling. A notable finding was the increased phosphorylation 
of glycogen synthase (GSK), possibly responsible for the 
decreased hepatic glycogen content in the PANTG mouse. In an 
effort to map out critical molecules involved in non-alcoholic 
fatty liver disease (NAFLD) pathogenesis, the same proteomic 
approach was carried out, providing a unique dataset of 
differentially expressed hepatic proteins due to a high at diet.
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Chapter 1 – Introduction 
Discovery and Characterization of Pancreatic Derived Factor 
PANcreatic-DERived Factor (PANDER) is a well characterized 
secreted hormone that was discovered through the use of the 
algorithm Ostensible Recognition of Folds (ORF) which predicted 
novel cytokine-like proteins based on secondary structure 
homology of several cytokines such as IL-2 - 7, -9, -10, and -
13. The secondary structure of many cytokines can be described 
as a four-helix bundle with up-up-down-down topology [2]. 
Therefore, ORF identified a novel family of proteins predicted 
to possess the secondary structure typical to many cytokines: 
FAMily with sequence similarity 3 (FAM3). The family of proteins 
consists of four constituents: FAM3A, FAM3B, FAM3C, and FAM3D. 
Northern blot analysis revealed mRNA expression to exist mainly 
in the pancreas of human and mouse (Figure 1) [1]. Further 
immunohistological staining revealed localization of PANDER in 
the Islet of Langerhans in both α and β-cells, specifically co-
localizing with insulin in secretory vesicles (Figure 2); FAM3B 
was later coined PANDER due to these features [1, 3, 4].  
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Figure 1: North analysis of PANDER mRNA in human tissues. PANDER 
indicated a high level of mRNA in pancreas, and to a lesser 
extent in small intestine and prostate. Figure from Zhu et al. 
[1]. 
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Figure 2: Immunogold electron microscopy localization of PANDER 
in secretory granules. Mouse islets were stained with rabbit 
anti-PANDER and mouse anti-insulin antibodies, followed by gold-
conjugated secondary antibodies, prior to electron microscopy. 
PANDER was labeled with 18 nm gold particles, insulin with 6 nm 
gold particles. The bar is 100 nm. Figure from Xu et al. [4].  
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The Pander Gene  
In humans, PANDER is located on the chromosome 21q22 [1]. The 
murine gene is located on chromosome 16B-C4 and consists of 
eight exons spanning approximately 32 kilo-base pairs [3]. In 
mice, the pancreatic transcriptional start site (TSS) is located 
520 base pairs upstream of the translational start codon in β-
cells. The murine promoter, between -335 and +523 relative to 
the pancreatic TSS, contain binding sites for A and E box 
elements, hepatic nuclear factors (HNF) 1 and 4α, and signal 
transducer and activation of transcription (STAT) 3, 5, and 6 
(Figure 3) [3]. More recently, an additional TSS has been 
identified as determined from examination of PANDER expression 
within primary hepatocytes.  The hepatic PANDER TSS was located 
26 base pairs upstream of the PANDER translational start site 
[5]. Under high glucose conditions, carbohydrate response 
element binding protein (ChREBP) has been shown to bind to the 
PANDER promoter and promote PANDER gene expression [5]. In the 
pancreas, the A box elements have been shown to confer tissue 
specific expression of PANDER in the pancreas by allowing for 
the interaction of the transcriptional factor 
Pancreatic/Duodenal Homeobox domain-1 (PDX-1) with the PANDER 
promoter [6]. Overall, the PANDER gene demonstrates strong 
expression by both the pancreatic islets and liver and is 
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heavily determined by regulatory elements within the promoter 
region many of which serve functions in metabolic regulation. 
 
Figure 3: DNA sequence from -829 to +29. The identified 
transcriptional start site is bolded and denoted by +1 hepatic. 
The previously identified pancreatic start site is denoted by +1 
pancreatic. Putative transcription factor binding sites as 
predicted by MatInspector 7.0 (Genomatix) are shown and 
underlined. These sites include A and E box elements, hepatocyte 
nuclear factor (HNF), signal transducer and activator of 
transcription (STAT) and octamer binding protein-1 (Oct-1). The 
PANDER translational start codon ATG is italicized and located 
at the end of the nucleotide sequence. Figure from Ratliff et 
al. [5]  
TGGGCTCCTT GGAAGAGGAG GAACAAGGAT GGAATAGAAT TCCTACAGCT –779 
    HNF-1 A box 
GGACTGGAGT CTCAGCTTGC CTTAGTTACT TAAGACCACT GTGACTCTAA –729 
        HNF-4/STAT5 A box 
TGAGCTAAAA AGTTCTGTGA AAACCTGAAC CCTGGAGATT GAGAGGGTAC –679 
        
TGTGCCTACT CAGGTGGAAG GGTGGGTAAA CCTAGGAAGC CTTCACCCAT –629 
   Oct-1 
TCACTTGACA CCATTTCTGA GTCCCATGTC CTTGTATATA CATATCCCAA –579 
  STAT3 A box 
GGGACCTGGA GCTCTTTCTC ACCTCATTTC CCTAAAATAA TCATCCCATC –529 
     +1(pancreatic) 
AGTAAAGAAG GAAGGGGTTG GCACCACACT GGGTC CATG TCAGCAAGGG -479 
   
GGCAGTGTGA CGACTTTGGA CACAATGTAG AGCCTTGGCA TTTGGAGCAG -429 
  
GAGCTTTGCT CTAGGATTCT GTGTTCATGA GGCTTGAGCC AGTCTATACT -379 
   STAT6  
TTACTGCCAT TTCTTGTGAA ACTAAGGTCG GGAATACTAT TGTTAGGGGC -329 
 
GCCTTAAAGT AAACTCTTGG TGTTCTTTCT CTGATTACAT TAGCTCTAGC -279 
HNF-4 (-)            E Box     
CTTTGGCCGT CTGTAGCCCC AGGTGAACAG GACAGAAAGT GCCTCCTGCT -229 
 E Box      
TCTTAGGTGA CCCTGGAGCT CCAGGGTGCT ACCAGCTGTG CAGCCCCACC -179 
  
CATACCTGCT AGCCTGCCAG TCTGCCAGCT ACTCTGAACC TTCCTGCTTT -129 
 E Box  
ATGGATCCTC CCATTTGCTG GGAATTGGTC CACCCTTTTC TGCCTGCCCC -79 
 A Box 
AAGGGCGGTC ATAATCTATG TGCAGCTCAA GCAGGTAGGC CAGCTTTCAT -29 
                               +1(hepatic) 
AGGTCCCTGG GGATTGCAGC CAAGAGCTGT GAGCTCCGCG AGCAGTTTCT +21 
 
GGAAGATG +29 
 
 
 
B 
A 
1 2 3 
BNLCL2 LIVER MARKER 
5’ CAP mRNA 1 
5’ CAP mRNA 2 
C 
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Structure of the Pander Protein  
In humans, PANDER contains 235 amino acids and shares a 78% 
sequence homology (including 4 conserved cysteines) with the 
murine form. Amino acid sequence homology ranges between 31.6% - 
53.3% amongst the FAM3 constituents and has no sequence homology 
to any known cytokine [7]. In 2013, the crystal structure of 
secreted PANDER was determined and revealed a unique globular β-
β-α fold as a major structural motif (Figure 4). This structure 
is conserved in all four constituents of FAM3 proteins. The 
crystal structure of PANDER contradicts the original assumption 
of the protein resembling a typical cytokine; therefore the 
structure of FAM3 represents a novel class of signaling 
molecules and is unlike that of any known cytokine [8]. 
 
Figure 4: PANDER structure. Murine PANDER structure above with 
diagram below colored from blue to red from N terminus to C 
terminus. Disulphide topology is indicated by dashed lines. 
Figure from Johansson et al. [8]. 
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Physiological Role of Pander in the Pancreas 
An initial in-vitro evaluation of the autocrine function of 
PANDER demonstrated that overexpression, either by exogenous 
recombinant PANDER treatment or PANDER adenoviral delivery in 
human, mouse, and rat islets, along with β-TC3 cells, induced 
apoptosis [7, 9]. Apoptotic mediators involved in cytokine-
induced apoptosis such as Akt, STAT1, NF-κB, and Fas were not 
affected. Instead, a caspase-dependent mechanism was observed, 
with cleavage of caspase-3 being central without the production 
of either Ca2+ or nitric oxide (NO), suggesting a non-canonical 
apoptotic pathway [7, 10]. Furthermore, a microarray study on 
PANDER-treated vs. control mouse islets revealed twenty-two 
genes with association to cell death to be differentially 
expressed [11]. Cyclin-dependent kinase inhibitor 1A (CDKN1A), 
also known as p21, was the most affected gene. The 
downregulation of p21 has been associated with cell death in 
other cell types [12]. Additionally this analysis revealed the 
activation of caspase-3, a molecule critically involved in  β-
cell death in autoimmune disease [13]. Caspase-3 has been 
demonstrated to cleave p21, which is an important mechanism for 
death-associated cyclin A/Cdk2 activation in various cell types 
[14]. Taken together, the marked downregulation of p21 and 
simultaneous activation of caspase-3 are central players in the 
PANDER-induced mechanism of apoptosis in islet cells [11].  
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Pander Expression, Localization and Regulation in Comparison to 
Insulin 
Initial evidence strongly supported the concept that PANDER is 
involved in glycemic regulation. In particular, PANDER was 
identified within the secretory granules of the pancreatic β-
cells in conjunction with insulin. As previously mentioned, 
PANDER is localized in the β-cell insulin granules which suggest 
that PANDER is co-secreted with insulin in response to glucose. 
Glucose treatment, in a time and dose dependent manner, 
increased PANDER and insulin secretion in β-cell lines. 
Treatment with insulin secretagogues, such as potassium 
chloride, markedly increased PANDER secretion. Glucose 
stimulation on mouse islets overexpressing PANDER in β-cells 
also significantly increased PANDER secretion [10, 15].  
Previous studies have demonstrated a role of PANDER impacting 
insulin secretion from β-cells, in turn affecting glucose 
metabolism. In β-TC3 cells, recombinant PANDER treatment 
decreased basal insulin secretion, however had no effect on β-
cell glucose metabolism or glucose stimulated secretion [1]. 
Additional experiments demonstrated the ability of PANDER 
overexpression to amplify signals of glucose stimulated insulin 
secretion (GSIS) by altering calcium signaling in pancreatic β-
cells. This was demonstrated by overexpressing PANDER in murine 
islets by exogenous recombinant PANDER application or adenoviral 
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PANDER delivery, where this had no impact on GSIS, however did 
impair insulin secretion in the presence of glucose with various 
insulin secretagogues such as carbachol or potassium chloride 
[9]. Taken together, PANDER secretion from pancreatic β-cells is 
thought to be regulated in a manner similar to that of insulin.   
Physiological Role of Pander in the Liver 
125I-PANDER saturation and competitive binding assays revealed 
the liver membrane as the primary target tissue involved in 
PANDER signaling. Similar analyses on brain, kidney, adipose, 
and pancreatic membrane tissue samples were performed with no 
significant positive findings; however, the receptor remains 
unknown. In the human hepatoma cell line HepG2, recombinant 
PANDER treatment impacted insulin signaling by suppressing 
activation of several signaling molecules: insulin receptor-β 
(IRβ), insulin receptor substrate-1 (IRS-1), 
phosphatidylinositol-3′-OH-kinase (PI3K), and Akt [16]. In 
primary mouse hepatocytes, either treated via adenoviral 
delivery or by exogenous treatment of PANDER, elevated 
gluconeogenic gene expression and glucose output was observed, 
accompanied by increased levels of cyclic adenosine 
monophosphate (cAMP) and cAMP-responsive element binding protein 
(CREB) signaling [17]. Although exogenous hepatic PANDER 
influences metabolic functions, the liver is the suggested novel 
target tissue of PANDER secretion from the  endocrine pancreas 
10 
 
[16]. We hypothesized that the pathophysiological conditions of 
metabolic disease increase circulating levels of PANDER; another 
group has reported evidence of this in an Asian population with 
varying degrees if insulin resistance. We now hypothesize that 
increased PANDER levels can act on the liver, promoting 
dangerous metabolic functions contributing to the 
pathophysiology of liver disease. 
Liver Derived Pander Impacts Hepatic Insulin Signaling in Murine 
Models 
There have been several animal models created in order to 
investigate the role of PANDER in the context of glucose and 
lipid metabolism in the liver with varying results being 
observed. In PANDER-deficient mice (PANKO), glucose intolerance 
was observed due to impaired insulin secretion from pancreatic 
β-cells [18]. However, in a similar study these mice also 
displayed increased hepatic insulin sensitivity due to decreased 
hepatic glucose production compared to wild-type mice in a 
hyperinsulinemic-euglycemic clamp assay [19, 20]. Conversely, 
liver-specific overexpression of PANDER increases the expression 
of important gluconeogenic genes such as phosphoenolpyruvate 
carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase), 
overall increasing hepatic gluconeogenesis [17]. Viral 
overexpression of PANDER in the liver of C57BL/6 mice increased 
lipogenesis, which was attributed to the decreased activation of 
11 
 
Akt and AMP-activated protein kinase (AMPK) and concordantly 
increasing levels of forkhead box 1 (FOXO1) protein expression 
[19]; a similar observation was made in vitro, where cultured 
murine hepatocytes overexpressing PANDER had suppressed insulin-
stimulated activation of Akt and subsequent FOXO1 inactivation. 
In these same mice, hepatic PANDER overexpression led to 
increased serum levels of very low density lipoprotein (vLDL) 
triglycerides causing global insulin resistance. Small 
interfering RNA (siRNA)-mediated knockdown of hepatic PANDER 
attenuates almost all of the effects observed during viral-
mediated overexpression of PANDER in diabetic mice. Hepatic 
steatosis is markedly decreased; PANDER knockdown increases 
activation of Akt and AMPK, while causing a reduction in FOXO1 
protein expression. PANDER knockdown also improved insulin 
resistance globally by reducing levels of circulating glucose 
and vLDL [19]. Taken together, it is difficult to distinguish if 
the physiological impact PANDER has on the liver is driven by 
islet or hepatic derived PANDER. Significant promoter activity 
of PANDER has been observed in hepatic cell lines [3]. As 
previously mentioned, our lab recently discovered a liver 
specific TSS of the PANDER gene in primary murine hepatocytes 
[5]. While some data does support liver derived PANDER as having 
an important role in insulin signaling and hepatic glucose 
production (HGP), the actual physiological impact and mechanisms 
12 
 
driving it remains largely unknown. However, the evidence more 
strongly supports islet derived PANDER acting on the liver via 
endocrine signaling interaction. In an effort to clear up these 
discrepancies, our lab created the only transgenic animal model 
stably overexpressing PANDER specifically in the endocrine 
pancreas.    
Pancreatic Derived Pander Impacts Hepatic Insulin Sensitivity 
and Lipid Metabolism  
The PANDER transgenic (PANTG) animal model has proven invaluable 
in the ongoing effort to better understand the endocrine 
function of pancreatic derived PANDER and its putative role in 
hepatic insulin signaling. These mice over-express PANDER from 
the pancreatic β-cells of the Islets of Langerhans and display 
elevated serum levels of PANDER [21]. As previously discussed, 
there is overwhelming evidence to support the liver as being the 
target organ of PANDER endocrine signaling and affecting the 
metabolism of glucose and lipids in the liver [5, 16, 19, 21, 
22]. Due to elevated circulating levels of PANDER in the blood 
of PANTG mice, males display fasting hyperglycemia and 
hyperinsulinemia as well as glucose intolerance during a glucose 
tolerance test. These same mice display increased hepatic 
glucose production and overall insulin resistances compared to 
wild-type mice during a hyperinsulinemic-euglycemic clamp study 
(Figure 5). 
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Figure 5: Metabolic phenotype of the PANTG mouse. PANTG mice 
display fasting hyperglycemia (left, top left) as well as 
glucose intolerance after a glucose tolerance test (left, top 
right) as compared to the wild-type mouse. Hepatic triglyceride 
content was significantly increased in the PANTG mouse livers 
(left, bottom right). HEC assays revealed steady glucose 
infusion rate (GIR) and glucose disposal (Rd) (right, top left 
and right, respectively, N=8). HEC assays also revealed impaired 
insulin signaling whereby hepatic glucose production is 
increased and HGP suppression decreased significantly (N=6-8, 
P<0.05 by students two-tail t-test). Figure from Robert-
Cooperman et al. [21]. 
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Additionally, and very interestingly, an increase in 
triglyceride content was observed in the livers of the PANTG 
mouse [21]. Type 2 diabetes is mainly characterized by insulin 
resistance in several organs, including the liver. Normal 
insulin signaling promotes hepatic lipogenesis, however in the 
state of T2D a metabolic anomaly occurs where insulin signaling 
selectively promotes hepatic lipogenesis but fails to suppress 
HGP, or selective hepatic insulin resistance (SHIR) [23, 24]. 
Considering the metabolic triad of type 2 diabetes, including 
hyperglycemia, hyperinsulinemia, and hyperlipidemia, SHIR is a 
severe metabolic defect and the mechanism driving its 
progression is largely unknown and will be discussed in greater 
detail later. Taken together, the PANTG mouse displays a very 
similar SHIR phenotype. The pleiotropic effect of PANDER 
overexpression causing increased hepatic triglyceride and 
glucose production could be attributed to decreased activation 
of Akt [16] and AMPK and ACC in the fasted state as shown by 
western blotting [21]. However, to comprehensively investigate 
the complex nature of the PANDER induced metabolic effects 
observed in the liver, our lab employed a quantitative mass 
spectrometry approach in order to compare the hepatic proteome 
of PANTG and wild-type mice. The metabolic pathology induced by 
PANDER overexpression is outline in Figure 6. 
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Figure 6: Mechanism of PANDER induced diabetes. The 
pathophysiological conditions of T2D can stimulate secretion of 
PANDER from the endocrine pancreas. PANDER overexpression has 
been shown to affect insulin signaling in the liver, whereby 
insulin signaling is blocked in terms of glucose metabolism yet 
lipogenesis is promoted mimicking a selective hepatic insulin 
phenotype.  
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Initial Proteomic Analysis of The Pander Transgenic Mouse Liver 
using Super Silac Aml-12 Cells  
The initial phenotype of the PANTG mouse can be characterized by 
increased fasting and fed circulating glycemic levels and 
increased hepatic triglyceride content due to insulin resistance 
in the liver. This bifurcation of events mimics the selective 
hepatic insulin resistant (SHIR) state seen in type 2 diabetes. 
Insulin signaling is a highly complex process that activates a 
tyrosine phosphorylation cascade affecting numerous biological 
functions [25, 26]. Insulin impacts over 100 proteins, many of 
which are involved in metabolic and mitogenic regulation [26, 
27]. Our hypothesis is that PANDER drives selective hepatic 
insulin resistance (SHIR) during pathophysiological conditions 
of type 2 diabetes. In order to detail the mechanism of PANDER 
induced hepatic signaling, we employed state of the art 
proteomic technology. The quantitative proteomic strategy, 
stable isotope labeling of amino acids in cell culture (SILAC), 
allows for the metabolic labeling of all proteins with either 
13C-lysine or 13C-arginine in a system; either in cell culture or 
whole animals [28, 29]. “Spike-In” SILAC employs heavy labeled 
reference proteins or proteomes that are added to the proteomes 
(primary tissue) under investigation. These protein mixtures can 
then be analyzed by liquid chromatography tandem mass 
spectrometry (LC-MS/MS) for the identification of peptides in 
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the sample. Relative quantification is possible when overlapping 
labeled “heavy” and “light” unlabeled peptides exist in the same 
sample, allowing for the differences in spectral intensities to 
be used in the calculation.  This method has become a relatively 
novel and highly useful tool because it allows one to take a 
molecular snap-shot of all the proteins in a mixture, or a 
proteome. The proteome can be used to identify networks of 
proteins that are differentially expressed and known to be 
involved in signaling cascades or metabolic pathways [29, 30], 
and the use of bioinformatics tools such as Ingenuity Pathway 
Analysis (IPA) greatly assist in doing so [31]. The initial 
proteomic analysis was performed on the liver lysate of six 
PANTG and wild-type mice using labeled ethanol-treated AML-12 
cell lysate, a murine liver cell line, for spike-in. Roughly 
1640 proteins were identified and quantified. Of those proteins, 
88 proteins were upregulated and 9 downregulated in the PANTG 
mouse liver. IPA identified lipid metabolism (Figure 7) as the 
top significantly affected protein network involving 20 
proteins, including sterol carrier protein (SCP2), acetyl CoA 
synthetase (ACSL1), ectonucleoside triphosphate 
diphosphohydrolase 5 (ENTPD5), and fatty acid binding protein 
(FABP1).  Further research would be required to elucidate a 
precise mechanism from this information. ACSL1 is an isozyme of 
the long-chain fatty-acid-coenzyme A ligase family that convert 
18 
 
free long-chain fatty acids into fatty acyl-CoA esters, and 
serve a central role in lipid biosynthesis [32]. FABP1 and SCP2 
serve as binding and carrier proteins involved in lipid 
homeostasis [33]. PRKAR2B and ENTPD5 are involved in the 
substrate production necessary for lipogenesis. In these 
instances, MS based proteomic techniques almost seem to have a 
drawback in that it provides too much information. However, the 
mass spectrometry (MS) method also revealed the upregulation of 
phosphoenol-pyruvate carboxykinase (PEPCK), up 3.5 fold in the 
PANTG mouse (Figure 7). PEPCK controls the rate limiting step in 
gluconeogenesis and suppression is expected under conditions of 
hyperglycemia and insulin secretion [34], however in the PANTG 
mouse liver the opposite is apparent, and is supported by both 
the results of the hyperinsulinemic euglycemic clamp study and 
glucose tolerance testing [21]. In this particular experiment, 
numerous factors existed that constrained us from get the best 
results, that is: most protein identification and mass accuracy. 
Despite these shortcomings, the MS based proteomic technique 
proved valuable in identifying key molecules involved in 
biochemical processes promoting the phenotype of PANDER 
overexpression. To circumvent this, we recently published a 
similar, refined study that was performed in order to analyze 
the PANTG mouse liver using age and gender matched mice in 
various controlled metabolic states [22]. 
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Figure 7: Proteomic analysis of PANTG mouse. Relative changes in 
the levels of identified proteins were determined by the ratio 
of PANTG to that of WT. (A) IPA analysis of predicted impacted 
metabolic functions indicates lipid metabolism as the top 
function altered in PANTG liver.  (B) Differentially expressed 
hepatic proteins identified in PANTG predicted to act in concert 
to increase triglyceride production. (C) Network analysis of 
differentially expressed proteins that molecularly interact 
involved in triglyceride production. Figure from Robert-
Cooperman et al. [36].  
Discussion
The hallmark characteristics of our PANTG model
in younger male mice demonstrated the following:
1) increased fasting hyperglycemia and insulinemia,
2) impaired glucose tolerance, 3) increased hepatic insulin
resistance, 4) increased proteomic profile of lipogenesis
and gluconeogenesis, 5) increased hepatic triglyceride
content, 6) decreased hepatic glycogen, and 7) decreased
p-AMPK signaling. These findings strongly suggest that
pancreas-specific PANDER can alter glycemic levels
through what appears to be a specific interaction with
the liver and impact phosphorylation of critical down-
stream hepatic signaling molecules such as AMPK. The
generation and evaluation of the pancreas-specific PAN-
DER overexpressing transgenic mouse allowed us to
evaluate the physiologic effects of secreted PANDER and
the impact on glycemic and lipid modulation.
To put our data in the context of other published
in-vivo studies, we compared our results to the overall
findings of others, albeit this comparison was made to
acute models (Table 1). The two other published studies
utilized tail vein-injected adenoviral-delivered PANDER to
induce a hepatic overexpression of PANDER (Wilson et al.
2010, Li et al. 2011). Some of the earliest reports detailing
the localization of PANDER did not find any expression
in the liver (Zhu et al. 2002), but recently others have
surfaced to demonstrate that PANDER is expressed within
this organ as well and is consistent with our findings
(Li et al. 2011, 2013, Mou et al. 2013). Therefore, there is
definitive physiological relevance to this approach but
does not take into account the biological influence of
pancreas-specific PANDER. Both prior studies evaluated
the impact of Ad-PANDER following either 3 (Li et al.
2011) or 7 days (Wilson et al. 2010) post viral
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Figure 7: Continued   
Discussion
The hallmark characteristics of our PANTG model
in younger male mice demonstrated the following:
1) increased fasting hyperglycemia and insulinemia,
2) impaired glucose tolerance, 3) increased hepatic insulin
resistance, 4) increased proteomic profile of lipogenesis
and gluconeogenesis, 5) increased hepatic triglyceride
content, 6) decreased hepatic glycogen, and 7) decreased
p-AMPK signaling. These findings strongly suggest that
pancreas-specific PANDER can alter glycemic levels
through what appears to be a specific interaction with
the liver and impact phosphorylation of critical down-
stream hepatic signaling molecules such as AMPK. The
generation and evaluation of the pancreas-specific PAN-
DER overexpressing transgenic mouse allowed us to
evaluate the physiologic effects of secreted PANDER and
the impact on glycemic and lipid modulation.
To put our data in the context of other published
in-vivo studies, we compared our results to the overall
findings of others, albeit this comparison was made to
acute models (Table 1). The two other published studies
utilized tail vein-injected adenoviral-delivered PANDER to
induce a hepatic overexpression of PANDER (Wilson et al.
2010, Li et al. 2011). Some of the earliest reports detailing
the localization of PANDER did not find any expression
in the liver (Zhu et al. 2002), but recently others have
surfaced to demonstrate that PANDER is expressed within
this organ as well and is consistent with our findings
(Li et al. 2011, 2013, Mou et al. 2013). Therefore, there is
definitive physiological relevance to this approach but
does not take into account the biological influence of
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the impact of Ad-PANDER following either 3 (Li et al.
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Stable isotope labeling of amino acids in cell culture (SILAC) analysis of
PANTG. Total protein isolate was prepared from isolated livers from PANTG
and WT mice (nZ6 per group) obtained during fed conditions. Following
processing and SILAC analysis, 1640 proteins were identified and
quantitated. Data were normalized and analyzed using the Ingenuity
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Liver X Receptor Modulates Pander Induced Hepatic Lipogensis  
Our proteomic investigation provided strong evidence to suggest 
that lipid metabolism is increased in the liver of the PANTG 
mouse by analysis of differentially expressed proteins. 
Additionally, several of these proteins are known to be 
modulated by the liver X receptor (LXR), an important 
transcriptional factor regulating lipid metabolism. In vitro, 
exogenous PANDER treatment stimulated LXR transcription using 
LXR reporter constructs. Due to the pleotropic action PANDER 
signaling elicits on the liver, LXR is suggested to play a key 
role in PANDER induced lipogenesis.  Liver X receptors (LXR) are 
transcription factors belonging to the class II nuclear receptor 
superfamily and are composed of 2 isoforms [37-39]. LXRα is 
highly expressed in the liver, intestine, and adipose tissues 
whereas LXRβ is ubiquitously expressed. Upon activation, LXRs 
form a heterodimer with the retinoid X receptor α (RXR) which 
binds to LXR response elements (LXREs) enhancing specific 
targeted gene expression in a functional dependent manner, 
outlined in Figure 8. Oxysterols are generally accepted as the 
endogenous LXR agonist in humans, with the most potent 
activators being 22(R)-hydroxycholesterol, 20(S)-
hydroxycholesterol, 24(S)-hydroxycholesterol and 24(S), 25-
epoxycholesterol [40-43]. LXR activity is not only governed by 
agonist and antagonists, but also by changes in expression which 
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LXR itself impacts by an auto-regulatory loop [44]. LXRs appear 
to regulate overall glucose, cholesterol, bile acid, and 
triglyceride homeostasis (Figure 8) [45]. LXRs were initially 
considered therapeutic targets for T2D but beneficial effects 
have been hampered with hyperlipidemia and hepatic steatosis 
[46, 47]. LXR agonists (such as T0901317) can directly activate 
critical genes necessary for hepatic de novo lipogenesis which 
serves as a contributor to triglyceride accumulation in non-
alcoholic fatty liver disease (NAFLD) [48, 49] either indirectly 
by increasing expression of SREBP-1c [50] and ChREBP [51], and 
directly by promoting transcription of SCD1 [52], FasN [53], and 
ACC [54]. In addition, LXR governs cholesterol transport by 
impacting ATP-binding cassette transporter a1 (Abca1) [55], 
Abcg1 [56], Abcg5 [57], and Abcg8 [57], and bile acid metabolism 
by CYP7A1 [58]. Previous research (reviewed in [59-61]) has 
strongly supported the implication that PANDER is involved in 
the pathogenesis of NAFLD and T2D. Our proteomic analysis of the 
PANTG liver demonstrates that lipid metabolism is strongly 
altered when compared to the wild-type mouse. Additional 
computational analysis with IPA was performed to identify 
canonical functions impacting the mechanism for the increased 
lipogenic state and the activation of the LXR pathway was a top 
candidate during all metabolic states [21, 35]. FasN is 
considered one of the most critical genes involved in LXR 
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governed hepatic lipogenesis [53] and was demonstrated to be 
upregulated in all three metabolic states. In addition, SCD1 was 
increased in the PANTG by 5.5 fold [22, 35]. SCD1 is crucial for 
the lipogenic effect of LXRs [52]. Other differentially 
expressed proteins within the LXR predicted network included 
ACC, CD36 and CYP7A1 (FIG) [22, 35]. Western blotting analysis 
confirmed an increase expression of FasN and Cyp7A1, as well as 
an increase of LXR expression within the PANTG liver (FIG). In 
vitro, reporter gene analysis was performed on BNL-CL2 liver-
derived cells transfected with LXRE-luciferase plasmids exposed 
to increasing concentrations of purified secreted PANDER 
(AstraZeneca) followed by measurement of luciferase activity, 
which displayed an increased activity of the LXR promoter in a 
dose-wise manner [22].  Taken together, the proteomic analysis 
resulting from the PANTG and in vitro functional assays 
indicated that PANDER may potentially impact hepatic lipogenesis 
via the LXR pathway and will be discussed in greater detail in 
Chapter 3. 
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Figure 8: Classical LXR activation. In the presence of 
oxysterols, LXRs form a heterodimer with the RXRs which binds to 
LXR response elements (LXREs) enhancing specific targeted gene 
expression in a functional dependent manner.   
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Hepatic Insulin Resistance in Type 2 Diabetes 
Type 2 diabetes has become one of the most major health 
epidemics of our time [62]. Incidence of T2D has increased 
drastically over the decades [63-65] with the pronounced changes 
in human behavior and the environment resulting in increased 
obesity to blame [66].  Humans with T2D exhibit the classic 
metabolic triad of hyperinsulinemia, hyperglycemia, and 
hypertriglyceridemia. Hyperglycemia in the presences of 
hyperinsulinemia is described as insulin resistance, with the 
major contributing organs being the liver, muscle, and adipose 
tissue. T2D has also been attributed to impaired β-cell function 
and/or loss of β-cell mass [67, 68]. In order to understand this 
metabolic dilemma, a rudimentary understanding of normal 
glycemic regulation is necessary (Figure 9). Under normal 
conditions, insulin is stored in the pancreatic β-cells until 
its release is required when blood glucose levels rise. Insulin 
signals for the muscle and liver to take up excess glucose which 
can then be used for cellular fuel or stored in the form of 
glycogen. Insulin signaling also suppresses hepatic glucose 
production and causes the release of fatty acids from adipocytes 
[69, 70]. In the diabetic state, however, almost every aspect of 
glucose and lipid metabolism goes awry (Figure 9). Impaired 
insulin secretion from pancreatic β-cells causes an overall 
decrease in insulin signaling, resulting in a lack of glucose 
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uptake which ultimately causes hyperglycemia.  This decrease in 
insulin sensitivity results in impaired glucose tolerance, 
increased hepatic glucose production, and increased fatty acid 
release from adipose tissue. In order to combat this, the 
pancreas continues producing insulin to no avail, leading to 
hyperinsulinemia. High levels of glucose and fatty acids in the 
blood promote this dangerous positive feedback loop, further 
driving insulin resistance and worsening of the 
pathophysiological progression of T2D [71]. How organs act in 
concert to promote insulin resistance is weakly understood, 
however the liver is arguably the most significantly 
dysregulated organ in T2D. The liver is responsible for both 
glycogenolysis [72], the breakdown of glycogen for energy, and 
gluconeogenesis [73], the conversion of non-carbohydrate sources 
to glucose. Normally, insulin suppresses the release of fatty 
acids in the blood from adipocytes [70, 74] and decreases blood 
glucose levels, however in an insulin resistant state, this is 
not the case. The excess of these oxidized compounds can 
accumulate in the liver which can lead to other metabolic 
diseases such as nonalcoholic fatty liver disease and ultimately 
cirrhosis of the liver [75, 76]. The major contribution the 
liver has in T2D was briefly mentioned previously: selective 
hepatic insulin resistance. Normally, insulin signals two major 
events to take place in the liver. The first is the decrease in 
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gluconeogenesis, whereby insulin allows for the phosphorylation 
of FOXO1 which inhibits its translocation to the nucleus, 
downregulating genes such as PEPCK and G6Pase required for 
gluconeogenesis [77]. Additionally, hepatic insulin signaling 
activates genes necessary for lipid synthesis. Insulin activates 
the transcription factor SREBP-1c which facilitates the 
transcription of genes responsible for fatty acid synthesis, 
such as ACC and FasN [78, 79]. In the liver of T2D patients, the 
FOXO1 pathway becomes insulin resistant, whereby gluconeogenesis 
continues despite elevated blood glucose levels. Simultaneously, 
the lipogenic gene pathways modulated by SREBP-1c are maintained 
and fatty acid synthesis persists [80]. This increase in hepatic 
glucose output and fatty acid synthesis only further contributes 
to the positive feedback loop promoting insulin resistance and 
the T2D metabolic triad. 
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Figure 9: Pathophysiology of T2D. In healthy individuals, the 
pancreas secretes insulin in response to elevated blood glucose. 
In response to insulin, skeletal muscles uptake glucose into the 
cells, the glucose production within the liver is suppressed and 
adipose tissue is prevented from releasing free fatty acids into 
the blood. Under conditions of diabetes, β-cell dysfunction 
causes a partial loss of insulin production. Insulin resistance 
in the tissues results in insulin action not being completed 
within the cells. Both conditions result in an increase in free 
fatty acids and glucose within the blood. Figure from Stumvoll 
et al. [81]. 
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Proteomics and Type 2 Diabetes Research 
With the completion of the human genome project, the study of 
molecular biology is shifting into what has been coined the “–
omics era”, where the utilization of high throughput technology 
and large scale databases can allow researchers to compare 
entire biological systems of disease models. In this brief 
review, the application of proteomics will be the major focus 
especially as this technical application we employed within my 
dissertation.  
Gel-Based Proteomics 
In order to appreciate the impact proteomics has made in 
molecular research, one must be familiar with the origins of 
this science. The term proteomics was first coined in 1997 by 
then Ph.D. student Marc Wilkins [82]. Presently, proteomics is 
often used to describe the analysis of entire sets of proteins 
in a system, or proteome. The method to study proteomics at this 
time was dominated by two-dimensional gel electrophoresis (2DE), 
which separates proteins based on their isoelectric point and 
mass, coupled with mass spectrometry for the identification of 
proteins of interest [83, 84]. Briefly, a control and perturbed 
protein lysate is separated by 2DE and differential spot sizes 
can correspond to differences in protein expression. The spot 
can be excised and the protein within can be identified by mass 
spectrometry, fragmenting peptides and identifying the amino 
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acid sequence based on Edman degradation. Recent developments 
have even been made on this technique, utilizing multi-color 
fluorescent labeling of two protein samples (such as control vs. 
perturbed) which rids many limitations inherent to 2DE [85], 
referred to as differential gel electrophoresis (DIGE). 2DE is 
still widely used today and can allow for quantitative 
differential analysis of hundreds to thousands of proteins in a 
given sample [86]. Because of this, proteomics offers unmatched 
insight of molecular biological systems, compared to genomics 
and transcriptomics, as it bridges the gap between gene, gene 
transcription, and gene expression which ultimately is most 
useful for understanding disease mechanisms [87].  
PROTEOMICS AND DIABETES USING 2DE 
2DE-MS has proven to be a valuable tool in the context of 
diabetes research. Sanchez et al. used gel based techniques to 
build shareable databases and has provided reference proteomes 
for several species, including human and mouse [88]. A similar 
reporting by Ahmed et al. included 66 proteins identified in 
human pancreatic islets, several of which were not previously 
described [89]. Both demonstrated proteomic based techniques in 
their ability to greatly aid in the construction of useful 
databases that can be used in many contexts. 2DE-MS can provide 
quantitative data as well, as demonstrated by Ahmed et al. where 
they investigated glucose induced changes of mouse islets, 
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successfully identifying 77 differentially expressed proteins 
[90]. Sparre et al. performed a similar study where 82 
differentially expressed proteins were identified out of 2,200 
total proteins in BB rat islets treated with IL-1β [91]. Many 
proteins that were differentially expressed were involved in 
energy production, protein synthesis, signal transduction, and 
apoptosis. This study demonstrated the strong utility proteomics 
has in understanding molecular pathways, as IL-1β influences 
several cellular events that inhibit β-cell function and induce 
apoptosis.  
Mechanisms of disease have been investigated using this method, 
where Tilton et al. described the changes in the renal cortical 
proteome in diabetic db/db mice. 147 proteins were 
differentially expressed and identified, most being involved in 
cellular metabolism [92]. Douette et al. described changes in 
the liver mitochondria proteome in steatotic ob/ob mice where 56 
differentially expressed proteins were identified and are 
involved in acetyl-CoA regulation and oxidative stress [93]. 
Molecular mechanisms impacted by therapeutic drugs such as PPARα 
and PPARγ agonists, used to treat hypertriglyceridemia [94-98], 
have been investigated using 2DE by the Dahllöf group in obese 
and diabetic ob/ob mice. The study identified 14 differentially 
expressed proteins in the liver and was able to provide evidence 
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that PPARα induces β-oxidation and upregulates enzymes involved 
in lipogenesis [99].  
The epigenetic effects of T2D have been explored, where skeletal 
muscle proteomes were compared in T2D and healthy individuals. 
The reporting from Højlund et al. concluded that cellular 
stress, alterations in mitochondrial metabolism, and ATP 
synthesis was dysregulated in skeletal muscle cells of T2D 
individuals as evident by the 10 differentially expressed 
proteins identified [100]. The application for proteomic studies 
is endless, with the only major drawback being the difficulty in 
interpretation following the accumulation of a complex 
compilation of differentially expressed proteins and potential 
networks. In the context of T2D, the mechanisms driving insulin 
resistance, β-cell dysfunction/death, and liver disease can be 
investigated as an entire system. The technology is certainly 
ever improving; recent advances in mass spectrometry, as well as 
liquid chromatography, have allowed for relative and absolute 
quantitation by either stable isotope labeling or label free 
techniques, drastically increasing the robustness of proteomic 
applications. 
Quantitative Mass Spectrometry Based Proteomics 
With the relative recent development of smaller, more accurate, 
and more economical mass analyzers, quantitative mass 
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spectrometry based proteomics has become a favorable high-
throughput method to study the unbiased large scale changes in 
protein expression as well as post translational modifications 
(PTMs) in several types of biological samples. Quantitative MS-
based proteomics relies on labeling techniques where one sample 
is labeled with a “heavy” reagent and the other a “light” (or 
unlabeled peptides) reagent which when mixed together can be 
analyzed by tandem mass spectrometry to identify the relative 
abundance, peptide identification, and origin of the peptide 
between the two samples (Figure 10).  In the early nineties, 
these methods could only be carried out on the Fourier transform 
ion cyclotron resonance mass spectrometers (FTICR) or other 
complicated arrangements of mass analyzers, which was not a 
feasible option for most. However, the invention of the Orbitrap 
has allowed researchers to harness the same sensitivity of FTICR 
mass spectrometers and perform more complicated analyses in less 
time. For precursor ion fragmentation, Orbitrap mass 
spectrometers harness the exclusive higher-energy collisional 
dissociation (HCD) cell, which allows for sensitive detection of 
low molecular weight isobaric tag reporter ions [101, 102], a 
useful feature in isobaric tag based techniques for quantitative 
proteomics. Many sources of error can be eliminated by this 
method, as the labeled peptides act as an internal standard, 
reducing error caused by sample preparations, variance between 
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individual chromatography separations, and mass spectrometry 
analyses. 
Gygi et al. first described a labeling method using isotope-
coded affinity tags (ICAT) [103], based off the earlier isotope 
dilution assay methods [104]. Since then, several labeling 
techniques have been developed; one being stable isotope 
labeling of amino acids in cell culture (SILAC) developed by the 
Mann lab [105]. Oda et al. set the stage for this method in 
yeast cells [106], however SILAC allows mammalian cells to 
metabolically incorporate heavy or light amino acids into their 
proteomes during synthesis by providing the either labeled or 
non-labeled essential amino acids lysine and/or arginine in the 
cell culture medium. This allows for the simultaneous comparison 
of two different treatment groups during LC-MS/MS. SILAC was 
formally restricted to in vitro applications; however, methods 
have been developed where peptides labeled in vitro can be 
“spiked-in” to corresponding animal protein lysate [107]. 
Additionally, multiple labeled cell type lysates can be combined 
which increases the protein overlap when spiked-in to the 
protein lysate under investigation [108], referred to as 
superSILAC. superSILAC for spike-in has improved, where yeast, 
fruit flies, and mice have been metabolically labeled in vivo by 
providing them the isotope via feeding over several breeding 
generations [109-112]. Lysates from labeled animals are 
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therefore superior for protein coverage, however they poses the 
drawback of being labeled with only one isotopic amino acid. For 
the study of human tissue, in vitro methods such as isobaric 
tags for relative or absolute quantitation (iTRAQ) [113], or 
isotopic reductive demethylation labeling [114, 115], both in 
vitro labeling methods, allow for the chemical labeling of 
peptides with covalently bonded isobaric tags for quantitation. 
With ever advancing technology in liquid chromatography and mass 
spectrometry, label-free quantitative methods are becoming 
possible, eliminating the need for the labeling of peptides and 
subsequent experimental error from doing so [116]. 
Coupling mass spectrometry with high performance liquid 
chromatography, or multidimensional protein identification 
technology (MudPIT), allows for greater identification of 
proteins in a complex mixture [117, 118]. This is achieved by 
first fractionating samples for MS by HPLC to reduce sample 
complexity, usually by strong cation exchange (SCX) 
chromatography, and then performing HPLC again on each fraction 
directly inline to MS, usually based on a chromatography method 
exploiting other physical properties, such as reverse phase (RP) 
chromatography. This method has allowed for the drastic 
improvement of protein identifications and high-throughput 
analyses of complex proteomes. See Figure 10 for a general 
proteomics workflow. 
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Figure 10: Typical mass spectrometry based proteomic workflow. 
Following sample preparation and protein extraction, purified 
proteins are digested, typically with the protease trypsin, 
generating tryptic peptides. The peptide mixture is then 
analyzed by mass spectrometry for the identification and 
abundance of protein. Differentially expressed proteins can be 
analyzed using IPA for the identification of differential 
protein networks and biochemical pathways.  
  
37 
 
PROTEOMICS AND DIABETES USING LC-MS/MS 
As evident from the literature, there is sparse use of 
quantitative mass spectrometry based proteomics in an effort for 
the functional understanding T2D pathology; that is, to identify 
altered mechanisms based on differences in protein expression. 
However early uses of LC-MS/MS provided enhanced proteome 
coverage when used as a tool for tissue profiling, as 
demonstrated by Metz et al. [119]. 2D LC-MS/MS was employed for 
the proteomic characterization of human pancreatic islets, where 
over 29,000 peptides were identified which corresponded to 3,365 
proteins, compared to the earlier mention of Ahmed et al. where 
only 66 proteins were identified [89, 119]. The significant 
highlights of this study included the observation of proteins 
involved in metabolic and cellular pathways, including MAP 
kinase, NF-κβ, and JAK/STAT signaling cascades. To date, this is 
the most comprehensive islet proteomic profiling analysis. To 
expand on this, Brunner et al. isolated insulin secreted 
granules from the rat insulin-secreting cell line INS-1E and 
identified 130 unique proteins by LC-MS/MS, in which 110 were 
not previously described [120]. Unfortunately, this 
investigation did not identify PANDER in their dataset. 
In an effort to detail the functional changes in the islets of 
the MKR mouse (a model of T2D), Lu et al. employed iTRAQ to 
investigate proteomic differences in the islet compared to the 
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wild-type mouse [121]. 159 differentially expressed proteins 
were identified in the islets of the MKR mouse as compared to 
control islets. Many of these proteins suggested differential 
regulation of protein biosynthesis, endoplasmic reticulum (ER) 
stress pathways, insulin secretion, energy utilization, and 
metabolism. Additionally, several differentially expressed 
proteins were observed that are linked to insulin-secretory 
defects in T2D. Several proteins were described for the first 
time with an association to islet dysfunction, including the 
unfolded protein response proteins (ERP72, ERP44, ERP29, PPIB, 
FKBP2, FKBP11, and DNAJB11), endoplasmic reticulum-associated 
degradation proteins (VCP and UFM1), and multiple proteins 
associated with mitochondrial energy metabolism (NDUFA9, UQCRH, 
COX2, COX4I1, COX5A, ATP6V1B2, ATP6V1H, ANT1, ANT2, ETFA, and 
ETFB). Interestingly, this study also investigated the 
differential expression of mRNAs to corresponding proteins 
identified by MS using microarray and quantitative real time 
PCR, in which a low correlation was found [121]; this does 
suggest strong post-translational regulation, but without going 
off-topic, also serves as additional supportive evidence that 
proteomics provides unique and valuable insight of biochemical 
changes driving β-cell dysregulation and insulin resistance 
[122]. 
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Yurong et al. investigated the proteome changes in liver 
mitochondria of mice on a high fat diet using iTRAQ. From this 
approach, 1508 proteins were identified, with 72 proteins 
predicted to be up-regulated and 20 proteins down-regulated 
[123]. Retinol metabolism was shown to be distinctly down-
regulated and the mitochondrial structural proteins—components 
of mitochondrial inter-membrane space bridging complex 
(Mitofilin, Sam50, and ChChd3), and Tim proteins, essential for 
protein import, were shown to be significantly up-regulated in 
HFD fed mice [123].  
More recently, a study by Han et al. utilized iTRAQ to compare 
the islet proteomes of Zucker Lean (ZL), Zucker Fat (ZF) and 
obese diabetic Zucker rats (ZDF) in an effort to propose 
potential factors mediating the progression of insulin 
resistance to T2D [124]. 54 and 59 differentially expressed 
proteins were observed between the ZDF vs. ZL and ZF vs. ZL, 
respectively. These proteins were involved in impaired insulin 
secretion, mitochondrial dysfunction, dysregulation of 
triglyceride/free fatty acid cycling, lipotoxicity, and 
microvascular dysfunction [124].  
To outline critical proteins involved in islet 
differentiation/regeneration, Jin et al. utilized iTRAQ and 
microarray analysis to identify differentially expressed 
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proteins in a human β-cell line [125]. Many proteins identified 
are involved in cell cycle, cell structure and developmental 
processes which were significantly downregulated, while proteins 
involved in lipid, fatty acid, steroid, and nucleotide 
metabolism were upregulated [125]. The information obtained from 
this study aided in the development of a large scale protein 
interaction map using GenBank and all available islet proteomic 
data by Levetan et al., which additionally led to the 
development of a pro-islet peptide that stimulates β-cell 
population growth  in vitro [126].  
The study of proteomics has allowed for tremendous strides to be 
made in the understanding of biological mechanisms underlying 
disease. Gene regulation and expression is an extremely complex 
and multifaceted process, however the ability to observe the 
overall end product, proteins, logically allows for the most 
pertinent understanding of disease. In this dissertation, mass 
spectrometry based proteomics is used as a powerful heuristic 
tool to outline critical proteins involved in the pathogenic 
effects of PANDER overexpression. In an additional and rather 
unique study, the same approach was employed to shed light on 
important protein expression changes in the liver due to a high 
fat diet exposure, and will be discussed in chapter 5. 
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Innovation   
Hepatic insulin resistance (HIRE) is a significant clinical 
hallmark of type 2 diabetes (T2D) that results in impaired 
insulin signaling, increased gluconeogenesis, hyperlipidemia, 
and progressive nonalcoholic fatty liver disease (NAFLD). The 
prevalence of NAFLD is approximately 30% of the US population 
and is a risk factor for T2D [127, 128]. NAFLD results in 
initial steatosis (fatty liver) due to increased hepatic 
lipogenesis [129]. Despite active investigation, therapeutic 
strategies are limited and there is much elucidation needed to 
determine the specific etiological molecules responsible for 
HIRE, NAFLD, and T2D. Over the past decade a wealth of data has 
been generated to support a role for pancreatic derived factor 
in the onset or progression of HIRE, NAFLD, and T2D [1, 4, 6, 9-
11, 15, 18, 130-135]. Our published findings from the PANDER 
transgenic (PANTG) mouse that displays increased circulating 
PANDER revealed a phenotype containing several T2D 
characteristics such as fasting hyperglycemia, glucose 
intolerance, hepatic insulin resistance and increased 
triglyceride production [21, 22]. Hepatic PANDER overexpression 
can promote hepatic steatosis resulting in increased 
triglycerides and very low density lipoprotein production, yet 
this effect has not been determined for pancreas derived PANDER 
[3, 17, 19, 21, 22, 60]. PANDER is a uniquely structured 
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molecule that is strongly expressed and secreted from the 
endocrine pancreas and other tissues such as the liver and 
intestines. Based on recent crystallography data, PANDER has a 
unique globular β-β-α fold structure not found in any other 
class of proteins [8]. The physiological function of PANDER is 
to regulate glycemic levels via interaction with the liver and 
pancreas [16]. However, the precise signaling mechanism of how 
PANDER regulates this multitude of effects is unknown.  
My innovative approach will hopefully have a high impact on the 
fields of liver metabolism and diabetes biology by 
identification of a causative molecule involved in hepatic 
insulin resistance and potentially T2D and NAFLD. These findings 
would also provide insight into novel mechanisms potentially 
regulating the liver X receptor (LXR) pathway. As strongly 
indicated by others, selective hepatic insulin resistance (SHIR) 
is a major uncharacterized problem in T2D and is a critical 
source of the cardiovascular complications identified with this 
disease [136, 137]. Our PANDER animal models and others [17-19, 
21, 138] have provided evidence that PANDER may impact SHIR and 
therefore suggest that PANDER is a potential cofactor involved 
in this pathogenic paradox. These findings may also provide 
additional therapeutic avenues for clinical intervention of T2D 
and NAFLD. In addition, an understanding of PANDER induced 
lipogenesis may also provide insight into the LXR signaling 
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mechanism and this is valuable since LXR clinical application 
has been hindered due to this detrimental outcome (25). 
Furthermore, our laboratory has generated the first and only 
PANDER animal models that are currently established and 
available for analysis of this unique secreted protein. 
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Chapter 2 – Generation of The Pander Transgenic Model for 
Identification of Pander-Induced Hepatic Proteome 
Abstract 
PANcreatic-DERived factor (PANDER) is a member of a superfamily 
of FAM3 proteins modulating glycemic levels by metabolic 
regulation of the liver and pancreas. The precise PANDER-induced 
hepatic signaling mechanism is still being elucidated and has 
been very complex due to the pleiotropic nature of this novel 
hormone. Our PANDER transgenic (PANTG) mouse displays a 
selective hepatic insulin resistant (SHIR) phenotype whereby 
insulin signaling is blunted yet lipogenesis is increased, a 
phenomenon observed in type 2 diabetes. To examine the complex 
PANDER-induced mechanism of SHIR, we utilized quantitative mass 
spectrometry based proteomic analysis using Stable Isotope 
Labeling by Amino Acids in Cell Culture (SILAC) as a heuristic 
technique to reveal the global hepatic proteome differences 
within the PANTG under the metabolic states of fasting, fed and 
insulin-stimulated conditions. 3304 hepatic proteins were 
identified with analysis comparing PANTG versus wild-type 
hepatic proteomes within a specific metabolic condition. Of 
those, there were 228, 239 and 189 differentially expressed 
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proteins in the fasted, fed and insulin-stimulated conditions 
within the PANTG liver as compared to WT, respectively, as 
determined by the Significance A outlier test in Perseus 
(P<0.05, N=3, combined prior to outlier test). 
Materials and Methods 
Generation of the Pander Transgenic Animal Colony 
The Fam3b (PANDER) gene cloned into the pCR2.1 cloning vector 
(Life Technologies) was kindly provided by GlaxoSmithKline. The 
PANDER gene was excised and ligated downstream of the Pdx1 
promoter which drives the expression exclusively in the 
endocrine tissue of the pancreas. This vector was obtained from 
Dr. Maureen Gannon, Vanderbilt University. B6SJLF (strain 
generated from a cross between C57BL/6J females and SJL/J males) 
transgenic mice were produced according to the protocol of the 
University of Pennsylvania Transgenic and Chimeric Mouse 
Facility. During the course of this investigation, the 
laboratory and animal colony were moved to the University of 
South Florida (USF) from the Children's Hospital of 
Philadelphia. Frozen embryos of the PANTG were shipped to the 
Moffitt Stabile Vivarium on the campus of USF and implanted into 
pseudo pregnant females for subsequent rederivation of murine 
colony. Animals were fed standard chow from Purina and given 
water ad libitum. All animals were handled according to the 
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guidelines established by the Institutional Animal Care and Use 
Committee at the University of South Florida and Children's 
Hospital of Philadelphia before relocation. Offspring were 
screened by PCR to confirm transgenic integration using primers 
specific (forward 5′-GCT GGA CAG GGG CAC GTC AGG AAT GAG CTC-3′ 
and reverse 5′-TAC TCT GAG TCC AAA CCG GGC CCC TCT GCT-3′) for 
the β-globin intron and PANDER transgene resulting in a 300 bp 
transgene-specific PCR product amplified from genomic DNA 
isolated from tail tissue (DNeasy Kit, Qiagen). All animals were 
born normally at the expected Mendelian frequency. Male mice 
aged 4 to 6 weeks were evaluated in this study and an effort was 
made to match mice by liter mates. Relative PANDER expression 
was determined by RT-PCR and western analysis (FIG). 
Metabolic Treatment of The Pander Transgenic Mouse 
The PANTG and wild-type mice were exposed to fasted, fed, and 
insulin stimulatory conditions prior to liver extraction and 
subsequent proteomic examination. All treatments were performed 
on PANTG and wild-type mice at six weeks of age. Fed and fasted 
mice were withheld from food for approximately 4 and 16 hours, 
respectively.  Following the 4 hour fast, fed mice were provided 
with chow ad-libitum for 2 hours. Insulin-stimulated mice were 
fasted for 4 hours prior to insulin injection (Humulin®, 1 
unit/kg). Insulin was diluted to a concentration of 20 units/ml 
and injected intraperitoneally with exposure for 15 minutes. 
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Mice were humanely euthanized by carbon dioxide asphyxiation and 
cervical dislocation following above described metabolic 
conditions. Livers were extracted immediately following exposure 
to described metabolic conditions, snap frozen and stored at -
80°C prior to proteomic analysis. 
Hepatic Protein Isolation 
Approximately 40 mg of tissue was excised from a lobe of mouse 
liver for tissue lysis. Tissue was submerged in cold lysis 
buffer (100mM Tris-HCl, 100mM DTT, 4% SDS and 1x HALT protease 
inhibitor) and homogenized using a Qiagen TissueRupter. Cell 
lysate was then heated at 95°C for five minutes followed by 
brief sonication. The tissue lysate was cleared by 
centrifugation at 16000 × g for 5 min and the supernatant was 
collected and stored at -80°C prior to further analysis. The 
same procedure for protein purification was performed on the 
“heavy” labeled (13C6 L-Lysine) murine male liver (MT-LYSC6-ML-PK, 
Cambridge Isotope Laboratories, Inc.). 
Sample Digestion, Desalt, and Scx Fractionation 
Protein concentration was quantified using the Pierce 660 nm 
protein assay kit supplemented with the provided ionic detergent 
compatibility reagent (IDCR). Equal mass of labeled and 
unlabeled protein or “light” and “heavy” protein respectively, 
were combined and digested using the filter-aided sample 
48 
 
preparation (FASP) method (Expedeon). Briefly, 30 µL of the 
protein mixture (~12.5mg/ml) was added to the spin column. The 
lysate buffer was exchanged to 8M urea using centrifugation 
prior to iodoacetamide alkylation and then exchanged to 50 mM 
ammonium bicarbonate for trypsin/Lys-C digestion at a ratio of 
1:40 (w/w). Digestion was carried out overnight in a humidified 
incubator at 37°C. Peptides were eluted off the column by 
addition of 0.5M NaCl followed by centrifugation. Samples were 
desalted using solid phase enrichment C18 columns (The Nest 
Group, Inc.). Briefly, columns were activated using 100% 
acetonitrile followed by equilibration with 0.1% formic acid in 
water. Samples were loaded onto the columns and washed three 
times using equal volumes of 0.1% formic acid in water. Samples 
were eluted using 90% acetonitrile / 0.1% formic acid in water 
and then concentrated in a vacuum concentrator (Thermo) prior to 
resuspension with 5 mM ammonium formate and 25% acetonitrile. 
Peptides were fractionated by strong cation exchange 
chromatography. 
Acquisition of Hepatic Proteome by LC-MS/MS  
Fractions were separated on a 10 cm × 75 µm I.D. reversed phase 
column packed with 5 µm C18 material with 300 Å pore size (New 
Objective) using 125 minute gradients of 2–40% ACN in 0.1% 
formic acid. Inline mass spectrometric analysis was performed on 
an Orbitrap XL (Thermo). Survey scans were performed at a 
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resolving power of 60000, and the top 10 most abundant peaks 
were selected for subsequent MS/MS analysis. 
Database Search for Identification and Quantification of 
Proteins 
Raw files were processed in MaxQuant 1.2.2.5 employing the 
Andromeda search algorithm and searched against the UniprotKB 
reference database for Mus musculus, concatenated with reversed 
protein sequences. A second database of known contaminants 
provided with the MaxQuant suite was also employed. All 
fractions for each biological sample were combined for analysis. 
Constant modification of carbamidomethylation of cysteine and 
variable modifications of oxidized methionine and acetylated 
protein N-termini were used. Additionally, Lys-6 for the spike-
in internal standard was set as a label in the group-specific 
parameter section. A false discovery rate of 1% was used for 
peptides and proteins. A minimum peptide length of 6 amino acids 
was used. Razor and unique peptides were used for identification 
and quantification. Protein ratio values were reconstructed 
using median peptide ratio values across all three biological 
replicates for each experimental group where the final ratio for 
each protein was calculated by determining the ratio-of-ratio 
(PANTG/Internal Standard) / (WT/Internal Standard). Final ratios 
were input into the Perseus processing suite (Perseus version 
1.2.0.13). Statistical analysis was performed using the 
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Significance A outlier test where statistical significance based 
on magnitude fold-change was established at P < 0.05. Ratio 
values and Uniprot Protein identification numbers of 
differentially expressed proteins were uploaded to Ingenuity 
Pathway Analysis (IPA) to determine canonical pathways, networks 
and upstream regulators in the liver affected by increased 
pancreas-secreted PANDER. The complete proteomic dataset, along 
with a modified proteinGroups spreadsheet has been deposited to 
the ProteomeXchange Consortium (http://www.proteomexchange.org) 
via the PRIDE partner repository with dataset identifiers PRIDE: 
PXD004171 and doi:10.6019/PXD004171 [35]. 
Results 
To comprehensively examine the PANDER-induced hepatic proteome, 
we performed SILAC-based quantitative proteomics on our PANTG 
model.  The PANTG mouse is an ideal candidate for our 
comparative investigation due to pancreatic-specific 
overexpression of PANDER resulting in robust increased 
circulating levels as compared to wild-type mice along with 
resultant impaired glucose tolerance, hepatic insulin resistance 
and increased hepatic triglyceride levels [21].  Our 
quantitative proteomic approach was performed on the PANTG model 
in comparison to WT mice in the context of 3 metabolic 
conditions of fasting, fed and insulin-stimulated to examine the 
impact of PANDER across numerous metabolic states.  Following 
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exposure to the various metabolic conditions, livers from PANTG 
and age/gender matched wild-type mice were collected and 
subsequently processed by tryptic digestion, desalting and SCX 
chromatography followed by mass spectrometry as detailed in 
Figure 11. Across all metabolic conditions, the MaxQuant search 
identified a total of 19,423 unique peptides (Complete data 
files deposited to the ProteomeXchange Consortium via the PRIDE 
partner repository with the dataset identifier PXD004171 and 
10.6019/PXD004171, Username: reviewer56976@ebi.ac.uk, Password: 
VtR5rnIR) correlating to a proteome of 3304 proteins identified 
from the liver. The distribution of these proteins in their 
respective metabolic state in the PANTG mouse liver proteome 
compared to that of the wild-type is displayed in Figure 12. Of 
those, there were 228, 239 and 189 significantly differently 
expressed and quantifiable proteins in the fasted, fed and 
insulin-stimulated conditions within the PANTG liver as compared 
to WT, displayed in tables 1, 2, and 3, respectively. 
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Figure 11: SILAC proteomic experimental approach for 
investigation of PANTG. A. & B. Age and gender matched PANTG and 
WT mice at six weeks of age (N=3 per condition) were exposed to 
three metabolic states prior to liver extraction: fed, fasted 
and insulin-stimulated. Livers were immediately extracted 
following exposure to described metabolic conditions, snap-
frozen and stored at −80 °C. C. & D. 40 mg of liver tissue were 
lysed in cold lysis buffer (100 mM Tris-HCl, 100 mM DTT, 4% SDS 
and 1× HALT protease inhibitor) prior to heating at 95 °C for 
five minutes followed by brief sonication. Identical processing 
was performed on livers obtained from metabolically labeled 
“SILAC” mice (Cambridge Isotopes). The “heavy” protein lysate 
was combined with each experimental mouse liver protein lysate 
prior to tryptic digestion utilizing the FASP (Expedeon) method. 
Samples were desalted using solid phase enrichment C18 columns 
(The Nest Group, Inc.). Prior to LC-MS/MS, sample complexity was 
reduced by strong cation exchange chromatography. E. & F. Each 
biological sample was analyzed by tandem mass spectrometry. 
Normalized ratios from MaxQuant for each biological sample were 
inputted into the Perseus processing suite to determine 
statistical significance of quantitation values using 
Significance A outlier test (P<0.05). 
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Figure 12: Distribution of proteins across metabolic conditions. 
Identification of unique proteins across metabolic states in the 
PANTG mouse liver. SILAC spike in fractionated protein extracts 
were analyzed by LC-MS/MS from age- and gender-matched wild-type 
and PANTG mice (N=3 per metabolic condition and genotype). 
Approximately 3300 proteins were confidently revealed that were 
shared across genotype and metabolic conditions with overlap 
indicated in Venn diagram. 
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Table 1: Differentially expressed proteins in the fasted state. 
Differentially expressed proteins (P<0.05 in a Significance A 
outlier test) in the PANTG liver compared to the wild type (n=3 
for each). See methods for metabolic treatment (Pages 54-61). 
Exp Fold 
Change 
ID Symbol Entrez Gene Name 
267.090 E9Q6Z0 CUL5 cullin 5 
9.844 Q8BFW7 LPP LIM domain containing preferred 
translocation partner in lipoma 
6.164 O08663 METAP2 methionyl aminopeptidase 2 
5.711 Q3TKD0 TNPO1 transportin 1 
4.723 P49586 PCYT1A phosphate cytidylyltransferase 1, 
choline, alpha 
4.203 Q9D1P4 CHORDC1 cysteine and histidine-rich domain 
(CHORD) containing 1 
4.004 P58467 SETD4 SET domain containing 4 
3.595 P58281 OPA1 optic atrophy 1 (autosomal dominant) 
3.476 Q9R099 TBL2 transducin (beta)-like 2 
3.449 Q8BYU6 TOR1AIP2 torsin A interacting protein 2 
3.403 B1AU76 NASP nuclear autoantigenic sperm protein 
(histone-binding) 
3.284 D3Z5G7 Ces1b/Ces1c carboxylesterase 1C 
3.179 P62960 YBX1 Y box binding protein 1 
3.014 Q01279 EGFR epidermal growth factor receptor 
2.976 O35350 CAPN1 calpain 1, (mu/I) large subunit 
2.835 Q01339 APOH apolipoprotein H (beta-2-glycoprotein 
I) 
2.735 Q9R0Q6 ARPC1A actin related protein 2/3 complex, 
subunit 1A, 41kDa 
2.698 A3KGU5 SPTAN1 spectrin, alpha, non-erythrocytic 1 
2.548 E9PVM7 GSTM3 glutathione S-transferase mu 3 (brain) 
2.537 P01872 IGHM immunoglobulin heavy constant mu 
2.478 Q9CRT8 XPOT exportin, tRNA 
2.467 P23953 Ces1b/Ces1c carboxylesterase 1C 
2.395 P01868 IGHG1 immunoglobulin heavy constant gamma 1 
(G1m marker) 
2.391 P14901 HMOX1 heme oxygenase 1 
2.366 O35857 TIMM44 translocase of inner mitochondrial 
membrane 44 homolog (yeast) 
2.336 Q9JJU9 CRYBB3 crystallin, beta B3 
2.316 P01029 C4A/C4B complement component 4B (Chido blood 
group) 
2.298 Q8K4H1 AFMID arylformamidase 
2.229 Q8BLN5 LSS lanosterol synthase (2,3-oxidosqualene-
lanosterol cyclase) 
2.222 Q99LM2 CDK5RAP3 CDK5 regulatory subunit associated 
protein 3 
2.175 Q00898 SERPINA1 serpin peptidase inhibitor, clade A 
(alpha-1 antiproteinase, antitrypsin), 
member 1 
2.172 Q9JLC3 MSRB1 methionine sulfoxide reductase B1 
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Table 1 (Continued) 
Exp Fold 
Change 
ID Symbol Entrez Gene Name 
2.172 Q71KU9 FGL1 fibrinogen-like 1 
2.133 P04919 SLC4A1 solute carrier family 4 (anion 
exchanger), member 1 (Diego blood 
group) 
2.085 Q9R1J0 NSDHL NAD(P) dependent steroid dehydrogenase-
like 
2.057 K3W4Q8 BSG basigin (Ok blood group) 
2.042 Q9R1Q6 TMEM176B transmembrane protein 176B 
2.001 Q9D6T0 NOSIP nitric oxide synthase interacting 
protein 
1.981 P06728 APOA4 apolipoprotein A-IV 
1.978 Q9DCT8 Crip2 cysteine rich protein 2 
1.929 P15327 BPGM 2,3-bisphosphoglycerate mutase 
1.925 P04104 KRT1 keratin 1, type II 
1.874 D3YUW7 CGN cingulin 
1.857 P08122 COL4A2 collagen, type IV, alpha 2 
1.849 Q8VCR2 HSD17B13 hydroxysteroid (17-beta) dehydrogenase 
13 
1.844 P00920 CA2 carbonic anhydrase II 
1.841 Q9QXK7 CPSF3 cleavage and polyadenylation specific 
factor 3, 73kDa 
1.830 J3QMN4 TXNRD2 thioredoxin reductase 2 
1.816 P28666 Mug1/Mug2 murinoglobulin 1 
1.807 Q00623 APOA1 apolipoprotein A-I 
1.805 Q8CIN4 PAK2 p21 protein (Cdc42/Rac)-activated 
kinase 2 
1.803 Q8CHW4 EIF2B5 eukaryotic translation initiation 
factor 2B, subunit 5 epsilon, 82kDa 
1.803 Q9CQ01 RNASET2 ribonuclease T2 
1.801 E9PV24 FGA fibrinogen alpha chain 
1.748 Q99K23 UFSP2 UFM1-specific peptidase 2 
1.740 P97311 MCM6 minichromosome maintenance complex 
component 6 
1.729 Q6P1D5 SEZ6L seizure related 6 homolog (mouse)-like 
1.728 P13634 CA1 carbonic anhydrase I 
1.712 Q8K0E8 FGB fibrinogen beta chain 
1.692 P07759 SERPINA3 serpin peptidase inhibitor, clade A 
(alpha-1 antiproteinase, antitrypsin), 
member 3 
1.676 Q8K310 MATR3 matrin 3 
1.657 Q9DBE0 CSAD cysteine sulfinic acid decarboxylase 
1.647 Q6P2B1 TNPO3 transportin 3 
1.640 Q6ZQ58 LARP1 La ribonucleoprotein domain family, 
member 1 
1.639 E9Q509 PKLR pyruvate kinase, liver and RBC 
1.622 P01837 IGKC immunoglobulin kappa constant 
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Table 1 (Continued) 
Exp Fold 
Change 
ID Symbol Entrez Gene Name 
1.614 Q9CQC6 BZW1 basic leucine zipper and W2 domains 1 
1.601 Q8K1J6 TRNT1 tRNA nucleotidyl transferase, CCA-
adding, 1 
1.594 Q9JJ28 FLII flightless I actin binding protein 
1.592 P60670 NPLOC4 NPL4 homolog, ubiquitin recognition 
factor 
1.591 Q921M3 SF3B3 splicing factor 3b, subunit 3, 130kDa 
1.586 Q9DBM2 EHHADH enoyl-CoA, hydratase/3-hydroxyacyl CoA 
dehydrogenase 
1.577 Q5SWU9 ACACA acetyl-CoA carboxylase alpha 
1.565 P01867 Ighg2b immunoglobulin heavy constant gamma 2B 
1.562 P20918 PLG plasminogen 
1.561 Q8BJL9 UGT2B7 UDP glucuronosyltransferase 2 family, 
polypeptide B7 
1.556 Q9D379 EPHX1 epoxide hydrolase 1, microsomal 
(xenobiotic) 
1.551 Q91VW5 GOLGA4 golgin A4 
1.550 Q8R480 NUP85 nucleoporin 85kDa 
1.548 P07309 TTR transthyretin 
1.545 Q8BL66 EEA1 early endosome antigen 1 
1.535 P61358 RPL27 ribosomal protein L27 
1.528 Q61171 PRDX2 peroxiredoxin 2 
1.522 A2A977 CYP4A11 cytochrome P450, family 4, subfamily A, 
polypeptide 11 
1.518 Q99J99 MPST mercaptopyruvate sulfurtransferase 
1.515 Q9CXI3 MOXD1 monooxygenase, DBH-like 1 
1.508 Q99PV0 PRPF8 pre-mRNA processing factor 8 
1.505 P26883 FKBP1A FK506 binding protein 1A, 12kDa 
1.503 E9QN99 ABHD14B abhydrolase domain containing 14B 
1.503 P29699 AHSG alpha-2-HS-glycoprotein 
1.499 D3Z3S1 PREB prolactin regulatory element binding 
1.492 P43883 PLIN2 perilipin 2 
 
1.489 
 
P23591 
 
TSTA3 
 
tissue specific transplantation antigen 
P35B 
1.486 E9QKL6 IFI16 interferon, gamma-inducible protein 16 
1.486 Q8K0U4 HSPA12A heat shock 70kDa protein 12A 
1.485 Q64435 UGT1A6 UDP glucuronosyltransferase 1 family, 
polypeptide A6 
1.484 D3YTY9 KNG1 kininogen 1 
1.480 Q8C1A5 THOP1 thimet oligopeptidase 1 
1.478 Q91X72 HPX hemopexin 
1.473 E9QA63 Macf1 microtubule-actin crosslinking factor 1 
1.470 P09528 FTH1 ferritin, heavy polypeptide 1 
1.469 Q9CQW9 IFITM3 interferon induced transmembrane 
protein 3 
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Table 1 (Continued) 
Exp Fold 
Change 
ID Symbol Entrez Gene Name 
1.469 Q9DCY0 Keg1 kidney expressed gene 1 
1.467 Q5SUH7 CLINT1 clathrin interactor 1 
1.465 Q8VCM7 FGG fibrinogen gamma chain 
1.463 Q91XL1 LRG1 leucine-rich alpha-2-glycoprotein 1 
1.458 Q9D0E1 HNRNPM heterogeneous nuclear ribonucleoprotein 
M 
1.455 P19096 FASN fatty acid synthase 
1.446 P24457 Cyp2d9  cytochrome P450, family 2, subfamily d, 
polypeptide 9 
1.437 Q61838 Pzp pregnancy zone protein 
1.430 Q9EP72 EMC7 ER membrane protein complex subunit 7 
1.426 A2ALV1 SH3GL2 SH3-domain GRB2-like 2 
1.425 Q8BXA1 GOLIM4 golgi integral membrane protein 4 
1.423 P48193 EPB41 erythrocyte membrane protein band 4.1 
1.422 Q9Z1D1 EIF3G eukaryotic translation initiation 
factor 3, subunit G 
1.422 P46935 Nedd4 neural precursor cell expressed, 
developmentally down-regulated 4 
1.422 P07724 ALB albumin 
1.422 Q810B6 ANKFY1 ankyrin repeat and FYVE domain 
containing 1 
1.421 Q8VBV7 COPS8 COP9 signalosome subunit 8 
1.418 Q5SW19 CLUH clustered mitochondria (cluA/CLU1) 
homolog 
1.417 Q9QXG4 ACSS2 acyl-CoA synthetase short-chain family 
member 2 
1.410 E9PZJ8 ASCC3 activating signal cointegrator 1 
complex subunit 3 
1.407 E0CYY1 CIAPIN1 cytokine induced apoptosis inhibitor 1 
1.407 Q9D6S7 MRRF mitochondrial ribosome recycling factor 
1.405 Q3UZ39 LRRFIP1 leucine rich repeat (in FLII) 
interacting protein 1 
1.399 Q64505 CYP7A1 cytochrome P450, family 7, subfamily A, 
polypeptide 1 
1.396 P28665 Mug1/Mug2 murinoglobulin 1 
1.395 Q9CY64 BLVRA biliverdin reductase A 
-1.356 Q9D1M0 SEC13 SEC13 homolog, nuclear pore and COPII 
coat complex component 
-1.359 Q8VCC1 HPGD hydroxyprostaglandin dehydrogenase 15-
(NAD) 
-1.361 P17879 Hspa1b heat shock protein 1B 
-1.367 P26645 Marcks myristoylated alanine rich protein 
kinase C substrate 
-1.373 Q61735 CD47 CD47 molecule 
-1.374 Q9JHJ0 TMOD3 tropomodulin 3 (ubiquitous) 
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Table 1 (Continued) 
Exp Fold 
Change 
ID Symbol Entrez Gene Name 
-1.383 Q8BK30 NDUFV3 NADH dehydrogenase (ubiquinone) 
flavoprotein 3, 10kDa 
-1.383 Q9ERR7 SEP15 15 kDa selenoprotein 
-1.384 Q8BH59 SLC25A12 solute carrier family 25 
(aspartate/glutamate carrier), member 
12 
-1.384 P50516 ATP6V1A ATPase, H+ transporting, lysosomal 
70kDa, V1 subunit A 
-1.384 P70671 IRF3 interferon regulatory factor 3 
-1.386 Q9D967 MDP1 magnesium-dependent phosphatase 1 
-1.394 Q3UID0 SMARCC2 SWI/SNF related, matrix associated, 
actin dependent regulator of chromatin, 
subfamily c, member 2 
-1.396 P24456 Cyp2d9 
(includes 
others) 
cytochrome P450, family 2, subfamily d, 
polypeptide 9 
-1.405 Q8VC97 UPB1 ureidopropionase, beta 
-1.408 Q9D517 AGPAT3 1-acylglycerol-3-phosphate O-
acyltransferase 3 
-1.411 Q9WUM3 CORO1B coronin, actin binding protein, 1B 
-1.415 Q60710 SAMHD1 SAM domain and HD domain 1 
-1.416 E9Q557 DSP desmoplakin 
-1.416 P61750 ARF4 ADP-ribosylation factor 4 
-1.416 P63321 RALA v-ral simian leukemia viral oncogene 
homolog A (ras related) 
-1.417 Q9R112 SQRDL sulfide quinone reductase-like (yeast) 
-1.419 F6U2C2 ATXN2 ataxin 2 
-1.422 A2AN08 UBR4 ubiquitin protein ligase E3 component 
n-recognin 4 
-1.422 P47754 CAPZA2 capping protein (actin filament) muscle 
Z-line, alpha 2 
-1.430 E9Q4G8 ALCAM activated leukocyte cell adhesion 
molecule 
-1.433 E9QAS4 CHD4 chromodomain helicase DNA binding 
protein 4 
-1.442 E9Q8N1 TTN titin 
-1.452 Q99KJ8 DCTN2 dynactin 2 (p50) 
-1.453 F8WJK8 ST13 suppression of tumorigenicity 13 (colon 
carcinoma) (Hsp70 interacting protein) 
-1.455 Q9JJU8 SH3BGRL SH3 domain binding glutamate-rich 
protein like 
-1.457 E9PXX7 TXNDC5 thioredoxin domain containing 5 
(endoplasmic reticulum) 
-1.462 Q2TPA8 Hsdl2 hydroxysteroid dehydrogenase like 2 
-1.469 Q3TH01 HLA-A major histocompatibility complex, class 
I, A 
-1.471 Q61879 MYH10 myosin, heavy chain 10, non-muscle 
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Table 1 (Continued) 
Exp Fold 
Change 
ID Symbol Entrez Gene Name 
-1.487 Q61990 PCBP2 poly(rC) binding protein 2 
-1.488 Q9R257 HEBP1 heme binding protein 1 
-1.489 Q3U0V1 KHSRP KH-type splicing regulatory protein 
-1.494 P50518 ATP6V1E1 ATPase, H+ transporting, lysosomal 
31kDa, V1 subunit E1 
-1.495 Q9JLJ5 ELOVL1 ELOVL fatty acid elongase 1 
-1.495 Q920A5 SCPEP1 serine carboxypeptidase 1 
-1.512 P08752 GNAI2 guanine nucleotide binding protein (G 
protein), alpha inhibiting activity 
polypeptide 2 
-1.524 Q7TMF3 NDUFA12 NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 12 
-1.537 Q9D1Q6 ERP44 endoplasmic reticulum protein 44 
-1.549 P28659 Celf1 CUGBP, Elav-like family member 1 
-1.550 Q8VHE0 SEC63 SEC63 homolog, protein translocation 
regulator 
-1.556 Q8VCH6 DHCR24 24-dehydrocholesterol reductase 
-1.574 Q924Z4 CERS2 ceramide synthase 2 
-1.584 P11930 NUDT19 nudix (nucleoside diphosphate linked 
moiety X)-type motif 19 
-1.589 Q07456 AMBP alpha-1-microglobulin/bikunin precursor 
-1.596 P97855 G3BP1 GTPase activating protein (SH3 domain) 
binding protein 1 
-1.623 A6X935 ITIH4 inter-alpha-trypsin inhibitor heavy 
chain family, member 4 
-1.631 Q921L6 CTTN cortactin 
-1.633 F8VPN4 AGL amylo-alpha-1, 6-glucosidase, 4-alpha-
glucanotransferase 
-1.646 Q3B7Z2 OSBP oxysterol binding protein 
-1.647 E9Q8K8 ZC3H4 zinc finger CCCH-type containing 4 
-1.650 P45376 AKR1B1 aldo-keto reductase family 1, member B1 
(aldose reductase) 
-1.651 P50462 CSRP3 cysteine and glycine-rich protein 3 
(cardiac LIM protein) 
-1.657 E9Q6R7 UTRN utrophin 
-1.668 P14094 ATP1B1 ATPase, Na+/K+ transporting, beta 1 
polypeptide 
-1.679 Q8VCC2 Ces1g carboxylesterase 1G 
-1.682 Q8BWM0 PTGES2 prostaglandin E synthase 2 
-1.690 P97792 CXADR coxsackie virus and adenovirus receptor 
-1.691 Q11136 PEPD peptidase D 
-1.694 P27612 PLAA phospholipase A2-activating protein 
-1.716 A2AJK8 TTC1 tetratricopeptide repeat domain 1 
-1.723 P02802 Mt1 metallothionein 1 
-1.792 Q8R0W0 EPPK1 epiplakin 1 
-1.810 Q8R1S9 SLC38A4 solute carrier family 38, member 4 
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Exp Fold 
Change 
ID Symbol Entrez Gene Name 
-1.826 H3BJ51 RETSAT retinol saturase (all-trans-retinol 
13,14-reductase) 
-1.866 Q9R092 HSD17B6 hydroxysteroid (17-beta) dehydrogenase 
6 
-1.933 Q9JI75 NQO2 NAD(P)H dehydrogenase, quinone 2 
-1.977 Q8JZK9 HMGCS1 3-hydroxy-3-methylglutaryl-CoA synthase 
1 (soluble) 
-2.006 Q9EP89 LACTB lactamase, beta 
-2.050 Q9JHG7 PIK3CG phosphatidylinositol-4,5-bisphosphate 
3-kinase, catalytic subunit gamma 
-2.098 Q9JKB1 UCHL3 ubiquitin carboxyl-terminal esterase L3 
(ubiquitin thiolesterase) 
-2.127 Q9D5T0 ATAD1 ATPase family, AAA domain containing 1 
-2.134 Q5XG73 ACBD5 acyl-CoA binding domain containing 5 
-2.163 P16546 SPTAN1 spectrin, alpha, non-erythrocytic 1 
-2.362 Q9D8Y0 EFHD2 EF-hand domain family, member D2 
-2.385 Q9Z329 ITPR2 inositol 1,4,5-trisphosphate receptor, 
type 2 
-2.391 Q9CQH7 BTF3L4 basic transcription factor 3-like 4 
-2.481 Q9JLI6 SCLY selenocysteine lyase 
-2.623 P14115 RPL27A ribosomal protein L27a 
-2.649 Q9CWL8 CTNNBL1 catenin, beta like 1 
-2.838 P35278 RAB5C RAB5C, member RAS oncogene family 
-2.888 Q9QYC0 ADD1 adducin 1 (alpha) 
-2.897 Q99MR6 SRRT serrate, RNA effector molecule 
-3.083 P02463 COL4A1 collagen, type IV, alpha 1 
-3.154 Q8R1J1 TM6SF2 transmembrane 6 superfamily member 2 
-3.171 Q8CCJ3 UFL1 UFM1-specific ligase 1 
-3.252 P61089 UBE2N ubiquitin-conjugating enzyme E2N 
-3.757 Q9Z2G9 HTATIP2 HIV-1 Tat interactive protein 2, 30kDa 
-3.758 D3YVR4 MESDC2 mesoderm development candidate 2 
-3.898 Q3THK7 GMPS guanine monophosphate synthase 
-4.233 Q9QYI4 DNAJB12 DnaJ (Hsp40) homolog, subfamily B, 
member 12 
-4.307 O35226 PSMD4 proteasome 26S subunit, non-ATPase 4 
-4.407 Q8BH78 RTN4 reticulon 4 
-4.492 Q99J77 NANS N-acetylneuraminic acid synthase 
-4.706 P60229 EIF3E eukaryotic translation initiation 
factor 3, subunit E 
-4.966 Q9EQF5 DPYS dihydropyrimidinase 
-5.054 E9PXN7 UGT1A7 
(includes 
others) 
UDP glucuronosyltransferase 1 family, 
polypeptide A10 
-5.710 Q91WC0 SETD3 SET domain containing 3 
-6.314 B1AZ15 COBLL1 cordon-bleu WH2 repeat protein-like 1 
 
61 
 
Table 1 (Continued) 
Exp Fold 
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ID Symbol Entrez Gene Name 
-6.517 P97370 ATP1B3 ATPase, Na+/K+ transporting, beta 3 
polypeptide 
-7.087 P10922 H1F0 H1 histone family, member 0 
-7.152 Q9CZW5 TOMM70A translocase of outer mitochondrial 
membrane 70 homolog A (S. cerevisiae) 
-7.326 P48024 Eif1 eukaryotic translation initiation 
factor 1 
-9.811 Q91XV3 BASP1 brain abundant, membrane attached 
signal protein 1 
-12.682 Q80W54 ZMPSTE24 zinc metallopeptidase STE24 
-19.627 Q8R016 BLMH bleomycin hydrolase 
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Table 2: Differentially expressed proteins in the fed state. 
Differentially expressed proteins (P<0.05 in a Significance A 
outlier test) in the PANTG liver compared to the wild type (n=3 
for each). See methods for metabolic treatment (Pages 62-68). 
Exp Fold 
Change 
ID Symbol Entrez Gene Name 
28.351 Q8R1S9 SLC38A4 solute carrier family 38, member 4 
10.609 P62960 YBX1 Y box binding protein 1 
9.943 Q61655 DDX19A DEAD (Asp-Glu-Ala-Asp) box polypeptide 
19A 
7.023 P58044 IDI1 isopentenyl-diphosphate delta isomerase 1 
6.515 Q9ESX5 DKC1 dyskeratosis congenita 1, dyskerin 
5.497 Q8BH78 RTN4 reticulon 4 
5.266 Q3UJB0 SF3B2 splicing factor 3b, subunit 2, 145kDa 
4.886 Q9JKF1 IQGAP1 IQ motif containing GTPase activating 
protein 1 
4.169 Q11136 PEPD peptidase D 
3.783 Q9Z2G9 HTATIP2 HIV-1 Tat interactive protein 2, 30kDa 
3.415 Q14DH7 ACSS3 acyl-CoA synthetase short-chain family 
member 3 
3.376 Q8VHE0 SEC63 SEC63 homolog, protein translocation 
regulator 
3.082 Q9DCT8 Crip2 cysteine rich protein 2 
2.822 Q9CW03 SMC3 structural maintenance of chromosomes 3 
2.629 Q9CZW5 TOMM70A translocase of outer mitochondrial 
membrane 70 homolog A 
(S. cerevisiae) 
2.457 Q9CY64 BLVRA biliverdin reductase A 
2.267 Q8R0V5 IDO2 indoleamine 2,3-dioxygenase 2 
2.200 Q3TKD0 TNPO1 transportin 1 
2.186 Q99J77 NANS N-acetylneuraminic acid synthase 
2.170 Q7TPV4 MYBBP1A MYB binding protein (P160) 1a 
2.158 P43883 PLIN2 perilipin 2 
2.156 Q9CQE8 C14orf166 chromosome 14 open reading frame 166 
2.143 O08529 CAPN2 calpain 2, (m/II) large subunit 
2.061 Q9CQ80 VPS25 vacuolar protein sorting 25 homolog (S. 
cerevisiae) 
2.030 D3YXZ7 SLC35A3 solute carrier family 35 (UDP-N-
acetylglucosamine (UDP-GlcNAc) 
transporter), member A3 
1.995 Q8VCH0 Acaa1b acetyl-Coenzyme A acyltransferase 1B 
1.969 Q5FW60 Mup1  major urinary protein 1 
1.943 Q9JIK5 DDX21 DEAD (Asp-Glu-Ala-Asp) box helicase 21 
1.914 Q921S7 MRPL37 mitochondrial ribosomal protein L37 
1.897 Q8BK64 AHSA1 AHA1, activator of heat shock 90kDa 
protein ATPase homolog 1 (yeast) 
1.896 Q9JJU8 SH3BGRL SH3 domain binding glutamate-rich protein 
like 
1.853 Q8VCI0 PLBD1 phospholipase B domain containing 1 
1.845 B7ZDD7 CRAT carnitine O-acetyltransferase 
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Table 2 (Continued) 
Exp Fold 
Change 
ID Symbol Entrez Gene Name 
1.827 Q3UZZ6 Sult1d1 sulfotransferase family 1D, member 1 
1.824 Q9JLV1 BAG3 BCL2-associated athanogene 3 
1.773 Q711T7 NADSYN1 NAD synthetase 1 
1.766 Q99JI6 RAP1B RAP1B, member of RAS oncogene family 
1.765 Q8VCC2 Ces1g carboxylesterase 1G 
1.762 Q8R0H9 GGA1 golgi-associated, gamma adaptin ear 
containing, ARF binding protein 1 
1.741 Q8R0J8 IDNK idnK, gluconokinase homolog (E. coli) 
1.720 Q91WG0 Ces2c carboxylesterase 2C 
1.687 Q3TP97 TARS2 threonyl-tRNA synthetase 2, mitochondrial 
(putative) 
1.685 Q5SQB0 NPM1 nucleophosmin (nucleolar phosphoprotein 
B23, numatrin) 
1.684 E9PZJ8 ASCC3 activating signal cointegrator 1 complex 
subunit 3 
1.680 Q61635 Ifi47 interferon gamma inducible protein 47 
1.648 F6RWR5 BC021614 cDNA sequence BC021614 
1.621 P15208 INSR insulin receptor 
1.614 Q8CEB6 AKR1E2 aldo-keto reductase family 1, member E2 
1.612 D3YYD5 VPS29 VPS29 retromer complex component 
1.610 G5E8X1 C16orf13 chromosome 16 open reading frame 13 
1.603 E9Q8N1 TTN titin 
1.599 E9PVM7 GSTM3 glutathione S-transferase mu 3 (brain) 
1.579 P42703 LIFR leukemia inhibitory factor receptor alpha 
1.578 Q8C8T8 TSR2 TSR2, 20S rRNA accumulation, homolog (S. 
cerevisiae) 
1.564 Q8JZK9 HMGCS1 3-hydroxy-3-methylglutaryl-CoA synthase 1 
(soluble) 
1.554 Q60737 CSNK2A1 casein kinase 2, alpha 1 polypeptide 
1.554 Q9D967 MDP1 magnesium-dependent phosphatase 1 
1.549 Q8CHW4 EIF2B5 eukaryotic translation initiation factor 
2B, subunit 5 epsilon, 82kDa 
1.546 Q8BGC4 ZADH2 zinc binding alcohol dehydrogenase domain 
containing 2 
1.530 P19096 FASN fatty acid synthase 
1.528 P54823 DDX6 DEAD (Asp-Glu-Ala-Asp) box helicase 6 
1.525 G5E8M7 Gstm6 glutathione S-transferase, mu 6 
1.518 Q3V117 ACLY ATP citrate lyase 
1.515 Q8BK30 NDUFV3 NADH dehydrogenase (ubiquinone) 
flavoprotein 3, 10kDa 
1.487 Q8CFB8 PARP3 poly (ADP-ribose) polymerase family, 
member 3 
1.478 F8WIT2 ANXA6 annexin A6 
1.477 O08738 CASP6 caspase 6, apoptosis-related cysteine 
peptidase 
1.471 O88325 NAGLU N-acetylglucosaminidase, alpha 
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Exp Fold 
Change 
ID Symbol Entrez Gene Name 
1.466 Q5HZI1 MTUS1 microtubule associated tumor suppressor 1 
1.457 P63073 EIF4E eukaryotic translation initiation factor 
4E 
1.457 Q9D023 MPC2 mitochondrial pyruvate carrier 2 
1.447 E9QAA5 SMPD4 sphingomyelin phosphodiesterase 4, 
neutral membrane (neutral 
sphingomyelinase-3) 
1.431 Q9JI78 NGLY1 N-glycanase 1 
1.429 B1AU76 NASP nuclear autoantigenic sperm protein 
(histone-binding) 
1.426 Q9EQF5 DPYS dihydropyrimidinase 
1.409 P24472 Gsta4 glutathione S-transferase, alpha 4 
1.407 Q91WS4 BHMT2 betaine—homocysteine S-methyltransferase 
2 
1.402 E9Q7G0 NUMA1 nuclear mitotic apparatus protein 1 
1.399 F6YBC9 CSNK1A1 casein kinase 1, alpha 1 
1.387 Q8C165 PM20D1 peptidase M20 domain containing 1 
1.382 Q9R099 TBL2 64ransducing (beta)-like 2 
1.378 Q99KR3 LACTB2 lactamase, beta 2 
1.377 P28650 ADSSL1 adenylosuccinate synthase like 1 
1.377 P01887 B2M beta-2-microglobulin 
1.374 Q9Z1P6 NDUFA7 NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 7, 14.5kDa 
1.373 Q8VE38 OXNAD1 oxidoreductase NAD-binding domain 
containing 1 
1.369 Q08857 CD36 CD36 molecule (thrombospondin receptor) 
1.367 Q9Z0M5 LIPA lipase A, lysosomal acid, cholesterol 
esterase 
1.365 F8WHU9 ZPR1 ZPR1 zinc finger 
1.360 P70677 CASP3 caspase 3, apoptosis-related cysteine 
peptidase 
1.359 Q8BJW6 EIF2A eukaryotic translation initiation factor 
2A, 65kDa 
1.357 Q8VCZ9 PRODH2 proline dehydrogenase (oxidase) 2 
1.357 P06801 ME1 malic enzyme 1, NADP(+)-dependent, 
cytosolic 
1.355 O88736 HSD17B7 hydroxysteroid (17-beta) dehydrogenase 7 
1.352 Q6ZQI3 MLEC malectin 
1.350 Q501J6 DDX17 DEAD (Asp-Glu-Ala-Asp) box helicase 17 
1.341 Q9QXZ6 Slco1a1 solute carrier organic anion transporter 
family, member 1a1 
1.334 B1AUN3 EIF2B3 eukaryotic translation initiation factor 
2B, subunit 3 gamma, 58kDa 
1.334 P62342 SELT selenoprotein T 
1.334 P97494 GCLC glutamate-cysteine ligase, catalytic 
subunit 
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Exp Fold 
Change 
ID Symbol Entrez Gene Name 
1.333 Q9D6S7 MRRF mitochondrial ribosome recycling factor 
1.332 Q8R1S0 COQ6 coenzyme Q6 monooxygenase 
1.329 Q64514 TPP2 tripeptidyl peptidase II 
1.329 O35350 CAPN1 calpain 1, (mu/I) large subunit 
1.328 Q78IK2 USMG5 up-regulated during skeletal muscle 
growth 5 homolog (mouse) 
1.322 Q3UIR3 DTX3L deltex 3 like, E3 ubiquitin ligase 
1.321 Q99L20 Gstt3 glutathione S-transferase, theta 3 
1.319 Q9DCM2 GSTK1 glutathione S-transferase kappa 1 
1.313 F6VK94 TOR1B torsin family 1, member B (torsin B) 
1.311 Q07797 LGALS3BP lectin, galactoside-binding, soluble, 3 
binding protein 
1.310 Q9ER72 CARS cysteinyl-tRNA synthetase 
1.309 Q8C1B7 SEPT11 septin 11 
1.308 Q9CQ54 NDUFC2 NADH dehydrogenase (ubiquinone) 1, 
subcomplex unknown, 2, 14.5kDa 
1.307 P52792 GCK glucokinase (hexokinase 4) 
1.301 Q8R4H7 NAGS N-acetylglutamate synthase 
1.301 Q8BXA1 GOLIM4 golgi integral membrane protein 4 
-1.479 P11276 FN1 fibronectin 1 
-1.480 P26638 SARS seryl-tRNA synthetase 
-1.480 P28658 ATXN10 ataxin 10 
-1.487 Q64511 TOP2B topoisomerase (DNA) II beta 
-1.488 P42669 PURA purine-rich element binding protein A 
-1.489 P12815 PDCD6 programmed cell death 6 
-1.491 Q9WV54 ASAH1 N-acylsphingosine amidohydrolase (acid 
ceramidase) 1 
-1.491 Q8CI94 PYGB phosphorylase, glycogen; brain 
-1.492 Q99MN1 KARS lysyl-tRNA synthetase 
-1.501 Q9WVK4 EHD1 EH-domain containing 1 
-1.505 P06683 C9 complement component 9 
-1.506 Q99KV1 DNAJB11 DnaJ (Hsp40) homolog, subfamily B, member 
11 
-1.507 P06728 APOA4 apolipoprotein A-IV 
-1.515 E9Q555 RNF213 ring finger protein 213 
-1.517 D3YZJ1 SQSTM1 sequestosome 1 
-1.525 D3Z0R5 GNPDA1 glucosamine-6-phosphate deaminase 1 
-1.525 Q9DBB9 CPN2 carboxypeptidase N, polypeptide 2 
-1.527 E9PWQ3 COL6A3 collagen, type VI, alpha 3 
-1.529 Q9EP69 SACM1L SAC1 suppressor of actin mutations 1-like 
(yeast) 
-1.547 P56380 NUDT2 nudix (nucleoside diphosphate linked 
moiety X)-type motif 2 
-1.550 P83940 TCEB1 transcription elongation factor B (SIII), 
polypeptide 1 (15kDa, elongin C) 
 
66 
 
Table 2 (Continued) 
Exp Fold 
Change 
ID Symbol Entrez Gene Name 
-1.551 Q8R0J7 VPS37B vacuolar protein sorting 37 homolog B (S. 
cerevisiae) 
-1.559 Q62165 DAG1 dystroglycan 1 (dystrophin-associated 
glycoprotein 1) 
-1.560 Q8BM72 HSPA13 heat shock protein 70kDa family, member 
13 
-1.568 Q3UNV4 Cyp2j13 cytochrome P450, family 2, subfamily j, 
polypeptide 13 
-1.574 D6RGA3 LPCAT3 lysophosphatidylcholine acyltransferase 3 
-1.577 E9PV24 FGA fibrinogen alpha chain 
-1.581 Q63886 UGT1A1 UDP glucuronosyltransferase 1 family, 
polypeptide A1 
-1.589 Q9JKX3 TFR2 transferrin receptor 2 
-1.592 Q9ESP1 SDF2L1 stromal cell-derived factor 2-like 1 
-1.600 Q91XL1 LRG1 leucine-rich alpha-2-glycoprotein 1 
-1.609 Q8C872 TFRC transferrin receptor 
-1.618 P58389 PPP2R4 protein phosphatase 2A activator, 
regulatory subunit 4 
-1.618 Q99K30 EPS8L2 EPS8-like 2 
-1.626 P08032 SPTA1 spectrin, alpha, erythrocytic 1 
-1.646 P01029 C4A/C4B complement component 4B (Chido blood 
group) 
-1.648 Q62313 Tgoln1 trans-golgi network protein 
-1.660 Q91W64 Cyp2c70 cytochrome P450, family 2, subfamily c, 
polypeptide 70 
-1.663 Q8CCJ3 UFL1 UFM1-specific ligase 1 
-1.669 Q61830 MRC1 mannose receptor, C type 1 
-1.670 P01027 C3 complement component 3 
-1.674 O54984 ASNA1 arsA arsenite transporter, ATP-binding, 
homolog 1 (bacterial) 
-1.695 P25233 NDN necdin, melanoma antigen (MAGE) family 
member 
-1.699 P15508 SPTB spectrin, beta, erythrocytic 
-1.725 Q8JZR2 CRK v-crk avian sarcoma virus CT10 oncogene 
homolog 
-1.726 P04919 SLC4A1 solute carrier family 4 (anion 
exchanger), member 1 (Diego blood group) 
-1.735 P00920 CA2 carbonic anhydrase II 
-1.789 Q9R257 HEBP1 heme binding protein 1 
-1.802 P70194 CLEC4F C-type lectin domain family 4, member F 
-1.805 Q9CQJ6 DENR density-regulated protein 
-1.806 Q91WT8 RBM47 RNA binding motif protein 47 
-1.810 Q8R0X7 SGPL1 sphingosine-1-phosphate lyase 1 
-1.831 Q9R1C7 PRPF40A PRP40 pre-mRNA processing factor 40 
homolog A 
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Exp Fold 
Change 
ID Symbol Entrez Gene Name 
-1.833 Q9QXK7 CPSF3 cleavage and polyadenylation specific 
factor 3, 73kDa 
-1.836 Q9CPX6 ATG3 autophagy related 3 
-1.849 E9Q179 GRSF1 G-rich RNA sequence binding factor 1 
-1.855 Q9D1M7 FKBP11 FK506 binding protein 11, 19 kDa 
-1.856 G5E8J2 ANK1 67nkyrin 1, erythrocytic 
-1.858 P43275 Hist1h1a histone cluster 1, H1a 
-1.859 E9QA15 Cald1 caldesmon 1 
-1.870 Q8CBM2 ASPH aspartate beta-hydroxylase 
-1.903 D3Z2Y7 GPX3 glutathione peroxidase 3 
-1.903 Q99JF5 MVD mevalonate (diphospho) decarboxylase 
-1.911 Q9JLC3 MSRB1 methionine sulfoxide reductase B1 
-1.913 E9Q4K7 KIF13B kinesin family member 13B 
-1.924 P48193 EPB41 erythrocyte membrane protein band 4.1 
-1.928 Q9DAS9 GNG12 guanine nucleotide binding protein (G 
protein), gamma 12 
-1.930 Q9D8B6 FAM210B family with sequence similarity 210, 
member B 
-1.940 Q00896 SERPINA1 serpin peptidase inhibitor, clade A 
(alpha-1 antiproteinase, antitrypsin), 
member 1 
-1.951 Q64282 IFIT1B interferon-induced protein with 
tetratricopeptide repeats 1B 
-1.953 Q8R1Q9 RBKS ribokinase 
-1.971 E9Q6Z0 CUL5 cullin 5 
-1.972 Q80VP1 EPN1 epsin 1 
-2.000 E9Q616 AHNAK AHNAK nucleoprotein 
-2.002 P09813 APOA2 apolipoprotein A-II 
-2.004 Q6IQY5 CEP70 centrosomal protein 70kDa 
-2.010 Q8VCC1 HPGD hydroxyprostaglandin dehydrogenase 15-
(NAD) 
-2.067 Q91YR7 PRPF6 pre-mRNA processing factor 6 
-2.097 G3UZX6 SUMO3 small ubiquitin-like modifier 3 
-2.136 A3KGB4 TBC1D8B TBC1 domain family, member 8B (with GRAM 
domain) 
-2.143 Q91X72 HPX hemopexin 
-2.143 Q80Y55 BSDC1 BSD domain containing 1 
-2.155 B1AZ15 COBLL1 cordon-bleu WH2 repeat protein-like 1 
-2.156 Q8K0Z7 TACO1 translational activator of 
mitochondrially encoded cytochrome c 
oxidase I 
-2.348 P23249 MOV10 Mov10 RISC complex RNA helicase 
-2.380 A2A998 C8A complement component 8, alpha polypeptide 
-2.428 Q9CSU0 RPRD1B regulation of nuclear pre-mRNA domain 
containing 1B 
-2.432 Q7TQD2 TPPP tubulin polymerization promoting protein 
 
68 
 
Table 2 (Continued) 
Exp Fold 
Change 
ID Symbol Entrez Gene Name 
-2.484 P58467 SETD4 SET domain containing 4 
-2.494 Q8BGS1 EPB41L5 erythrocyte membrane protein band 4.1 
like 5 
-2.515 O35226 PSMD4 proteasome 26S subunit, non-ATPase 4 
-2.696 E9Q415 FCGR2B Fc fragment of IgG, low affinity IIb, 
receptor (CD32) 
-2.756 Q8K1Z0 COQ9 coenzyme Q9 
-2.813 P10107 ANXA1 annexin A1 
-2.862 Q64505 CYP7A1 cytochrome P450, family 7, subfamily A, 
polypeptide 1 
-2.994 Q05920 PC pyruvate carboxylase 
-3.063 Q01339 APOH apolipoprotein H (beta-2-glycoprotein I) 
-3.083 Q61646 HP haptoglobin 
-3.094 Q8BM55 TMEM214 transmembrane protein 214 
-3.204 A6X935 ITIH4 inter-alpha-trypsin inhibitor heavy chain 
family, member 4 
-3.296 Q9CY02 Ahsp alpha hemoglobin stabilizing protein 
-3.451 P31001 DES desmin 
-3.566 P48024 Eif1 eukaryotic translation initiation factor 
1 
-3.699 Q3TUE1 FUBP1 far upstream element (FUSE) binding 
protein 1 
-3.729 E9Q852 MLLT4 myeloid/lymphoid or mixed-lineage 
leukemia; translocated to, 4 
-4.531 Q8R1Q8 DYNC1LI1 dynein, cytoplasmic 1, light intermediate 
chain 1 
-4.541 P11031 SUB1 SUB1 homolog, transcriptional regulator 
-6.484 Q8CI51 PDLIM5 PDZ and LIM domain 5 
-6.690 Q9DBE0 CSAD cysteine sulfinic acid decarboxylase 
-7.503 Q3UFF7 LYPLAL1 lysophospholipase-like 1 
-11.102 Q925P2 CEACAM1 carcinoembryonic antigen-related cell 
adhesion molecule 1 (biliary 
glycoprotein) 
-25.054 P00688 AMY2B amylase, alpha 2B (pancreatic) 
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Table 3: Differentially expressed proteins in insulin stimulated 
state. Proteins (P<0.05 in a Significance A outlier test) in the 
PANTG liver compared to the wild type (n=3 for each). See 
methods for metabolic treatment (Pages 69-75). 
Exp Fold 
Change 
ID Symbol Entrez Gene Name 
21.746 Q8BG73 SH3BGRL2 SH3 domain binding glutamate-rich 
protein like 2 
18.470 Q8CI94 PYGB phosphorylase, glycogen; brain 
15.400 Q8BFW7 LPP LIM domain containing preferred 
translocation partner in lipoma 
12.723 P70227 ITPR3 inositol 1,4,5-trisphosphate receptor, 
type 3 
10.300 P09813 APOA2 apolipoprotein A-II 
9.967 P47963 RPL13 ribosomal protein L13 
9.156 P43883 PLIN2 perilipin 2  
6.153 Q8R1S9 SLC38A4 solute carrier family 38, member 4 
5.500 P13516 SCD stearoyl-CoA desaturase (delta-9-
desaturase) 
5.322 Q8VCH0 Acaa1b acetyl-Coenzyme A acyltransferase 1B 
5.077 Q64511 TOP2B topoisomerase (DNA) II beta 
4.938 Q91YS7 MAP2K2 mitogen-activated protein kinase 
kinase 2 
4.832 P06801 ME1 malic enzyme 1, NADP(+)-dependent, 
cytosolic 
3.609 J3QML2 ABCC3 ATP-binding cassette, sub-family C 
(CFTR/MRP), member 3 
3.145 P62960 YBX1 Y box binding protein 1 
3.072 Q64458 CYP2C8 cytochrome P450, family 2, subfamily 
C, polypeptide 8 
2.917 Q99KR3 LACTB2 lactamase, beta 2 
2.897 Q8BJL9 UGT2B7 UDP glucuronosyltransferase 2 family, 
polypeptide B7 
2.894 H3BL34 Ces1e carboxylesterase 1E 
2.856 P47740 ALDH3A2 aldehyde dehydrogenase 3 family, 
member A2 
2.834 Q91X77 Cyp2c54 
(includes 
others) 
cytochrome P450, family 2, subfamily 
c, polypeptide 54 
2.765 Q924Y0 BBOX1 butyrobetaine (gamma), 2-oxoglutarate 
dioxygenase (gamma-butyrobetaine 
hydroxylase) 1 
2.747 Q8VCC2 Ces1g carboxylesterase 1G 
2.698 O54754 AOX1 aldehyde oxidase 1 
2.632 Q8VHE0 SEC63 SEC63 homolog, protein translocation 
regulator 
2.624 P26369 U2AF2 U2 small nuclear RNA auxiliary factor 
2 
2.616 Q9ESX5 DKC1 dyskeratosis congenita 1, dyskerin 
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Table 3 (Continued) 
Exp Fold 
Change 
ID Symbol Entrez Gene Name 
2.609 Q9DBM2 EHHADH enoyl-CoA, hydratase/3-hydroxyacyl CoA 
dehydrogenase 
2.607 Q05D44 EIF5B eukaryotic translation initiation 
factor 5B 
2.561 G3XA17 EIF4G2 eukaryotic translation initiation 
factor 4 gamma, 2 
2.510 Q64459 CYP3A5 cytochrome P450, family 3, subfamily 
A, polypeptide 5 
2.489 P28666 Mug1/Mug2 murinoglobulin 1 
2.450 P24472 Gsta4 glutathione S-transferase, alpha 4 
2.447 D3Z0Z6 ELOVL5 ELOVL fatty acid elongase 5 
2.407 P19096 FASN fatty acid synthase 
2.403 Q91X75 CYP2A6 
(includes 
others) 
cytochrome P450, family 2, subfamily 
A, polypeptide 6 
2.387 Q3UP75 UGT3A1 UDP glycosyltransferase 3 family, 
polypeptide A1 
2.362 Q9Z211 PEX11A peroxisomal biogenesis factor 11 alpha 
2.354 E9PZJ8 ASCC3 activating signal cointegrator 1 
complex subunit 3 
2.336 H7BX26 CEP170 centrosomal protein 170kDa 
2.333 P16015 CA3 carbonic anhydrase III 
2.318 Q91WG0 Ces2c carboxylesterase 2C 
2.286 Q9D6Y9 GBE1 glucan (1,4-alpha-), branching enzyme 
1 
2.245 Q8BFZ9 ERLIN2 ER lipid raft associated 2 
2.204 P40936 INMT indolethylamine N-methyltransferase 
2.192 Q62417 SORBS1 sorbin and SH3 domain containing 1 
2.184 Q6XVG2 Cyp2c54 
(includes 
others) 
cytochrome P450, family 2, subfamily 
c, polypeptide 54 
2.172 Q8BK48 Ces2e carboxylesterase 2E 
2.164 Q8BYU6 TOR1AIP2 torsin A interacting protein 2 
2.157 J3KMG3 MIA3 melanoma inhibitory activity family, 
member 3 
2.146 Q8R480 NUP85 nucleoporin 85kDa 
2.141 P10649 GSTM5 glutathione S-transferase mu 5 
2.126 Q9DBE0 CSAD cysteine sulfinic acid decarboxylase 
2.117 A2ATU0 DHTKD1 dehydrogenase E1 and transketolase 
domain containing 1 
2.035 Q8VCT4 CES1 carboxylesterase 1 
2.029 Q3V117 ACLY ATP citrate lyase 
2.027 P16045 LGALS1 lectin, galactoside-binding, soluble, 
1 
2.016 P19639 Gstm3 glutathione S-transferase, mu 3 
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Table 3 (Continued) 
Exp Fold 
Change 
ID Symbol Entrez Gene Name 
1.997 E9Q509 PKLR pyruvate kinase, liver and RBC 
1.931 P35492 HAL histidine ammonia-lyase 
1.929 Q61133 GSTT2/2B glutathione S-transferase theta 2 ( 
1.925 D3YVR4 MESDC2 mesoderm development candidate 2 
1.923 Q62048 PEA15 phosphoprotein enriched in astrocytes 
15 
1.921 D3Z3E6 TMEM56 transmembrane protein 56 
1.917 Q9WV68 DECR2 2,4-dienoyl CoA reductase 2, 
peroxisomal 
1.890 P55050 FABP2 fatty acid binding protein 2, 
intestinal 
1.888 Q9WV98 TIMM9 translocase of inner mitochondrial 
membrane 9 homolog (yeast) 
1.884 Q80WJ7 MTDH metadherin 
1.864 P13634 CA1 carbonic anhydrase I 
1.856 P54728 RAD23B RAD23 homolog B, nucleotide excision 
repair protein 
1.852 Q921H8 ACAA1 acetyl-CoA acyltransferase 1 
1.839 Q7TSH2 PHKB phosphorylase kinase, beta 
1.829 Q62264 THRSP thyroid hormone responsive 
1.810 Q99L20 Gstt3 glutathione S-transferase, theta 3 
1.805 Q91X70 C6 complement component 6 
1.797 Q91VF2 HNMT histamine N-methyltransferase 
1.792 O88696 CLPP caseinolytic mitochondrial matrix 
peptidase proteolytic subunit 
1.792 Q9CXN7 Pbld2 phenazine biosynthesis-like protein 
domain containing 2 
1.788 Q9D379 EPHX1 epoxide hydrolase 1, microsomal 
(xenobiotic) 
1.785 Q9WUZ9 ENTPD5 ectonucleoside triphosphate 
diphosphohydrolase 5 
1.783 G5E8R3 PC pyruvate carboxylase 
1.780 A2AIH8 PIR pirin (iron-binding nuclear protein) 
1.769 Q9CWS0 DDAH1 dimethylarginine 
dimethylaminohydrolase 1 
1.769 F8VPN4 AGL amylo-alpha-1, 6-glucosidase, 4-alpha-
glucanotransferase 
1.758 Q5FW57 Gm4952 predicted gene 4952 
1.753 P56654 Cyp2c54 
(includes 
others) 
cytochrome P450, family 2, subfamily 
c, polypeptide 54 
1.747 P70362 UFD1L ubiquitin fusion degradation 1 like 
(yeast) 
1.747 P12710 FABP1 fatty acid binding protein 1, liver 
1.733 Q61733 MRPS31 mitochondrial ribosomal protein S31 
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Table 3 (Continued) 
Exp Fold 
Change 
ID Symbol Entrez Gene Name 
1.727 Q91XT4 SEC16B SEC16 homolog B, endoplasmic reticulum 
export factor 
1.726 Q9CQR4 ACOT13 acyl-CoA thioesterase 13 
1.719 Q91WU0 Ces1f carboxylesterase 1F 
1.718 Q8QZR3 Ces2a carboxylesterase 2A 
1.707 Q8VIJ6 SFPQ splicing factor proline/glutamine-rich 
1.706 Q3TI14 MRPS23 mitochondrial ribosomal protein S23 
1.683 Q9DB26 PHYHD1 phytanoyl-CoA dioxygenase domain 
containing 1 
1.680 Q9R0H0 ACOX1 acyl-CoA oxidase 1, palmitoyl 
1.673 Q8K4H1 AFMID arylformamidase 
1.666 G5E8M7 Gstm6 glutathione S-transferase, mu 6 
1.660 P99025 GCHFR GTP cyclohydrolase I feedback 
regulator 
1.651 P55096 ABCD3 ATP-binding cassette, sub-family D 
(ALD), member 3 
1.643 Q8R0V5 IDO2 indoleamine 2,3-dioxygenase 2 
1.642 O70194 EIF3D eukaryotic translation initiation 
factor 3, subunit D 
1.639 Q9QUH0 GLRX glutaredoxin (thioltransferase) 
1.626 Q91V76 C11orf54 chromosome 11 open reading frame 54 
1.616 P16406 ENPEP glutamyl aminopeptidase 
(aminopeptidase A) 
1.597 G3X982 Aox3 aldehyde oxidase 3 
-1.695 P21981 TGM2 transglutaminase 2 
-1.696 Q923D5 WBP11 WW domain binding protein 11 
-1.698 P97855 G3BP1 GTPase activating protein (SH3 domain) 
binding protein 1 
-1.711 P46638 RAB11B RAB11B, member RAS oncogene family 
-1.713 Q3TML0 PDIA6 protein disulfide isomerase family A, 
member 6 
-1.724 Q61247 SERPINF2 serpin peptidase inhibitor, clade F 
(alpha-2 antiplasmin, pigment 
epithelium derived factor), member 2 
-1.727 Q9CRD0 OCIAD1 OCIA domain containing 1 
-1.738 P09528 FTH1 ferritin, heavy polypeptide 1 
-1.739 Q3TDQ1 STT3B STT3B, subunit of the 
oligosaccharyltransferase complex 
(catalytic) 
-1.761 E9PYH3 ETNPPL ethanolamine-phosphate 72hosphor-lyase 
-1.762 P08113 HSP90B1 heat shock protein 90kDa beta (Grp94), 
member 1 
-1.765 P51150 RAB7A RAB7A, member RAS oncogene family 
-1.765 Q61699 HSPH1 heat shock 105kDa/110kDa protein 1 
-1.781 E9QNH6 MYO1B myosin IB  
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Table 3 (Continued) 
Exp Fold 
Change 
ID Symbol Entrez Gene Name 
-1.783 P57716 NCSTN nicastrin  
-1.797 Q9ESP1 SDF2L1 stromal cell-derived factor 2-like 1 
-1.799 Q9QZ85 Iigp1 interferon inducible GTPase 1 
-1.810 Q99KF1 TMED9 transmembrane p24 trafficking protein 
9 
-1.813 P04919 SLC4A1 solute carrier family 4 (anion 
exchanger), member 1 (Diego blood 
group) 
-1.838 P06683 C9 complement component 9 
-1.844 O55137 Acot1 acyl-CoA thioesterase 1 
-1.853 Q64339 ISG15 ISG15 ubiquitin-like modifier 
-1.867 P01867 Ighg2b immunoglobulin heavy constant gamma 2B 
-1.874 Q8CHP5 PYM1 PYM homolog 1, exon junction complex 
associated factor 
-1.878 P14901 HMOX1 heme oxygenase 1 
-1.884 P01837 IGKC immunoglobulin kappa constant 
-1.908 P58021 TM9SF2 transmembrane 9 superfamily member 2 
-1.933 E9PV24 FGA fibrinogen alpha chain 
-1.940 Q8VC97 UPB1 ureidopropionase, beta 
-1.985 Q60991 CYP7B1 cytochrome P450, family 7, subfamily 
B, polypeptide 1 
-2.001 O70400 PDLIM1 PDZ and LIM domain 1 
-2.011 Q9DBG7 SRPR signal recognition particle receptor 
(docking protein) 
-2.015 G3X9T8 CP ceruloplasmin (ferroxidase) 
-2.015 Q9D8B6 FAM210B family with sequence similarity 210, 
member B 
-2.016 P50462 CSRP3 cysteine and glycine-rich protein 3 
(cardiac LIM protein) 
-2.020 P53994 RAB2A RAB2A, member RAS oncogene family 
-2.033 P01027 C3 complement component 3 
-2.034 O35226 PSMD4 proteasome 26S subunit, non-ATPase 4 
-2.047 P70441 SLC9A3R1 solute carrier family 9, subfamily A 
(NHE3, cation proton antiporter 3), 
member 3 regulator 1 
-2.058 Q80ZP8 MANF mesencephalic astrocyte-derived 
neurotrophic factor 
-2.063 Q99NB9 SF3B1 splicing factor 3b, subunit 1, 155kDa 
-2.066 Q8K0E8 FGB fibrinogen beta chain 
-2.131 P01029 C4A/C4B complement component 4B (Chido blood 
group) 
-2.165 Q8BLN5 LSS lanosterol synthase (2,3-
oxidosqualene-lanosterol cyclase) 
-2.167 Q9CQJ6 DENR density-regulated protein 
-2.179 E9QA15 Cald1 caldesmon 1 
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Table 3 (Continued) 
Exp Fold 
Change 
ID Symbol Entrez Gene Name 
-2.185 Q8BWN8 ACOT4 acyl-CoA thioesterase 4 
-2.229 O35864 COPS5 COP9 signalosome subunit 5 
-2.233 Q9EQ32 PIK3AP1 phosphoinositide-3-kinase adaptor 
protein 1 
-2.246 H3BKR2 GNB1 guanine nucleotide binding protein (G 
protein), beta polypeptide 1 
-2.253 Q91V77 S100A1 S100 calcium binding protein A1 
-2.275 B1AQR8 LGALS9B lectin, galactoside-binding, soluble, 
9B 
-2.276 Q8K0Z7 TACO1 translational activator of 
mitochondrially encoded cytochrome c 
oxidase I 
-2.278 P62264 RPS14 ribosomal protein S14 
-2.330 Q8K2Q0 COMMD9 COMM domain containing 9 
-2.352 P58281 OPA1 optic atrophy 1 (autosomal dominant) 
-2.352 P11276 FN1 fibronectin 1 
-2.359 Q91X72 HPX hemopexin 
-2.361 Q61990 PCBP2 poly(rC) binding protein 2 
-2.368 Q8VCM7 FGG fibrinogen gamma chain 
-2.402 Q9D7X3 DUSP3 dual specificity phosphatase 3 
-2.423 P17879 Hspa1b heat shock protein 1B 
-2.487 A6X935 ITIH4 inter-alpha-trypsin inhibitor heavy 
chain family, member 4 
-2.516 Q99K30 EPS8L2 EPS8-like 2 
-2.520 P97315 CSRP1 cysteine and glycine-rich protein 1 
-2.636 Q8CGR7 UPP2 uridine phosphorylase 2 
-2.825 E9PUZ8 C4bp complement component 4 binding protein 
-2.834 Q9QXK7 CPSF3 cleavage and polyadenylation specific 
factor 3, 73kDa 
-2.861 P32921 WARS tryptophanyl-tRNA synthetase 
-2.934 Q9D1J3 SARNP SAP domain containing 
ribonucleoprotein 
-2.949 P01868 IGHG1 immunoglobulin heavy constant gamma 1 
(G1m marker) 
-3.288 Q923B6 STEAP4 STEAP family member 4 
-3.436 E0CYI9 GCC2 GRIP and coiled-coil domain containing 
2 
-3.825 Q01279 EGFR epidermal growth factor receptor 
-3.944 P47809 MAP2K4 mitogen-activated protein kinase 
kinase 4 
-4.097 Q8BJW6 EIF2A eukaryotic translation initiation 
factor 2A, 65kDa 
-4.131 D3Z368 CAMK1 calcium/calmodulin-dependent protein 
kinase I 
-5.378 Q61646 HP haptoglobin 
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Table 3 (Continued) 
Exp Fold 
Change 
ID Symbol Entrez Gene Name 
-5.563 P62281 RPS11 ribosomal protein S11 
-6.881 P60229 EIF3E eukaryotic translation initiation 
factor 3, subunit E 
-7.557 O55239 NNMT nicotinamide N-methyltransferase 
-13.618 Q9JIK5 DDX21 DEAD (Asp-Glu-Ala-Asp) box helicase 21 
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Discussion 
This proteomic examination of the PANTG provided important 
mechanistic insight pertaining to the putative mechanism 
impacting lipid metabolism in the liver of mice with increased 
circulating PANDER sourced from the endocrine pancreas. 
Additionally, we demonstrated the strong utility for the 
implementation of quantitative mass spectrometry based 
proteomics for the investigation of metabolic disorders or the 
characterization of novel hormones regulating intracellular 
signaling.  
With the creation of our pancreas-specific overexpressing mouse 
model, we have recently reported that the PANTG mice display 
fasting hyperglycemia attributed to impaired hepatic insulin 
sensitivity when circulating PANDER is overexpressed. A similar 
proteomic approach in the PANTG revealed upregulation of PEPCK 
and indicated a mechanism of PANDER-induced gluconeogenesis 
[21]. This approach was limited though since our previous SILAC 
analysis employed ethanol treated AML-12 cells (murine hepatic 
cell line) to serve as the control “spike-in” internal standard 
for the liver and utilized for protein comparison. In addition, 
the prior proteomic examination was performed during a random 
re-fed uncontrolled metabolic state. This experimental design 
was certainly not ideal for making important comparisons during 
metabolic states and examining changes in the hepatic proteome. 
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Therefore, our current approach employed controlled metabolic 
states (fasting, controlled fed, and insulin-stimulated) with a 
SILAC-labeled C57BL/6J murine liver (not AML-12 cell line) and 
evaluated in the established PANTG model. In this current study, 
we utilized a metabolically labeled “SILAC” mouse liver to 
provide a superior internal standard enhancing the capability to 
capture differences in the PANTG liver proteome as compared to 
the WT control. In all, this is the first dataset to detail 
global proteome changes in the liver of the PANDER transgenic 
mouse model, a disease model of selective hepatic insulin 
resistance and metabolic disease.  
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Chapter 3 – Investigation of the Pander Transgenic Hepatic 
Proteome 
Introduction 
Over the past decade PANcreatic-DERived factor (PANDER or FAM3B) 
has been investigated with regard to secretion from the 
endocrine pancreas and biological impact on glycemic regulation 
both in-vitro and in-vivo [1, 4, 6, 9-11, 15, 18, 130-135]. Our 
recently generated pancreas specific overexpressing transgenic 
mouse model exhibits both fasting and fed glucose intolerance 
primarily attributed to impaired hepatic insulin signaling 
concordantly coupled with both increased gluconeogenesis and 
lipogenesis [21]. This result is consistent with other PANDER 
animal models that acutely express PANDER within the liver via 
adenoviral delivery  [19]. The mechanism by which PANDER 
inhibits hepatic insulin signaling has been attributed to 
suppressed phosphorylation of Akt [16] and AMPK [21] both of 
which serve as major regulators of gluconeogenesis. However, a 
major paradox to PANDER signaling has been the documented 
increase in hepatic lipogenesis despite inhibited insulin 
signaling [19, 21]. This bifurcation of signaling results in a 
selective insulin resistant state that mimics what is observed 
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in T2D animal models and humans [137, 139]. Encompassing prior 
PANDER research, an emerging hypothesis suggests that the 
pathophysiological conditions of T2D could potentially induce 
increased circulating PANDER levels contributing to selective 
hepatic insulin resistance resulting in increased hepatic 
glucose output and lipogenesis [59, 60], as precisely observed 
in our PANTG model.  Recent evidence has now indicated that 
circulating PANDER levels are elevated and associated with 
metabolic syndrome components in a Chinese population [140].  
Plasma PANDER levels significantly correlated with fasting 
plasma glucose, 2 hour plasma glucose, and triglyceride levels. 
Between animal model results and recent clinical studies, an 
emerging theme with PANDER is the role this novel hormone may 
contribute to in the promotion of hepatic insulin resistance and 
lipogenesis. Despite this importance, the precise PANDER-induced 
signaling mechanisms in the liver have yet to be determined. 
To elucidate PANDER-induced hepatic molecular mechanisms, we 
utilized quantitative mass spectrometry based proteomic analysis 
via stable isotope labeling by amino acids in cell culture 
(SILAC) as a heuristic tool to characterize hepatic proteomic 
differences between the PANTG murine liver with that of wild-
type mice under three metabolic states: fasting, fed, and 
insulin-stimulated. To achieve this, SILAC-labeled (13C6-Lys) 
mouse liver was utilized as an internal standard for relative 
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quantification of global proteome differences in the liver, a 
technique rarely used to study metabolic disorders yet 
previously validated by the examination of insulin signaling and 
liver proteomic characterization [29]. Differentially expressed 
proteins using this approach can be analyzed with bioinformatics 
tools such as Ingenuity Pathway Analysis (IPA) in order to 
reveal altered molecular networks and their function as well as 
differences in canonical pathways that can be later validated 
via additional molecular approaches. This unbiased, global-scale 
approach has led to novel insight into PANDER-induced hepatic 
pathway alterations in our PANTG model, in particular, those 
related to increased lipogenesis.  
In all three metabolic states lipid metabolism and fatty acid 
synthesis were identified as top cellular functions altered in 
the PANTG mouse. Specific molecules that were differentially 
expressed include fatty acid synthase (FASN), apolipoprotein A1 
(ApoA1) and A4 (ApoA4), acetyl-CoA carboxylase (ACC), stearoyl-
CoA desaturase-1 (SCD1), cholesterol 7 alpha-hydroxylase 
(CYP7A1) and CD36. Furthermore, the activation of the liver X 
receptor (LXRα) pathway was predicted which is a central 
modulator to these differentially expressed proteins. Taken 
together, this data suggest a high level of correlation with the 
available literature on the effects of PANDER overexpression on 
the liver. Our study also revealed numerous unidentified 
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differentially expressed proteins and pathways due to PANDER 
overexpression from the pancreas, many of which are involved in 
hepatic lipogenesis and lipid transport. Apart from these 
pathways, our proteomic approach revealed a number of molecules 
related to glycogen metabolism. Initial proteomic 
characterization of the PANTG mouse revealed glycogen 
phosphorylase to have a marked increase in mice treated with 
insulin. Additionally, our phosphoproteomic approach revealed an 
increase in an uncharacterized phosphorylation site on glycogen 
synthase (GSK), concordant with prior evidence of our PANTG 
mouse demonstrating decreased hepatic glycogen content. 
Materials and Methods 
Statistics And Pathway Analysis 
Raw files from LC-MS/MS (Orbitrap XL) were processed in MaxQuant 
1.2.2.5 employing the Andromeda search algorithm and searched 
against the UniprotKB reference database for Mus musculus, 
concatenated with reversed protein sequences. A second database 
of known contaminants provided with the MaxQuant suite was also 
employed. All fractions for each biological sample were combined 
for analysis. Constant modification of carbamidomethylation of 
cysteine and variable modifications of oxidized methionine and 
acetylated protein N-termini were used. Additionally, Lys-6 for 
the spike-in internal standard was set as a label in the group-
82 
 
specific parameter section. A false discovery rate of 1% was 
used for peptides and proteins. A minimum peptide length of 6 
amino acids was used. Razor and unique peptides were used for 
identification and quantification. Protein ratio values were 
reconstructed using median peptide ratio values across all three 
biological replicates for each experimental group where the 
final ratio for each protein was calculated by determining the 
ratio-of-ratio (PANTG/Internal Standard / (WT/Internal 
Standard)). Final ratios were input into the Perseus processing 
suite (Perseus version 1.2.0.13). Statistical analysis was 
performed using the Significance A outlier test where 
statistical significance based on magnitude fold-change was 
established at P<0.05. Ratio values and Uniprot Protein 
identification numbers of differentially expressed proteins were 
uploaded to Ingenuity Pathway Analysis (IPA) to determine 
canonical pathways, networks and upstream regulators in the 
liver affected by increased pancreas-secreted PANDER. We note 
that the outlier test based on the ratio distribution of the 
combined replicates was performed to increase coverage depth of 
differentially expressed proteins. The limitation of this 
approach is the increased false discovery rate of differentially 
expressed proteins as variance within groups is not specifically 
considered in the statistical filtering. Given only lysine-
terminated tryptic peptides were used for relative quantitation, 
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coverage of quantifiable proteins was limited (more so for lower 
abundance proteins) and therefore the Significance A filtering 
approach was utilized in order to enhance bioinformatic 
analysis. Additionally, we have generated a modified 
proteinGroups file generated by MaxQuant that lists relative 
expression ratios for each biological replicate, showing all 
proteins with measurable relative standard deviation (RSD) 
values. In order to achieve statistical significance based on 
1.5-fold change in expression (relative to wild-type, which is a 
value close to the Significance A test cut-off for significance 
at P<0.05 for the three metabolic conditions) using the 
Student’s t-test (with the assumption that variance is the same 
at higher expression), approximately 30% RSD (after error 
propagation from ratio-of-ratio calculation) or less would be 
needed. For higher fold-change values (>2-fold), statistical 
significance using the Student’s t-test could be achieved at RSD 
values measured for most proteins in the modified proteinGroups 
file. The modified protein list represents all hepatic proteins 
that are quantifiable with the methodology and instrumentation 
used in this study. This file as well as all mass spectrometric 
data has been deposited to the ProteomeXchange Consortium via 
the PRIDE partner repository with the dataset identifier 
PXD004171 and 10.6019/PXD004171. In addition, further raw data 
and a detailed description of the proteomic analysis can be 
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found in the Data in Brief manuscript associated with this study 
including Venn-Diagrams of unique proteins across metabolic 
states (Figure 12) and complete listing of all differentially 
expressed proteins [35]. 
Hepatic Phosphoproteomic Analysis of The Insulin Stimulated 
PANTG Mouse 
For the analysis of phosphoproteomic changes in the liver of the 
PANTG mouse, the same lysate was used from the insulin 
stimulated condition. Protein concentration was quantified using 
the Peirce 660 nm protein assay kit supplemented with the 
provided ionic detergent compatibility reagent (IDCR). Equal 
mass of labeled and unlabeled protein (~1.2mg per sample) or 
“light” and “heavy” protein respectively, were combined and 
digested using the filter aided spin procedure (FASP) method 
(Expedeon). Briefly, 30 µL of the protein mixture (~12.5mg/ml) 
was added to the spin column and lysate buffer exchanged to 8M 
urea using centrifugation prior to iodoacetamide alkylation and 
then exchanged to 50 mM ammonium bicarbonate for trypsin/Lys-C 
digestion at a ratio of 1:40 (w/w). Digestion was carried out 
overnight in a humidified incubator at 37°C. Protein was eluted 
off the column by addition of 0.5M NaCl followed by 
centrifugation. Samples were desalted using solid phase 
enrichment C18 columns (The Nest Group, Inc.). Briefly, columns 
were activated using 100% acetonitrile followed by equilibration 
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with 0.1% formic acid in water. Samples were loaded onto the 
columns and washed three times using equal volumes of 0.1% 
formic acid in water. Samples were eluted using 90% acetonitrile 
/ 0.1% formic acid in water. Prior to strong cation exchange 
fractionation samples were concentrated in a vacuum concentrator 
(Thermo) prior to resuspension with 5 mM ammonium formate and 
25% acetonitrile.  
Fractionated “spiked-in” peptides were enriched for 
phosphopeptides using the PolyMAC-Ti magnetic bead 
phosphopeptide enrichment kit (Expedeon). Samples were handled 
following kit guidelines. Briefly, samples are re-suspended and 
incubated with magnetic capture beads. Using a magnetic test 
tube rack, beads are captured to allow for the exchange of 
buffers for several wash steps. Beads are then re-suspended in 
elution buffer. The eluted peptides were concentrated in a 
vacuum concentrator (Thermo) and re-suspended in 0.1% formic 
acid in water prior to liquid chromatography tandem mass 
spectrometry (LC-MS/MS) using the same method as previously 
mentioned. 
Raw files were processed in MaxQuant 1.2.2.5 as previously 
outlined, with the additional parameter of the variable 
modification phospho STY selected. For statistical analysis, the 
average intensity of each representational peptide for 
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phosphorylated proteins in each biological replicate was used to 
determine a ratio average (PANTG average / WT average) for the 
determination of increased or decreased modification. To test 
for significance, a Welch’s two-tailed t-test was carried out 
using the same intensity values.  
Immunoblotting 
Approximately 100 mg of tissue was excised from a lobe of mouse 
liver for tissue lysis. Liver samples were identical from those 
obtained during the SILAC analysis as detailed earlier. In 
brief, following isolation the liver was submerged in cold T-PER 
lysis buffer (Thermo) supplemented with 1X HALT protease 
inhibitor and lysed using a Qiagen TissueRupter until tissue 
debris was no longer visible. Cellular lysate was then heated at 
95 °C for five minutes followed by brief sonication. The tissue 
lysate was cleared by centrifugation at 16,000× g for 5 min and 
the supernatant was collected and stored at −80 °C prior to 
further analysis. Protein concentration was quantified using the 
Pierce BCA Protein assay following the manufacturer’s protocol. 
Fifty µg was separated by SDS-PAGE (Mini-PROTEAN TGX Pre-Cast 
gels, 4–20%) and electro-transferred to a PVDF membrane using 
the iBlot semi-dry transfer apparatus (Invitrogen). PVDF 
membranes were then probed with primary antibodies against FAS, 
(C20G5, Cell Signaling Technology), LXRα (P-20, Santa Cruz), and 
CYP7A1 (ab65596, Abcam). All primary antibodies were diluted 
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1:500 in StartBlock Blocking Buffer (Thermo). Detection was 
achieved utilizing horseradish-peroxidase-conjugated goat 
secondary antibody (Bio-Rad) diluted 1:10,000 in StartBlock 
followed by chemiluminescence detection using Pierce ECL Western 
Blotting Substrate (Thermo). Emitted signal was detected using 
the Amersham™ Imager 600 (GE Healthcare Life Sciences). Relative 
protein levels were normalized to GAPDH (2118, Cell Signaling) 
and expression levels and densitometry analysis were quantified 
with ImageQuantTL (GE Healthcare Life Sciences). 
Cell Culture and Transient Transfection 
BNL-CL2 (BALB/c embryonic normal liver) cells were cultured 
until passage five in standard DMEM (4.5 g/L glucose, L-
glutamine and sodium pyruvate) supplemented with 10% FBS and 1% 
PenStrep (Thermo) at 37 °C, 5% CO2. Approximately 2 × 105 cells 
per well were plated in a tissue culture treated 24-well dish 
(Becton-Dickinson). After 24 h, media was replaced with DMEM 
without glucose, L-glutamine and sodium pyruvate supplemented 
with 1% FBS for 4 h prior to transfection. LXRα signaling 
plasmids and control plasmids (Cignal Reporter Assay Kit, 
Qiagen) were transfected using Lipofectamine 2000 (Invitrogen, 
Carlsbad, CA). Transfection of each plasmid was performed in 
triplicate in two independent experiments. Two hours post 
transfection, media was replaced with DMEM supplemented with 1% 
FBS and 1% PenStrep with the addition of PANDER (0.25 nM, 0.5 nM 
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and 1 nM) for 18 h. Cells were washed with PBS and lysed in 
100 µl of 1X Glo Lysis Buffer (Promega), utilizing the Dual-
Luciferase Reporter Assay System (Promega) for luciferase 
activation. Signal emission was detected with a Monolight 3010 
luminometer (Analytical Luminescence Laboratory, San Diego, CA). 
In a similar experiment, 1.1B4 cells (hybrid cell line formed by 
the electrofusion of a primary culture of human pancreatic 
islets with PANC-1, a human pancreatic ductal carcinoma cell 
line) cultured identically as previously mentioned were 
transfected as previously described with the same LXRα signaling 
plasmid. This cell type was chosen because LXRα is described to 
be active in the Islets of Langerhans [45, 141, 142] and 
displayed higher transfection efficiency. As a positive control 
the known non-steroidal agonist of LXRα (T0901317, SigmaAldrich, 
20 nm) and antagonist (GSK 2033, AxonMedChem, 20 nm) were used 
in addition to treatment with exogenous PANDER (0.25 nm, 0.5 nm, 
1 nm, 2nm, 4nm, 8nm) for analysis of synergistic effects. 
Significance in all experiments was determined by a student’s 
two-tailed t-test. 
Results 
Network and Pathway Analysis 
Of the 228, 239 and 189 significantly differentially expressed 
and quantifiable proteins in the fasted, fed, and insulin-
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stimulated conditions within the PANTG liver as compared to WT, 
respectively (Figure 12), IPA analysis revealed the top 
predicted primary molecular and cellular functions altered in 
the PANTG for all metabolic states was lipid metabolism based on 
–log(p-value) score (Figure 13). Within the fasting, fed and 
insulin-stimulated conditions, 51, 42 and 50 differentially 
expressed proteins, respectively, with lipogenic associated 
functions were identified. The most significant metabolic 
changes in the predicted activation state were found during 
insulin stimulation with numerous functions having a significant 
predicted activation as determined by z-score in IPA (z-score 
values >2 or <−2 indicate activation or inhibition, 
respectively) (Figure 15). These functions included fatty acid 
synthesis, concentration of lipid, concentration of fatty acid, 
and oxidation of lipid and conversion of lipid (Table 4). The 
most significantly activated lipogenic that were identified 
included fatty acid synthesis and concentration of lipid with 27 
proteins converging on these predicted activated networks 
(Figure 14).  
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Figure 13: IPA determination of altered molecular and cellular 
functions with the PANTG liver. Molecular and cellular function 
analysis was determined based on the identified differentially 
expressed proteins of the PANTG and WT liver expression Only 
functions that were identified in all metabolic states of 
insulin stimulated (top bar, white fill), fed (middle bar, grey 
fill), and fasting (bottom bar, black fill) conditions with a 
score cutoff of –log(p-value) greater than two are shown as 
determined by Fisher’s Exact test. 
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Table 4: List of metabolic functions with significantly 
predicted increased activation state based on activation z-score 
identified during insulin conditions within PANTG liver as 
compared to WT. 
 
  
Biological 
function 
Activatio
n z-score 
Molecules involved 
Fatty-acid 
metabolism 
2.751 ABCC3, ABCD3, ACAA1, ACLY , Acot1, 
ACOT4, ACOX1, APOA2, Ces1d, 
CYP2C18, CYP2C8, DECR2, EGFR, 
EHHADH, ELOVL5, EPHX1, FABP1, 
FABP2, FASN, HMOX1, MAP2K4, ME1, 
PLIN2, SCD, SLC9A3R1 
Conversion of 
fatty acid 
2.219 ACLY, ACOX1, CYP2C8, DECR2, FASN 
Concentration of 
triacylglycerol 
2.019 ACLY ,ACOT13, APOA2 ,C3, CES1, 
Ces1d, LOVL5, ENTPD5, FABP1, FASN, 
PEX11A, PLIN2, SCD, SORBS1, 
STEAP4, THRSP 
Concentration of 
acylglycerol 
2.008 FABP1, SORBS1, SCD, STEAP4, PLIN2, 
C3, APOA2, THRSP, ACOT13, ENTPD5, 
CES1, PEX11A, ELOVL5, ACLY, EGFR, 
FASN 
Concentration of 
fatty acid 
2.543 ACLY, ACOT13, APOA2, C3, Ces1d, 
EGFR, EHHADH, ELOVL5, FABP1, 
HMOX1, PEX11A, PLIN2, SCD 
Concentration of 
lipid 
1.945 ABCC3, ACLY ,ACOT13, APOA2, C3, 
CES1, Ces1d, CYP3A5, EGFR, EHHADH, 
ELOVL5, ENTPD5, FABP1, FABP2, 
FASN, HMOX1, HP, PEX11A, PLIN2, 
RAB7A, SCD, SORBS1, STEAP4, TGM2, 
THRSP 
Concentration of 
cholesterol 
0.686 ACOT13, APOA2, CES1, Ces1d, 
CYP3A5, ENTPD5, FABP1, FABP2, HP, 
RAB7A, SCD, STEAP4, TGM2 
Oxidation of 
lipids 
2.224 ABCD3, ACAA1, ACOX1, AOX1, Aox3, 
APOA2, C3, CYP2C8, CYP3A5, EHHADH, 
FABP1, FABP2, SCD 
Beta-oxidation of 
fatty acid 
2.418 ABCD3,ACAA1,ACOX1,EHHADH,FABP1,FAB
P2,SCD 
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Figure 14: Network analysis of significantly differentially 
expressed lipogenic associated proteins during insulin 
stimulatory conditions in PANTG liver. Proteins with a positive 
association with increased lipogenic states of both fatty acid 
metabolism and concentration of lipid are shown. Orange dotted 
lines indicated strong direct association between shown proteins 
and the predicted activation of fatty acid metabolism and 
concentration of lipid. The outer nodes represent differentially 
expressed proteins where red and green represent up and down 
regulation, respectively. Protein names are as follows: CYP2C8- 
cytochrome P450, family 2, subfamily C, polypeptide 8, ACLY- ATP 
citrate lyase, ACOT13-acyl-CoA thioesterase 13, C3-complement 
component 3, ENTPD5-ectonucleoside triphosphate 
diphosphohydrolase 5, EPHX1-epoxide hydrolase 1, FABP1 fatty 
acid binding protein 1, FABP2- fatty acid binding protein 2, 
FASN- fatty acid synthase, HMOX1-heme oxygenase 1, LSS- 
lanosterol synthase, SCD-stearoyl-CoA desaturase, SEC16B- SEC16 
homolog B, endoplasmic reticulum export factor, SLC9A3R1-solute 
carrier family 9, subfamily A (NHE3, cation proton antiporter 
3), member 3 regulator 1, SORBS1- sorbin and SH3 domain 
containing 1, STEAP4- STEAP family member 4, and THRSP- thyroid 
hormone responsive. 
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Proteomic Identification of Pander-Induced Hepatic LXR Pathway 
Due to the significant change in hepatic lipogenesis as 
determined by our proteomic approach, a mechanism or canonical 
pathway was then evaluated to potentially identify the etiology 
supporting this phenotype. Therefore, IPA was used to identify 
putative canonical pathways in all metabolic states that could 
potentially regulate the observed lipogenic pathways. Network 
analysis revealed that Liver X Receptor activation was 
identified as the most significantly predicted overall affected 
pathway across metabolic states (Figure 15). In addition, acute 
phase response signaling was also revealed as a significant 
canonical pathway. 
 
Figure 15: Canonical pathway analysis of significantly 
differentially expressed proteins during all metabolic 
conditions in PANTG liver. Canonical pathways with a score 
cutoff of –log(p-value) greater than 4 as determined by Fisher’s 
Exact test and z-score greater than 2 are shown in metabolic 
states of insulin-stimulated (top bar, white fill, fed (middle 
bar, grey fill), and fasting (bottom bar, black fill). 
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Validation of Pander-Induced Hepatic LXR Pathway and Fatty Acid 
Synthase Expression  
Liver X receptors (LXR) are transcription factors belonging to 
the class II nuclear receptor superfamily and are composed of 2 
isoforms [37-39]. LXRα is highly expressed in the liver, 
intestine, and adipose tissues whereas LXRβ is ubiquitously 
expressed. Upon activation, LXRs form a heterodimer with the 
retinoid X receptor α, which binds to LXR response elements and 
enhances targeted gene expression in a functional-dependent 
manner. LXRs appear to regulate overall glucose, cholesterol, 
bile acid, and triglyceride homeostasis [45]. One of the most 
critical gene targets governed by LXR involved in lipogenesis is 
FasN, which was shown by our proteomic analysis to be 
significantly increased in PANTG livers in all metabolic states 
[53, 54]. Several LXR targets including FasN and SCD1 not only 
pass the Significance A outlier test based on the ratio 
distribution of the combined biological replicates but also 
demonstrate statistical significance using the t-test (p < 0.05) 
in the insulin-stimulated group. Other targets such as Cyp7A1 
and CD36 are lower abundance proteins with limited peptide 
coverage, which affect quantitation accuracy. Therefore, these 
proteins require further validation by a targeted approach such 
as western blot analysis. We then sought to precisely examine 
expression of LXR and dominant targets of LXR such as FasN and 
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Cyp7A1 in the PANTG liver. Livers obtained during the proteomic 
investigation of PANTG were also examined for levels of LXRα 
expression. In brief, PANTG and WT livers obtained and snap-
frozen as previously detailed for the proteomic analysis were 
probed for LXRα, FasN and Cyp7A1 expression by western analysis. 
Samples from the insulin-stimulated conditions were examined 
since this metabolic condition demonstrated the most significant 
differentially expressed lipid metabolism network (Figure 16). 
During insulin-stimulated conditions, LXRα was significantly 
increased (Image J, P < 0.05) as compared to WT liver expression 
(Figure 16). In addition, hepatic expression of FasN and Cyp7A1 
were increased during insulin-stimulated conditions (Image J, 
P < 0.05). In summary, LXRα and critical LXRα targets such as 
FasN and Cyp7A1 were increased in PANTG model and indicates this 
pathway may potentially be activated during conditions of high 
circulating PANDER. 
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Figure 16: Western blotting and validation of LXRα and LXR 
targets (FASN and CYP7A1) in insulin stimulated PANTG mice. (A) 
Liver lysate (40 µg) from age and gender matched PANTG mice 
during overnight fasting and insulin-stimulated conditions 
(n = 3). Immunoblotting was performed to measure expression of 
LXRα, FASN, CYP7A1 and loading control of GAPDH. Lanes: 1–3 and 
4–6 are WT and TG liver lysate, respectively. Densitometry 
analysis on (B) LXRα expression; (C) FASN and (D) CYP7A1. 
(P<0.05, ImageJ) for both conditions. 
  
97 
 
Pander Stimulates LXR Transcriptional Activity In-Vitro 
The above studies examined the abundance of LXR and targets of 
LXR in the PANTG liver. However, we also wanted to determine if 
PANDER may govern or induce LXR transcriptional activity. To 
examine this, reporter gene analysis was performed using a 
commercially available LXR response element (LXRE) mediated 
luciferase assay (Qiagen, Cignal LXR Reporter Kit). This LXRα 
reporter assay measures the transcriptional activity of liver X 
receptor (LXR) and this was determined in the context of 
exogenous PANDER application. A liver derived cell line, BNL-
CL2, was exposed to increasing concentrations of purified 
secreted PANDER (AstraZeneca) and LXR-directed transcriptional 
activity was measured. PANDER can significantly increase LXRE 
directed luciferase expression at a range of concentrations from 
0.25 to 1 nM in a dose-dependent manner (Figure 17).  
Due to limitations of transfection efficiency in the BNL-CL2 
cell line, 1.1B4 cells were used to test the effects of the non-
steroidal agonist and antagonist T0901317 and GSK 2033, 
respectively, as well as in the presence of exogenous PANDER. At 
various concentrations of exogenous PANDER, LXRE directed 
luciferase expression was increased in a dose-dependent manner 
(Figure 18). The average fold change between 0 nm PANDER 
treatment and 1 nm PANDER treatment is 1.7 (N=6, P=1.5986E-06) 
and 1.96 between 0 nm and 8 nm PANDER treatment (N=6, 
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P=8.83022E-08) (Figure 19).  The agonist T0901317 promoted LXRE 
directed luciferase expression 3.6 fold on average (N=6, 
P=1.6538E-06) at a concentration of 20 nm and 4.8 fold increase 
on average in the presence of 8 nm PANDER (N=6, P=2.88502E-07) 
(Figures 21 and 22). Between the agonist and agonist + PANDER 
treatment, a significant 1.3 fold increase was observed 
(P=0.00012) (Figure 21). In the presence of the antagonist GSK 
2033, LXRE directed luciferase expression was decreased 0.31 
fold on average (P=1.01421E-05) (Figures 23 and 24). The 
presence of 8 nm PANDER was able to attenuate the effects of GSK 
2033 by increasing luciferase expression 1.19 fold (P=0.008) 
(Figure 23). Taken together, as matched with increased LXR 
expression in the liver of the PANTG, PANDER is also capable of 
directly stimulating LXR-directed transcriptional activity in-
vitro and synergizes or attenuates the effects of the agonist 
and antagonist, respectively.  
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Figure 17: PANDER increased LXRE transcriptional activity in 
BNL-CL2 cells. Reporter gene analysis was performed on BNL-CL2 
liver-derived cells transfected with LXRE-luciferase plasmids 
exposed to increasing concentrations of purified secreted PANDER 
(AstraZeneca) followed by measurement of luciferase activity. 
Treatments performed in triplicate in duplicate biological 
experiments. *** denotes P < 0.001 as determined by Student’s t-
test from 0 nM PANDER condition. 
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Figure 18: PANDER increased LXRE transcriptional activity in 
1.1B4 cells. Reporter gene analysis was performed on 1.1B4 human 
islet-like cells transfected with LXRE-luciferase plasmids 
exposed to increasing concentrations of purified secreted PANDER 
(AstraZeneca) followed by measurement of luciferase activity. 
Treatments performed in sextuplicate in one experiment.  
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Figure 19: PANDER increased LXRE transcriptional activity in 
1.1B4 cells. Reporter gene analysis was performed on 1.1B4 human 
islet-like cells transfected with LXRE-luciferase plasmids 
exposed to increasing concentrations of purified secreted PANDER 
(AstraZeneca) followed by measurement of luciferase activity. 
Treatments performed in sextuplicate in one experiment. The 
average fold change between 0 nm PANDER treatment and 1 nm 
PANDER treatment is 1.7 (N=6, P=1.5986E-06) and 1.96 between 0 
nm and 8 nm PANDER treatment (N=6, P=8.83022E-08)  
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Figure 20: T0901317 and/with PANDER increased LXRE 
transcriptional activity in 1.1B4 cells. Reporter gene analysis 
was performed on 1.1B4 human islet-like cells transfected with 
LXRE-luciferase plasmids exposed to increasing concentrations of 
purified secreted PANDER (AstraZeneca) followed by measurement 
of luciferase activity. Treatments performed in sextuplicate in 
one experiment.  
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Figure 21: T0901317 and/with PANDER increased LXRE 
transcriptional activity in 1.1B4 cells. Reporter gene analysis 
was performed on 1.1B4 human islet-like cells transfected with 
LXRE-luciferase plasmids exposed to increasing concentrations of 
purified secreted PANDER (AstraZeneca) followed by measurement 
of luciferase activity. Treatments performed in sextuplicate in 
one experiment. The agonist T0901317 promoted LXRE directed 
luciferase expression 3.6 fold on average (N=6, P=1.6538E-06) at 
a concentration of 20 nm and 4.8 fold increase on average in the 
presence of 8 nm PANDER (N=6, P=2.88502E-07). Between the 
agonist and agonist + PANDER treatment, a significant 1.3 fold 
increase was observed on average (P=0.00012).  
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Figure 22: GSK 2033 and/with PANDER increased LXRE 
transcriptional activity in 1.1B4 cells. Reporter gene analysis 
was performed on 1.1B4 human islet-like cells transfected with 
LXRE-luciferase plasmids exposed to increasing concentrations of 
purified secreted PANDER (AstraZeneca) followed by measurement 
of luciferase activity. Treatments performed in sextuplicate in 
one experiment.  
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Figure 23: GSK 2033 and/with PANDER increased LXRE 
transcriptional activity in 1.1B4 cells. Reporter gene analysis 
was performed on 1.1B4 human islet-like cells transfected with 
LXRE-luciferase plasmids exposed to increasing concentrations of 
purified secreted PANDER (AstraZeneca) followed by measurement 
of luciferase activity. Treatments performed in sextuplicate in 
one experiment. In the presence of the antagonist GSK 2033, LXRE 
directed luciferase expression was decreased 0.31 fold on 
average (P=1.01421E-05). The presence of 8 nm PANDER was able to 
attenuate the effects of GSK 2033 by increasing luciferase 
expression 1.19 fold (P=0.008) 
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Phosphoproteomic Analysis Reveals Increased Phosphorylation of 
Glycogen Synthase 
In order to reveal altered signaling events in the PANTG liver, 
a similar proteomic profiling approach was employed with the 
addition of a phosphopeptide enrichment step. 1,142 phosphosites 
were identified in the PANTG mouse under insulin stimulated 
condition as predicted by MaxQuant. Of those, 198 peptides were 
quantifiable and 20 peptides significantly differentially 
expressed (Table 20). Most notably a recently identified but 
uncharacterized phosphosite was identified on serine 627 on GSK 
with a confidence of 98.7% as predicted by MaxQuant [143] 
(Figure 24. 
Apart from altered biochemical pathways pertaining to lipid 
metabolism and fatty acid synthesis, our initial proteomic 
analysis revealed several proteins responsible for the 
phosphorylation of glycogen synthase (GSK), most notably in the 
insulin stimulated condition. Glycogen phosphorylase kinase 
(PHK) was increased 1.84 as well as Glycogen phosphorylase 
increased 18.5 fold in the PANTG mouse under insulin stimulation 
(Table 3), evidence that further suggests increased 
phosphorylation of glycogen synthase. 
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Table 5: List of significantly differentially modified 
(phosphorylated) proteins in the PANTG mouse. For statistical 
analysis, the average intensity of each representational peptide 
for phosphorylated proteins in each biological replicate was 
used to determine a ratio average (PANTG average / WT average) 
for the determination of increased or decreased modification 
where a value over 1 is increased and below 1 is decreased. To 
test for significance, a student’s two-tailed t-test was carried 
out using the same intensity values. The probability from 
MaxQuant is shown, where a value closer to one correlates to 
stronger confidence. Here a probability cut-off was set to 0.90, 
with the exception of the proteins displayed in the first two 
rows. 
  
Protein name Phospho (STY) Probabilities RATIO 
AVERAG
E 
T 
TEST 
General transcription 
factor IIIC, polypeptide 
3 
S(0.5)S(0.5)PKENPDDSEVPSSSGIDSAK 0.904 0.005 
General transcription 
factor IIIC, polypeptide 
3 
S(0.5)S(0.5)PKENPDDSEVPSSSGIDSAK 0.904 0.005 
Acyl-CoA dehydrogenase 
family member 11  
METDVT(0.034)S(0.909)DT(0.058)VEVIPQHK 1.735 0.007 
Glycogen [starch] 
synthase, liver OS=Mus 
musculus  
FHIEPT(0.012)S(0.987)PPT(0.001)TDGFK 1.625 0.007 
40S ribosomal protein S3 
OS=Mus musculus  
DEIIPT(0.005)T(0.993)PIS(0.002)EQK 0.554 0.010 
Nucleolar protein 58 
OS=Mus musculus  
EEPIS(1)EEEPCTSTAVPS(1)PEK 1.242 0.020 
Serine/arginine 
repetitive matrix 
protein 2 
SEQPISQVIPS(0.015)IS(0.985)PEHK 0.842 0.025 
Thyroid hormone 
receptor-associated 
protein 3  
FSGEEGEIEDDES(0.997)GT(0.003)ENREEK 1.208 0.026 
Ribonuclease H2 subunit 
A  
EAEDVIWEDS(1)EAEEDPERPGK 1.251 0.030 
Pinin  SIS(1)PGKENINSQEVEK 1.240 0.031 
Gephyrin  EVHDEIEDIPS(1)PPPPIS(0.989)PPPT(0.008)T(0.002)S(0.001)P
HK 
1.662 0.032 
Eukaryotic translation 
initiation factor 3 
subunit G  
GIPIPT(0.003)GDT(0.172)S(0.825)PEPEIIPGDPIPPPK 0.863 0.036 
2-hydroxyacyl-CoA lyase 
A lyase 1 
PES(1)NSAEGSDRSEEQVSGAK 1.756 0.039 
Trans-Golgi network 
integral membrane 
protein 1 
GDKS(0.993)S(0.007)EPTEDVETK 1.209 0.039 
GMP synthase [glutamine-
hydrolyzing] 
TINMT(0.002)T(0.043)S(0.955)PEEK 1.676 0.040 
Serine/threonine-protein 
kinase PAK 2 
YIS(1)FTPPEK 0.946 0.042 
Myosin-9 OS=Mus musculus GTGDCS(1)DEEVDGK 0.808 0.053 
Synaptosomal-associated 
protein (Fragment)  
ATWGDGGDNS(1)PSNVVSK 1.131 0.058 
Nuclear ubiquitous 
casein and cyclin-
dependent kinase 
substrate 1 
TPSPKEEDEEAES(1)PPEKK 1.232 0.058 
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Figure 24: Increased phosphorylation of glycogen synthase at 
Ser627. Annotated MS/MS spectra of glycogen synthase peptide 
showing phosphorylation detection at Serine 627.  
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Discussion 
This proteomic examination of the PANTG provided important 
mechanistic insight pertaining to the putative mechanism 
impacting lipid metabolism in the liver of mice with increased 
circulating PANDER sourced from the endocrine pancreas. 
Additionally, we demonstrated the strong utility for the 
implementation of quantitative mass spectrometry based 
proteomics for the investigation of metabolic disorders or the 
characterization of novel hormones regulating intracellular 
signaling. Evidence to date has demonstrated that PANDER can 
promote a selective hepatic insulin resistant (SHIR) phenotype 
whereby insulin signaling is partially inhibited and therefore 
hepatic glucose production and lipogenesis is increased [21], 
phenomena observed in T2D animal models and clinical human 
observations  [137]. Earlier studies demonstrated that PANDER 
overexpression induces fasting hyperglycemia by upregulating 
gluconeogenic gene pathways and subsequently increasing hepatic 
glucose output in mice [17, 19, 21]. These effects were 
attributed to the presence of increased transcript levels of 
PEPCK and Glucose 6 phosphatase (G6Pase) due to inhibited 
phosphorylation of critical insulin signaling molecules such as 
Akt and AMPK. However, these similar studies revealed increased 
hepatic lipogenesis despite suppressed insulin signaling. 
Therefore, due to the complex nature of this metabolic process, 
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we employed a comprehensive proteomic approach to identify 
putative novel mechanisms of this process. Our MS based methods 
demonstrated a proteomic profile similar to the observed 
lipogenic phenotype and supports the utility of using this tool 
to unravel complex signaling mechanisms.  
Our proteomic data strongly complements the described published 
studies on PANDER’s role in the mouse liver with regard to 
inducing increased hepatic lipogenesis which has long been 
attributed to hyperinsulinemia [144], a hallmark of T2D and non-
alcoholic fatty liver disease [145, 146]. However, pertaining to 
lipid metabolism in the PANTG liver, little is known of the 
biochemistry generating the increase of lipid production, 
especially fatty acid synthesis and lipogenesis. In our study we 
have provided data indicating that PANDER overexpression acts to 
increase gene expression modulated by a similar nuclear binding 
protein: the liver X receptor (LXR). Insulin mediated activation 
of lipogenic pathways has been described extensively. LXR has 
been shown to drive overexpression of lipogenic genes in 
hyperinsulinemia conditions [51, 147]. Since the most 
significant effects of PANDER were observed during insulin-
stimulatory conditions, our data suggests that PANDER acts in 
concert with insulin to potentially promote hepatic lipid 
production and fatty acid synthesis. Given the fact that PANDER 
does appear to be located within pancreatic β-cell insulin 
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granules [4, 7], this co-packaging may indicate complementary 
functionality in terms of distal biological effects on target 
tissues such as the liver. Increased hepatic lipid metabolism 
was also observed by proteomic analysis during fasting and fed 
conditions but not to the same level of statistical significance 
as insulin-stimulated. There are several potential putative 
mechanisms describing this effect. As mentioned previously, 
increased lipogenic gene regulation by PPARγ regulation has been 
described by blunted FOXO1 signaling [19]. Interestingly, our 
network analysis also indicated that PPARγ was a significantly 
predicted upstream regulator of the observed lipogenic effect in 
our PANTG model (data not shown). Alternatively, recent studies 
have indicated that Carbohydrate-Responsive Element Binding 
Protein (ChREBP) binds directly to the PANDER promoter [5]. This 
gene plays a key role in the control of lipogenesis through the 
regulation of lipogenic genes [148, 149]. PANDER may be acting 
in concert with ChREBP enhancing PANDER-induced lipogenesis [5]. 
Our current data suggests a novel putative mechanism that 
implicates LXR as a key modulator of genes driving a hepatic 
steatotic phenotype in the PANTG mice. In the insulin-stimulated 
condition we saw this effect exaggerated where downstream 
targets of LXR such as FASN, ApoA1, ApoA4, ACC, SCD1, CYP7A1 and 
CD36 are all upregulated. Additionally, vLDL was increased in 
the PANTG liver suggesting an increase of intercellular 
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oxysterols. Oxysterol is the main activating ligand required for 
LXR-RXR dimerization [41]. LDL influx is mediated by certain 
cell membrane transporters, CD36 being one of them [150], 
leading to an increase in intracellular cholesterol content that 
can be subsequently oxidized [151]. Taken together, we have 
demonstrated and validated that the LXR signaling pathway may be 
involved in PANDER-induced hepatic lipogenesis.   
As detailed in prior review articles, PANDER has widespread 
interactions with both the liver and the endocrine pancreas [59-
61]. Pancreatic islets obtained from the PANDER knockout mouse 
(PANDER KO) displayed an impaired glucose stimulated insulin 
secretion (GSIS) [18].  The mechanism for this decreased 
biological function has yet to be determined precisely, although 
the observed inhibited intracellular Ca2+ response is believed to 
have a role in the impaired GSIS of the PANKO model.  
Importantly, LXR activation has been demonstrated to stimulate 
insulin secretion upon T0901317 (agonist of LXR) activation and 
promoting expression of FASN and ACC (also increased in our 
PANTG) in pancreatic islets [152, 153]. Concordantly, pancreatic 
islets from LXR knockout mice have disrupted GSIS with increased 
lipid deposition [154]. Although not experimentally confirmed in 
the PANKO model, the absence of PANDER may have inhibited 
pancreatic LXR expression resulting in the observed impaired 
GSIS. Another highly relevant finding is that chronic LXR 
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activation particularly under high glucose conditions promotes 
pancreatic β-cells apoptosis [155]. An identical biological 
effect was initially reported for PANDER overexpression [7].  
Some of the earliest investigations demonstrated that PANDER 
could induce apoptosis of pancreatic β-cells and cell lines in a 
time and dose dependent manner [7, 9]. Taken together, PANDER 
induced LXR activation may provide a central rationale for the 
observed pleiotropic actions of this novel hormone in both the 
liver and pancreas.  
Previously described glycogen content is decreased in the PANTG 
mouse liver [21].  In our current study, we demonstrated 
proteomic evidence supporting this phenotype. In the insulin 
stimulated condition, glycogen phosphorylase kinase (PHK) and 
glycogen phosphorylase was significantly upregulated compared to 
the wild-type control. Additionally our phosphoproteomic 
experiment revealed an increase of the phosphorylation site 
serine 627 on glycogen synthase which has been characterized but 
its biological role is unknown, although thought to be active 
[156-159]. This phosphorylation site may present a novel role in 
signaling events regulating glycogenolysis. Taken together, this 
data suggest an increase in the phosphorylation of glycogen 
synthase which is known to inactivate the protein leading to 
decreased glycogen content [160].  
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Cao et al. revealed systemic PANDER levels are significantly 
correlated with increased fasting blood glucose (FBG), 
triglycerides, and high-density lipoprotein cholesterol in an 
Asian population (N=212, aged40-65) with varying degrees of 
glucose intolerance and T2D. Furthermore, logistic regression 
analysis showed circulating PANDER was associated with increased 
risk of IGT or T2D following cofounder adjustment. In general, 
they found that elevated plasma PANDER was significantly 
associated with numerous metabolic syndrome components, which is 
certainly consistent with our proteomic investigation and other 
animal model studies revealing increased lipogenesis or hepatic 
steatosis during conditions of increased PANDER expression 
[161]. Further studies are needed and the almost near absence of 
human clinical and physiological in-vivo data presents a major 
limitation in the understanding of PANDER and etiological role 
within T2D. However, our proteomic investigation certainly 
supports the findings of this initial clinical study in that 
increased PANDER levels are associated with both increased 
hepatic lipogenesis and its potential consequences in humans 
such as promoting or initiating T2D or Metabolic Syndrome.  
Given that LXR is an important gene in the regulation and 
homeostasis of cholesterol [162], PANDER-induced effects on 
cholesterol may also be mediated by the LXR pathway. LXR also 
regulates the transcription of CYP7A1, the rate limiting step of 
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converting cholesterol to bile acid as to effectively rid the 
cell of cholesterol [163]. LXR activation also promotes the 
generation of other lipogenic genes increasing lipid 
accumulation and fatty acid synthesis. Accompanying this is the 
evidence of increased triglycerides seen phenotypically in the 
PANTG mouse in previous studies [19, 21]. Additional studies are 
needed to precisely address both the molecular mechanism of 
PANDER-induced lipogenesis and the potential detrimental 
consequences when circulating levels are increased in humans in 
terms of the role in both initiation and onset of T2D or hepatic 
steatosis.  
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Chapter 4 – Exploring Proteomic Changes in the Fatty Liver 
Abstract 
Fatty liver disease is a looming problem, especially in the 
United States where an estimated 30% of obese individuals 
manifest signs of non-alcoholic fatty liver disease (NAFLD). 
NAFLD can progress into more sever disease, such as non-
alcoholic steatohepatitis (NASH) and cirrhosis, and even provoke 
hepatic tumorigenesis. In an effort to outline mechanistic 
features of fatty liver pathophysiology, stable isotope labeling 
of amino acids in cell culture was used as a quantitative 
proteomic approach to compare mice on a longitudinal high fat 
diet (HFD) to those on a normal diet. In all, there were 224, 
234, 189, and 179 differentially expressed proteins at the 1, 2, 
5, and 9 week time points, respectively. Several of these 
proteins were predicted to be involved in lipid metabolism, 
autophagy, and phagocytosis. LXR was identified as a predicted 
canonical pathway active after two weeks HFD exposure. The 
suggested biomarker, FABP5, was downregulated ~2 fold in 3 of 
the 4 proteomic time points. In an effort to outline mechanistic 
details in parallel to gross metabolic phenotype, glucose 
intolerance and insulin resistance were measured by GTT and ITT, 
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respectively, resulting in insignificant results. In all, the 
dataset provides a general proteomic overview of critical 
proteins altered due to high fat diet induced liver disease. 
Introduction 
With the worsening global obesity epidemic, recognition of non-
alcoholic fatty liver disease (NAFLD) and its significance in 
metabolic disease has been increasing in recent years [164]. The 
prevalence of NAFLD is weakly estimated in the general 
population ranging from 5 to 30% and in 75% of patients with 
obesity and T2D [164-166]. Although usually those with NAFLD are 
obese [167, 168], not all obese individuals develop the disease 
and the reason why, even when the severity of obesity is the 
same, is poorly understood [169].  
NAFLD is used to describe several liver diseases such as 
steatosis, and can develop into more sever diseases such as non-
alcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular 
carcinoma [170]. It is generally accepted that once the liver is 
fatty, it becomes insulin resistant [171, 172], whereby the 
overproduction of glucose and fatty acids lead to the dangerous 
combination of hyperglycemia and hypertriglyceridemia [172, 
173]. Much is known about the gross metabolic phenotype of 
obesity and fatty liver disease, but precisely how the liver 
becomes fatty is weakly understood. Peripheral insulin 
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resistance has been thought to contribute to the disease by 
increasing plasma concentrations of glucose and fatty acids, 
known to promote hepatic fatty acid synthesis while impairing β-
oxidation [75, 174]. On the contrary, Kraegen et al. reported 
that the liver in rodents was insulin resistant even before 
muscle became insulin resistant when on a high fat diet [175]. 
Taken together, the mechanism by which hepatic fat accumulation 
occurs and how it leads to hepatic insulin resistance is still 
undetermined. Regardless, rodents fed a high fat diet, 
particularly C57/BL6 mice (that can spontaneously develop 
impaired insulin secretion and glucose intolerance), are prone 
to global insulin resistance and obesity [176-179], due to a 
high availability of free fatty acids (FFAs) relative to 
peripheral requirements. One consequence of elevated FFAs in the 
serum is decreased β-oxidation in the liver resulting in hepatic 
triglyceride accumulation [137, 169, 180, 181]. 
Proteomic analyses offer unparalleled utility when studying the 
molecular changes of a biological system in a heuristic manner, 
allowing for the elucidation of underlying mechanisms of 
disease. The use of proteomics has been employed in a number of 
ways to investigate fatty liver and hepatitis, identifying 
protein markers of disease and the effects of diet/obesity and 
insulin resistance [76, 182-188]. Although the information 
gained from these studies is valuable, recent technological 
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advances in mass spectrometry have allowed for improved protein 
identification and quantification by eliminating issues 
associated with 2DE coupled with mass spectrometry. Mass 
spectrometry based proteomics has been on the rise in the study 
of metabolic disease (see review in Chapter 1), as well as in 
the study of NAFLD. iTRAQ has been used to identify non-invasive 
markers of NAFLD [189] and to study the effects of drugs against 
the disease [190]. Here we used spike-in SILAC in this 
longitudinal study for the identification of protein profile 
changes in the liver of C57/BL6 mice on a high fat diet (HFD). 
Metabolic phenotyping, including glucose and insulin tolerance 
testing (GTT and ITT, respectively) was performed in order to 
demonstrate glucose intolerance and insulin resistance due to a 
high fat diet over the course of nine weeks. High fat fed and 
control mice were sacrificed to determine hepatic proteomic 
changes during the time course. This unique experimental design 
allows for the determination of differentially expressed 
proteins involved in hepatic insulin signaling and altered 
mechanisms of lipid and glucose metabolism during global insulin 
resistance due to a high fat diet. 
120 
 
Materials and Methods 
Animals and Diet 
Normal, young C57BL/6 mice were obtained from the Jackson 
Laboratory (Bar Harbor, Maine). The mice were provided food and 
water ad libitum (unless otherwise specified) and at six weeks 
of age began the nine week trial of either receiving normal chow 
(NC) or high fat diet (HFD) food. Mice were randomly separated 
into two major groups, either for metabolic testing or proteomic 
analysis, and caged individually. Testing was performed at five 
time points (T0, week 1, 2, 5, and 9) in which mice.  
Glucose and Insulin Tolerance Testing 
In an effort to test for insulin resistance, the same group of 
ten mice (5 NC, 5 HFD) was used in both GTTs and ITTs. Prior to 
each test, mice were fasted for 18 hours. All mice were either 
dosed dextrose (2g/kg) or insulin (1u/kg, Humulin) by an 
intraperitoneal (IP) injection for glucose or insulin tolerance 
testing. Blood glucose levels were recorded using a TrueTrack 
blood glucose monitor on blood obtained from the tail vein at 
each time point (T0, 15, 30, 60, 120 minute). Mice were allowed 
to return to resting metabolic conditions for at least two days 
between GTT and ITT. Data was recorded and statistical analysis 
performed (student’s two tailed t-test of average values) in 
GraphPad version 5 and Microsoft Excel. 
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Proteomic Experimental Design 
At each time point, mice (N=3, either normal chow or HFD fed 
mice) were humanly euthanized and livers snap frozen in liquid 
nitrogen as previously described and stored at -80°C. All sample 
preparations for mass spectrometry analysis, including protein 
extraction, FASP digestion, desalt, SCX chromatography, and LC-
MS/MS was performed as previously described (see Chapter 2). 
Statistical and Pathway Analysis 
Statistical analysis comparing the hepatic proteome between the 
control and HFD fed mice was performed as previously described 
(see Chapter 2). Briefly, normalized intensity values selected 
by a significance outlier test (SigA) were tested for 
significance using the Welch’s 2-tailed t-test. Median ratio 
values of time-lapse matched mice (i.e. week 2 HFD vs week 2 NC 
mice) were used for calculated protein fold change (median HFD / 
median NC) and Uniprot Protein identification numbers of 
differentially expressed proteins were uploaded to Ingenuity 
Pathway Analysis (IPA) to determine canonical pathways, 
networks, and predicted disease states in the liver affected by 
a high fat diet. 
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Results 
Metabolic Phenotyping 
During the first three weeks, mice on a HFD did not display a 
significant difference in body mass compared to NC control mice 
(Figure 25). After nine weeks on a high fat diet, the liver of 
those mice exhibited characteristics of a fatty liver disease; 
physical increase in size and the appearance of lipid 
accumulation (Figure 26). Although insignificant, those mice on 
a HFD trend towards peripheral glucose intolerance during a GTT 
after 1 week, as made apparent at the 30 minute time point 
(P=0.08, HFD 502.6±76.1 vs NC 396±94.4) (Figure 27). Peripheral 
glucose tolerance was unremarkable in mice after two weeks on a 
HDF (Figure 28). 
Mice on a HFD were able to manifest an insulin resistant 
phenotype as demonstrated by ITT. After injection with a bolus 
of insulin, mice on the NC diet maintained lower blood glucose 
levels with significance at the 60 minute time point (P=0.008, 
HFD 391.7±41.8 vs NC 223.33±20.6) (Figure 29). After two weeks 
on a HFD, blood glucose levels of the HFD fed mice, in response 
to a bolus of insulin, was similar to that of the NC control 
mice (Figure 30).   
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Figure 25: Weight gain of HFD or NC fed mice. Prior to metabolic 
testing, mice were weighed. Values are expressed as means plus 
standard deviation (N=10, 5 HFD vs 5 NC fed mice, no 
significance by student’s two-tailed t-test). 
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Figure 26: Physical signs of fatty liver. Shown in A is a 
representation of the liver of mice on a NC diet. B represents a 
liver of mice on a HFD, where the physical appearance of 
increased size (images are to scale) and lipid accumulation is 
apparent.  
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Figure 27: GTT after one week on high fat chow. Glucose 
tolerance testing was performed after an 18 hour fast followed 
by IP injection of dextrose at 2g/kg and blood glucose readings 
measured at the times indicated. Values are expressed as means 
plus standard deviation. (P=0.08, HFD 502.6±76.1 vs NC 396±94.4 
at 30 minutes). 
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 Figure 28: GTT after two weeks on high fat chow. Glucose 
tolerance testing was performed after an 18 hour fast followed 
by IP injection of dextrose at 2g/kg and blood glucose readings 
measured at the times indicated. Values are expressed as means 
plus standard deviation.  
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Figure 29: ITT after one week on high fat chow. Insulin 
tolerance testing was performed after an 18 hour fast followed 
by IP injection of insulin (Humulin) at 1u/kg and blood glucose 
readings measured at the times indicated. Values are expressed 
as means plus standard deviation (P=0.008, HFD 391.7±41.8 vs NC 
223.33±20.6 at 60 minutes). 
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 Figure 30: ITT after two weeks on high fat chow. Insulin 
tolerance testing was performed after an 18 hour fast followed 
by IP injection of insulin (Humulin) at 1u/kg and blood glucose 
readings measured at the times indicated. Values are expressed 
as means plus standard deviation.   
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Proteomic Characterization of the HFD Liver and Network Analysis 
In order to comprehensively dissect the global hepatic proteome 
changes as a result of longitudinal high fat diet, spike-in 
SILAC was performed on mice fed a HFD and compared to mice on a 
normal diet. Diet induced obesity in C57/BL6 mice have 
demonstrated remarkable ability to act as a model of insulin 
resistance and fatty liver disease [191]. The quantitative 
proteomic approach compared mice on a HFD and NC diet over the 
time-span of 9 weeks at 4 intervals (1, 2, 5, and 9 weeks). 
Metabolic testing, including GTTs and ITTs were performed in 
parallel to identify incidence of insulin resistance. Following 
dietary exposure, livers were extracted and processed by tryptic 
digestion, desalting, SCX chromatography, and finally analyzed 
by LC-MS/MS. Across all dietary conditions, there were 18,058 
unique peptides correlating to 3,310 quantifiable proteins. Of 
those, there were 224, 234, 189, and 179 differentially 
expressed proteins at the 1, 2, 5, and 9 week time points, 
respectively (listed in Appendix II). 
Proteomic Analysis: Effects After 2 Weeks HFD 
Proteomic examination of the differentially expressed proteins 
using IPA revealed the most significant changes existing at the 
two week time point. Several hepatic cellular functions were 
altered in HFD fed mice having a predicted activation or 
inactivation by z-score in IPA (z-score <2 or >2 indicating 
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activation or inhibition, respectively). Increased functions 
included engulfment and phagocytosis of cells, autophagy, and 
quantity of carbohydrate (Figure 30). A major decrease in cell 
death was predicted with a z-score<-3 (Figure 30). At two weeks, 
several disease functions were identified to be altered, 
including damage and necrosis of liver tissue, apoptosis of 
hepatocytes, and increased indication of NAFLD and hepatic 
steatosis (Figure 31). The canonical pathway involving the DNA 
binding protein, LXR, a known modulator of lipid metabolism, is 
predicted active based on activation z-score (z-score>2.646 
P=6.14E6). 
 Figure 31: Cellular functions altered after 2 week HFD exposure. 
Proteins with a positive association with increased phagocytosis 
of cells and engulfment of cells are shown. Orange dotted lines 
indicated strong direct association between shown proteins and 
the predicted activation of phagocytosis of cells and engulfment 
of cells are shown. The outer nodes represent differentially 
expressed proteins where red and green represent up and down 
regulation, respectively.  
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Figure 31: Continued. Proteins with a positive association with 
increased macroautophagy and autophagy of cells are shown. 
Orange dotted lines indicated strong direct association between 
shown proteins and the predicted activation of macroautophagy 
and autophagy of cells. The outer nodes represent differentially 
expressed proteins where red and green represent up and down 
regulation, respectively.  
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Figure 31: Continued. Proteins with a positive association with 
increased organism death are shown. Orange dotted lines 
indicated strong direct association between shown proteins and 
the predicted activation of organism death. The outer nodes 
represent differentially expressed proteins where red and green 
represent up and down regulation, respectively.  
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Figure 32: Disease functions altered after 2 weeks HFD. Proteins 
with an association with necrosis of liver, apoptosis of 
hepatocytes, damage of liver, and hepatic steatosis are shown. 
Orange dotted lines indicated strong direct association between 
shown proteins and the predicted activation of macroautophagy 
and autophagy of cells. The outer nodes represent differentially 
expressed proteins where red and green represent up and down 
regulation, respectively.  
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Table 6: Proteins modulated by LXR activation after 2 weeks HFD. 
Protein Name Fold 
Change 
acetyl-CoA carboxylase 
alpha 
1.376 
alpha 2-HS glycoprotein 1.445 
albumin 1.372 
apolipoprotein H 1.64 
CD36 molecule 1.559 
fibrinogen alpha chain 1.467 
paraoxonase 3 1.365 
stearoyl-CoA desaturase 2.203 
serpin family A member 1 1.428 
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Proteomic Analysis: Effects After 9 Weeks HFD 
High fat diet induced insulin resistance is expected to be in 
full swing after 9 weeks. 5 proteins, including fatty acid amide 
hydrolase (FAAH), fatty acid synthase (FasN), 1-acly-sn-
glycerol-3-phosphate acyltransferase beta (AGPAT), glycerol-3-
phosphate acyltransferase 1 (GPAM), and low density lipoprotein 
receptor (LDLR) were involved in cellular functions related to 
the metabolism and synthesis of triacylglycerol, as well as the 
synthesis and deposition of lipids (Figure 32). Perhaps 
outlining an imperfection of IPA, apparent in the two week 
analysis, too, is the predicted “protection” of inflammation and 
necrosis of the liver and hepatic steatosis, when the opposite 
is beyond doubt the case (Figure 33). 
Interestingly, FABP5, a protein known to be involved in NAFLD 
and thought to perhaps represent a novel biomarker of the 
disease [192-194], is markedly downregulated (~-2 fold on 
average) in 3 of the 4 time points (Figure 34).   
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Figure 33: Proteins involved in the synthesis and metabolism of 
triacylglycerol and lipids after 9 weeks on HFD. Proteins with a 
positive association with increased metabolism of acylglycerol, 
synthesis of triacylglycerol, synthesis of lipid, deposition of 
lipid are shown. Orange dotted lines indicated strong direct 
association between shown proteins and the predicted activation 
of aforementioned functions. The outer nodes represent 
differentially expressed proteins where red and green represent 
up and down regulation, respectively. 
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Figure 34: Disease functions altered after 9 weeks HFD. Proteins 
with an association with necrosis of liver, inflammation of 
liver, and hepatic steatosis are shown. Orange dotted lines 
indicated strong direct association between shown proteins and 
the predicted activation of necrosis of liver, inflammation of 
liver, and hepatic steatosis. The outer nodes represent 
differentially expressed proteins where red and green represent 
up and down regulation, respectively. 
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Figure 35: Heat-map of proteins involved in NAFLD. Blue 
suggested inactivation based on prediction on z-score. Red 
indicates proteins that are upregulated and green indicating 
proteins that are down regulated.  
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Discussion 
To the best of my knowledge, this is the first experiment of its 
kind to employ quantitative mass spectrometry based proteomics 
in parallel with metabolic testing in an effort to outline 
mechanistic features of the onset and progression of fatty liver 
disease. The information gained from this study was not ideal 
for unraveling or providing major mechanistic insight in the 
pathogenesis or pathological progression of NAFLD, however did 
provide a languid proteomic overview of the pathophysiology of 
fatty liver disease. Regardless, such analyses can certainly 
provide a strong foundation for the understanding of the disease 
and the potential for novel drug targets [195-197]. This could 
be highly useful since the options are limited, medication wise, 
for the treatment of NAFLD. Most treatment options are insulin 
sensitizing agents, such as the biguanide metformin and 
thiozoladinediones (TZDs). Since insulin resistance is commonly 
associated in patients with NAFLD and is involved in hepatic 
lipid accumulation [75, 198], insulin sensitizing agents 
demonstrate better efficacy compared to insulin injections, 
since hyperinsulinemia is most likely present and increasing 
insulin action by flooding the system with more insulin becomes 
redundant [199]. Metformin is an interesting drug being that its 
mechanism of action is weakly understood [200]. Even still, 
metformin is considered the “go to” drug for decades now, since 
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its ability to improves global insulin sensitivity also extends 
to the benefit of the liver by decreasing hepatic steatosis by 
downregulating TNFα and lipid associated transcription factors 
[201]. Activation of PPARγ has been shown to improve insulin 
sensitivity, and agonist, such as those belonging to the TZD 
drug class [202], have been demonstrated clinically to protect 
against liver inflammation and fibrosis by inhibiting activation 
of hepatic stellate cells [203, 204]. A better understanding of 
pathways promoting NAFLD could potentially allow for the 
development of novel therapeutics. An initial hypothesis 
proposed by Christopher Day and Oliver James proposed the “two-
hit” explanation of the pathogenesis of NASH. The accumulation 
of lipids in the form of triglycerides in the liver is required 
for the onset of NASH and constitutes the first “hit”. 
Subsequently this would cause injury to the fatty hepatocytes in 
the form of oxidative stress and would trigger the second “hit”, 
where inflammation and necrosis, the histopathological hallmarks 
of NASH, become apparent [205, 206]. Decades have passed since 
this proposal has been made popular and yet the story of how 
NASH occurs is still not well established. More recent data 
suggests that the accumulation of triglycerides in the form of 
lipid droplets does not directly play a role in inflammation and 
cellular injury [207, 208], but instead lipid peroxidation 
causing steatohepatitis. A parallel hypothesis is certain 
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metabolites of fatty acids causing damage to the liver and 
promoting NASH. Recent data suggests that metabolites of free 
fatty acids can cause lipotoxic effects in the liver by means of 
endoplasmic reticulum (ER) stress, inflammation, apoptosis, 
necrosis, and dysmorphic features including ballooning and 
Mallory-Denk body formations (aggregates in the cytoplasm of 
liver cells) [209-213]. Because of this, metabolomics, or the 
large scale study of biochemical intermediates, may offer unique 
insight in the pathophysiology of NAFLD and NASH.  
To begin the discussion of the proteomic data, proteins that are 
known to be involved in major pathways implicated in fatty liver 
disease, such as fatty acid uptake, de novo lipogenesis, and 
fatty acid oxidative pathways, will be analyzed.  
FFA absorption into the liver is mediated by plasma membrane 
transporters, namely fatty acid translocase (FAT or CD36), fatty 
acid binding proteins (FABPs), and fatty acid transporter 
proteins (FATP). Although we did not detect levels of FATPs 
directly, at nine weeks a suggested increase in cellular 
functions was detected by IPA: metabolism of acylglycerol and 
synthesis of triacylglycerol mediated by fatty acid amide 
hydrolase (FAAH) and FasN (see Figure 32). FATBs are known to 
contain motifs for fatty acyl-CoA synthetase function [214, 215] 
similar to long-chain fatty acid CoA ligase 4 (Acsl4), shown to 
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be significantly downregulated at the first two proteomic time 
points. CD36 is a transmembrane protein that promotes fatty acid 
uptake [216] and its expression is known to be upregulated in 
response to diet-induced obesity [217] and was observed by our 
proteomic approach after two weeks of HFD exposure. FABPs have 
demonstrated a crucial role regarding intracellular transport of 
FFAs [218]. In animal models, knocking out FABP1 protects the 
animal from diet-induced obesity [219]. FAB4 and FAB5 expression 
has been correlated with hepatic fatty acid uptake in those with 
NAFLD [192], and could potentially serve as novel biomarkers of 
disease. The expression patterns of FAPBs are unclear under 
normal or pathophysiological conditions. Here, FABP4 was down 
regulated at the two week time point and FABP5 downregulated at 
the 2nd, 5th, and 9th week proteomic time points. 
De novo lipogenesis is characterized by the integration 
triglyceride synthesis, saturated fatty acid synthesis, and 
glycolysis. In this proteomic analysis, several key rate 
limiting enzymes were upregulated in the HFD mice (Figures 33 
and 34), including acetyl-CoA carboxylase alpha (ACACA), fatty 
acid synthase (FasN), and stearoyl-CoA desaturase (SCD), 
suggesting increased lipogenesis during disease state. ACACA 
catalyzes the rate limiting step in fatty acid biosynthesis 
converting acetyl-CoA to malonyl-CoA [220], two metabolites 
utilized by FasN in the last step of fatty acid biosynthesis 
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synthesizing long-chain saturated fatty acids [221]. SCD is 
responsible for the formation of monounsaturated fatty acids 
from saturated fatty acyl-CoAs [222], and suppression resulted 
in the amelioration of hepatic steatosis in mice by decreased 
lipogenesis and increased fatty acid beta oxidation [223]. These 
molecules share strong implications in the pathophysiology of 
fatty liver disease as TG synthesis is known to be active during 
disease conditions [224].   
In the proteomic analysis, LXRα was identified as a canonical 
pathway predicted to be upregulated in IPA after 2 weeks HFD. As 
discussed previously, LXRα regulate overall glucose, 
cholesterol, bile acid, and triglyceride homeostasis (Figure 8) 
[45]. LXRα can directly activate critical genes necessary for 
hepatic de novo lipogenesis which serves as a contributor to 
triglyceride accumulation in non-alcoholic fatty liver disease 
(NAFLD) [48, 49] either indirectly by increasing expression of 
SREBP-1c [50] and ChREBP [51], and directly by promoting 
transcription of SCD1 [52], FasN [53], and ACC [54]. 
Recent studies suggest that Kupffer cells (KCs), stellate 
macrophages in the liver, play an important role in the 
pathophysiology of NAFLD. It has been characterized that 
defective phagocytic function may impede the clearance of 
substances that can lead to the destruction of hepatocytes, 
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leading to inflammation and hepatic steatosis [225-234]. After a 
two week HFD exposure, IPA predicted phagocytosis and engulfment 
of cells as two activated cellular functions in the liver. The 
literature is sparse on the topic, but KP cell phagocytic 
ability can be exploited to detect early and late stages of NASH 
by magnetic resonance imaging [235, 236]. Carbamazepine, an 
anticonvulsant, has been shown to stimulate autophagic 
functions, decreasing fibrosis in an animal model [237]. It is 
unknown whether agents that can enhance autophagic function can 
induce the removal of hepatic lipids and treat/prevent cellular 
damage.    
Autophagy has recently been characterized as an important 
function in hepatic lipid metabolism [238] as the lysosome can 
contain lipases that degrade exogenous lipoproteins and 
intracellular lipids. This suggests that the regulation of the 
breakdown of lipids, or lipolysis, is related to macroautophagy 
[239]. The proteomic evaluation predicted autophagy and 
macroautophagy as cellular functions upregulated after 2 weeks 
of HFD exposure (Figure 30), perhaps defining a compensatory 
function in order to decrease intracellular lipid accumulation.  
Liver disease has been directly correlated to hepatocellular 
carcinoma (HCC) [240]. Once the liver is in crisis due to 
oxidative stress and cirrhosis, hepatocellular carcinoma is a 
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common cancer that can develop from cirrhosis [241]. The factors 
leading to HCC are poorly defined [242]. In terms of autophagy, 
it may promote cancer cell survival or serve as a tumor 
suppressor [243], and in HCC impairment is not characterized. 
After 2 weeks HFD exposure, a major downregulation of organism 
death was predicted by IPA with a z-score < -3 including 66 
proteins (Figure 30). Taken all together, the proteomic data 
suggests that the liver is in state of distress. 
Limitations of this study are most likely related to the 
uncontrolled metabolic states that the mice were in. As 
previously mentioned, C57/BL6 mice are known to spontaneously 
develop impaired insulin signaling and glucose intolerance [176-
179]. Additionally, a HFD affects the mice’s metabolism 
dramatically; after a short span of even days, mice can develop 
insulin resistance in several tissues, including the muscle, 
adipose, pancreases, and liver [244], making precise 
measurements at critical instances and occurrences of disease 
convoluted and difficult. At the time this dissertation was 
drafted, the approach taken for the comparison effects of a HFD 
could perhaps be improved on. HFD fed mice were compared to mice 
on a normal diet that were the same age. Given the physiology of 
the C57/BL6 mice, the design compared a diseased mouse to a more 
diseased mouse. To circumvent this, perhaps the median fold 
change of HFD fed mice to the youngest mice on a NC diet would 
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provide clearer data, as the younger mouse is less diseased at 
that point. Another approach is to reduce hepatic lipid 
accumulation by use of certain drugs. One such drug, 2, 4-
dinitrophenol (2,4-DNP), a mitochondrial uncoupler, was used by 
Samuel et al. to increase energy expenditure and prevent hepatic 
accumulation. HFD fed mice proteomes were then compared to 2,4-
DNP treated control mice on a normal diet by 2DE [170]. 
Nevertheless, the proteomic analysis at hand provides an 
expansive dataset comprising of hepatic proteins involved in 
early and late stages of disease due to dietary induced 
metabolic disease. Additionally, the study at hand demonstrates 
the utility of mass spectrometry based proteomics in elucidating 
important molecular characteristics of disease.    
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Chapter 5 – Conclusions and Future Directions 
Overview and Summary of Major Findings 
Metabolic disease and type 2 diabetes are characterized by 
insulin resistance and generally glucose intolerance, resulting 
in the overall conditions of hyperglycemia, hyperinsulinemia, 
and hyperlipidemia [68]. In this dissertation, quantitative mass 
spectrometry based proteomics was used as a heuristic tool for 
the discovery of disease mechanisms driving these conditions in 
two proven animal models representing insulin resistance. 
Hepatic Proteome Characterization of the PANTG Mouse  
Inflammatory cytokines and similar signaling molecules have long 
been implicated in the onset and progression of T2D [245]. 
Pancreatic-derived factor is one such protein that elicits a 
pleiotropic affect promoting the pathophysiological conditions 
of T2D, such as promoting ß-cell destruction and impacting 
hepatic insulin signaling. The major focus of this dissertation 
was to analyze the hepatic proteome changes under elevated 
circulating levels of PANDER in the PANTG mouse model under 
controlled metabolic states. The spike-in SILAC method was able 
to produce a dataset of over 3,000 quantifiable proteins and 
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revealed that increased endocrine signaling of PANDER from the 
pancreases acts on the liver to promote hepatic lipogenesis 
(Tables 1, 2, and 3). Most marked differences were seen in the 
insulin stimulatory conditions, where important molecules 
involved in lipid biogenesis, such as ACC, FasN, SCD1, and CD36, 
were significantly upregulated (Figure 15). Additionally, IPA 
analysis revealed several cellular functions pertaining to lipid 
metabolism to be significantly up-regulated by predicted z-score 
activation, including fatty-acid metabolism, conversion of fatty 
acid,  concentration of acylglycerol, concentration of 
triacylglycerol, concentration of fatty acid, concentration of 
lipid, oxidation of lipids, and concentration of cholesterol 
(Table 4). Also revealed by IPA analysis was the predicted 
canonical pathway activation of the liver X receptor (LXR). LXR 
is responsible for the expression of several genes related to 
lipid metabolism, and many of them were identified to be 
upregulated in the PANTG mice (Figure 15). In addition to 
lipogenic genes modulated by LXR, Cyp7A1, an important transport 
molecule for the export of cholesterol as bile acid, displayed 
increased expression in the PANTG mouse liver. FasN and Cyp7A1 
were used as targets for validation by Western blotting (Figure 
16). In relation to the known phenotype of the PANTG mouse, 
whereby increased circulating levels of PANDER seems to promote 
a selective hepatic insulin resistant state [21, 138], the study 
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at hand shed light on specific proteins and biochemical pathways 
driving it, providing valuable information for the elucidation 
of the mechanisms driving PANDER induced disease.  
Pander Affects LXR Promoter Activity 
In addition to lipogenic protein targets and suggested LXR 
canonical pathway activation by IPA, LXRα expression was up-
regulated in the PANTG mouse liver during the insulin stimulated 
condition as shown by Western blotting, demonstrating its self-
promoting regulation. To characterize this interesting finding 
further, luciferase assays using LXR signaling constructs were 
used to investigate PANDER induced LXR activation. In BNL-CL2 
cells, a mouse liver cell line, exogenous PANDER treatment 
increased LXR promoter activity in a dose-wise dependent manner 
(Figure 17). The effects of the potent non-steroidal agonist and 
antagonist, T090137 and GSK 2033, respectively, were used as 
positive and negative controls for LXR promoter activity. In 
addition, the synergistic effects of the compounds were 
investigated by dually treating cells in vitro with various 
concentrations of exogenous PANDER. Initially this was carried 
out in the BNL-CL2 cell line, but due to technical limitations, 
a cell line that displayed higher transfection efficiency, 1.1B4 
cells (fusion between human islet cells and PANC-1 cells), was 
used. In this model, LXR promoter activity was increased in 
response to exogenous PANDER treatment in a dose-dependent 
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manner (Figure 18 and 20). Although the agonist and antagonist 
affected LXR promoter activity as expected, a marked synergistic 
affect was observed when 1.1B4 cells were dually treated with 
PANDER and the drugs. PANDER treatment increased LXR promoter 
expression 1.3 fold in 1.1B4 cells when also treated with the 
agonist T0901317, suggesting that PANDER directly or indirectly 
increases LXR promoter activity (Figure 20 and 22). GSK 2033 
markedly lowered LXR promoter activity by 70% in 1.1B4 cells 
(Figure 22 and 24), however dual PANDER treatment, although 
slight, attenuated the effects of the antagonist 1.2 fold 
(Figure 23). 
Hepatic Phosphoproteome Analysis of the PANTG Mouse Liver 
Phosphoproteomic analysis allows for the unique large-scale 
observation of the assemblage of phosphorylated proteins. 
Protein phosphorylation is a reversible post-translational 
modification and is and is thought of as a molecular switch; 
these “switching” events are critical in several intercellular 
signaling pathways. Having the ability to observe whole systems 
and their relative phosphorylation state can provide even more 
in-depth knowledge of intercellular biochemical pathways altered 
by disease. This is because several protein pathways rely on 
changes in phosphorylation state, not exclusively changes in 
protein expression. Cellular events triggered by insulin 
signaling, by way of interaction with membrane proteins, are 
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almost entirely reliant on changes in phosphorylation state 
[246]. Because PANDER displays a profound pleiotropic effect due 
to altered hepatic insulin signaling, a phosphoproteomic 
analysis would allow for an enhance understanding of mechanistic 
abnormalities due to increased circulating levels of PANDER. In 
the PANTG mouse, hepatic glycogen content is markedly reduced 
compared to wild-type mice [21]. In another animal model, acute 
hepatic overexpression of PANDER elevated the gluconeogenic 
genes PEPCK and G6Pase in the liver due to increased 
phosphorylated cAMP-binding protein levels. Here, SILAC spiked-
in protein lysate from the same mice used for the proteomic 
analysis was enriched for phosphoproteins using a titanium-based 
nanopolymer in combination with SCX chromatography. The enriched 
phosphoproteome was analyzed by LC-MS/MS for the identification 
and relative quantitation of phosphorylated peptides. 1,157 
phosphorylated peptides were identified using this method.  
However, due to technical limitations, many were not 
quantifiable, and will be discussed shortly. Of the quantifiable 
proteins, only 20 were considered statistically significant. The 
most notable protein was the increased phosphorylation of 
glycogen synthase (Table 5, Figure 24). Although the information 
about the particular phosphosites (Ser627 on glycogen synthase) 
it is hypothesized to be active. Phosphorylation of glycogen 
synthase inactivates the proteins anabolic ability to synthesize 
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glycogen. Further evidence to support elevated phosphorylation 
of GSK was the observation of glycogen phosphorylase kinase 
(PHK) being increased 1.84 as well as glycogen phosphorylase 
increased 18.5 fold in the PANTG liver during insulin 
stimulation. Both of these molecules are responsible for 
promoting the phosphorylation state of GSK. Taken together, 
combining the proteomic and phosphoproteomic analysis revealed a 
functional pathway driving the decrease of glycogen content seen 
in the PANTG liver and provided evidence of a novel active 
phosphorylation site on glycogen synthase 
LIMITATIONS OF THE STUDY 
The expected cause of the low number of quantifiable 
phosphopeptides during this experiment was due to the fact that 
the SILAC labeled mouse liver used for spike-in only produces 
peptides labeled with the heavy lysine isotope; even though 
arginine is considered an essential amino acid, the mouse is 
able to produce it on its own [247], hence why only lysine is 
used for metabolic labeling in the animal. Digestion with 
trypsin and LysC produce peptides terminated on the carboxyl end 
with both lysine and arginine, convoluting the mixture with 
peptides that cannot be relatively quantified. In the proteomic 
study, this was not an issue because the magnitude of proteins 
that can be confidently identified and quantified by using heavy 
labeled mouse lysate is much higher, simply because compared to 
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the available peptides post phospho-enrichment are much lower. 
On the contrary, the amount of protein needed suitable for 
phosphoproteomic analysis is high; in the case of this 
experiment, 1.2 mg of protein (spike-in + lysate) was used for 
phosphoproteome analysis as compared to 0.4 mg (spike-in + 
lysate) for the proteome analysis of the PANTG mouse. Achieving 
this amount of protein by tissue procurement can be challenging; 
combined with the high cost of isotopes used in the culture 
media makes typical phosphoproteomic analyses costly and 
difficult. Albeit the price of SILAC labeled mouse livers are 
high, the protein yield obtainable from these tissues decreases 
experimental error and heterogeneity between individual protein 
lysate samples compared to lysates obtained from tissue 
procurement. A potential renovation to circumvent this problem 
could be combining tissue lysate from heavy arginine labeled 
tissue from procurement with heavy lysine labeled tissue from 
mice. Theoretically, the method would work, as one would want 
the spike-in lysate to be as complex as possible; as in having a 
high degree of peptide overlap with the lysate under 
investigation. SILAC relies on relative peptide abundance for 
quantitation; therefore large differences in peptide abundance 
would not hinder the comparison as long as peptide abundance 
exists in a measurable amount. 
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Metabolic and Proteomic Evaluation of High Fat Diet Fed Mice 
High fat diet induced insulin resistance and fatty liver are 
well characterized abnormalities in mice. In this study, gross 
metabolic phenotyping was performed in an effort to outline 
critical instances of fatty liver onset in parallel to hepatic 
proteomic analysis for the identification of key proteins 
involved in non-alcoholic fatty liver disease. Unfortunately, 
due to a low N size and technical limitations, the metabolic 
studies were terminated pre-maturely and the data acquired from 
them was largely insignificant. However, several studies have 
previously outlined the toxic effect a high fat diet has on the 
murine liver. The major goal and focus of this study was to 
identify differentially expressed proteins to characterize early 
and late stages of disease onset by means of SILAC based 
proteomics, an experimental approach non-existent in the 
literature.  In all, out of 18,058 peptides correlating to 3,310 
quantifiable proteins, 224, 234, 189, and 179 differentially 
expressed proteins where characterized in the HFD mouse liver as 
compared to their respective control (Appendix II). The data 
suggest that lipid metabolism, including free fatty acid 
absorption and de novo lipogenesis is highly altered at the two 
week time-point; LXR activation was a predicted canonical 
function by use of IPA. The predicted activation of LXR was due 
to increased expression of CD36, SCD, and FasN (FasN at the 9 
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week time-point) (Table 6). Fatty acid binding proteins 4 and 5 
were downregulated in the HFD mouse (Figure 34). FABPs have been 
suggested as novel biomarkers of NAFLD progression, and their 
expression during the diseased state is poorly characterized. 
Here, FABP5 demonstrated marked downregulation at the 2, 5, and 
9 week time-points (~-2 fold). This data suggests that 
downregulation of certain FABPs can be used to predict NAFLD and 
similar disease’s progression. Autophagic cellular functions 
were predicted to be active in the HFD liver, suggesting an 
important role in lipid metabolism. Recent studies have shown 
that lysosomes contain lipases for the degradation of excess 
intercellular lipid content and relates lipolysis and 
macroautophagy [238]. Here, it is suggested that macroautophagy 
is a critical cellular function for lipid homeostasis (Figures 
32 and 33). Autophagy has also been implicated in hepatocellular 
carcinoma (HCC), but its role is poorly defined [243].  
LIMITATIONS OF THE STUDY 
For the metabolic assays, simply increasing the N size and 
performing the analysis over a longer time-span would 
undoubtedly produce significant results. As previously 
mentioned, it is well accepted that glucose intolerance develops 
rapidly in mice on a high fat diet. Tissue sections from the HFD 
mouse liver can be compared to those mice on a normal diet, most 
likely displaying increased lipid accumulation.  
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As for the proteomic analysis, there were several limitations. 
With so much data, analyzing it can become extremely 
challenging, especially when time-point analyses are accounted 
for. Less time points and shorter time in between them could 
give rise to clearer global hepatic proteomic changes. The 
comparison strategy could be optimized; as previously discussed, 
the low confidence when discerning proteomic differences between 
the NC fed mice from their matched HFD fed mice was due to the 
ability of C57/BL6 mice to develop metabolic syndrome 
spontaneously. The analysis could be performed again, this time 
comparing the HFD time points to a single group of NC fed mice. 
Additionally, the use of 2, 4-DNP could further reduce the onset 
of spontaneous disease in the black mouse.  
Certainly hepatic steatosis and other related inflammatory 
disease are expected to be increased in HFD fed mice, however 
IPA predicted the opposite. Here, it is difficult to tell where 
lays the issue.  Certain predictions made by IPA are based on 
limited information, sometimes backed by a single experiment 
reporting changes in mRNA expression instead of actual protein 
expression; therefore one must be cautious when using IPA to 
draw relevant conclusions. Contrary, perhaps more suitable 
controls could circumvent this problem, as well. 
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Future Directions 
In this dissertation, the major studies were focused on the 
proteomic characterization of the PANDER transgenic mouse liver. 
Due to the pleiotropic nature of the molecule, the PANTG mouse 
is a unique model due to its inherent ability to simulate 
selective hepatic insulin resistance, a poorly understood 
metabolic phenomenon. The proteomic dataset obtained during this 
investigation shed light on key features driving lipogenesis in 
the PANTG liver; yet there is still a wealth of information to 
be analyzed within it. This information could be valuable for 
the future research of pancreatic derived-factor, as there are 
many facets to the PANDER story still undetermined. The major 
studies also demonstrated the strong utility of the use of 
proteomics in the field of endocrinology, as displayed in the 
high fat diet induced fatty liver analysis. 
Unexplored Information In The PANTG Proteomic Dataset  
The overall phenotype of the PANTG mouse led to focused and 
logical attention on proteins involved in lipid metabolism. 
Regardless of such molecules being identified as the most 
profound metabolic targets, the proteomic dataset also contains 
information regarding the transport of cholesterol and various 
other molecules, a topic so far only under brief investigation. 
Several differentially expressed proteins included those in the 
ATP-binding cassette (ABC) transporter families. These molecules 
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are responsible for transporting several small biological 
molecules, namely cholesterols, across cell membranes [248]. 
Closely related to these transport molecules were the 
identification of several proteins in the incredibly diverse 
cytochrome p450 (CYPs) super-family. CYPs in general are 
involved in enzymatic reactions and their levels of expression 
can have considerably metabolic consequences [249]. In our study 
one such molecule, Cyp7A1, was of focus due to its important 
role in bile acid synthesis [250]. There are several other 
important CYP proteins differentially expressed under the 
various metabolic conditions which could potentially hold 
information relating to the hepatic metabolome, a topic that 
will be disused in greater length shortly. A hypothesis could be 
drawn from this information alone relating the influx or 
creation of oxysterols necessary for LXR activation. Apart from 
these metabolic proteins, the focus of the dataset presented in 
this thesis was a figurative handful of molecules, not a reason 
for scientific discontent. As with any –omic study, researchers 
are using the technique to a fraction of its potential; the 
field is still in its infancy. Put simply, more information is 
obtained than one research knows what to do with. Here, the 
dataset can serve as a bench mark for decades of PANDER research 
if one was so inclined.  
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Improvement of the Experimental Design 
Technology 
Technology is something that is ever improving, and that extends 
to mass spectrometry. During the course of this investigation, 
there have been several recent developments in mass analyzers. 
Not long after the dataset was acquired using an Orbitrap XL, 
the core facility which housed the instrumentation for this 
study obtained the more recent Q Exactive. This mass analyzer 
features a hybrid quadrupole-orbitrap allowing for much higher 
resolution when compared to the Orbitrap XL, increasing the 
potential for more protein IDs and more sensitive quantitative 
analysis. Improvements have not only been made for mass 
spectrometers, but also during the separation of the sample 
during high-performance liquid chromatography. Temperature 
enclosed housing of the RP column inline to mass spectrometry 
greatly increases the reproducibility of respective retention 
times between HPLC runs, another technology obtained, 
unfortunately, too late. An interesting direction the PANTG 
proteomic experiment could take is simply repeating it this 
enhanced technology, producing a refined dataset. 
Creating a Better Mouse 
Performing a backcross of the PANTG mouse onto a strain with 
pure genetics, such as the C57/BL6 mouse, would produce a mouse 
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with less genetic variability. This would undoubtedly translate 
to an enhanced phenotype as it did for the PANDER knockout 
(PANKO) mouse [18, 20]. Phenotypic analysis, including 
hyperinsulinemic-euglycemic clamp assays, glucose tolerance 
testing, fasting glycemia, and insulin tolerance testing could 
be performed, as well as measurements of important dietary 
hormones, or metabolic biomolecules such as hepatic glycogen and 
lipid content. Such an animal model would most likely decrease 
proteome variability between individual experimental groups, 
allowing for a higher number of confident quantifiable proteins. 
METABOLOMICS 
The study or large scale analysis of biological intermediates, 
metabolites, in a biological system is referred to as 
metabolomics. This research field allows for the indirect view 
of cellular function, allowing for a unique and informative look 
into functional genomics by determining phenotypes caused by 
differences in gene expression. The metabolome has more 
traditionally been analyzed using nuclear magnetic resonance 
(NMR) spectroscopy [251, 252], however mass spectrometry has 
entered the field, offering more robust capabilities [253]. 
Metabolomics offers, reasonably, enhance insight into T2D 
research, due to the ability to detect long and short term 
physiological changes by more stable patterns of metabolite 
expression, as well as a tool for biomarker discovery [254]. 
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Proteomic Evaluation of Other Tissues in the PANTG Mouse 
Much of the focus regarding PANDER’s biological role has been in 
the pancreas. Various models have demonstrated the ability for 
PANDER to induce β-cell destruction via apoptosis, impaired 
insulin secretion, and impaired response to insulin stimulating 
secretagogues (see Chapter 1). Evaluating functional changes in 
these models using proteomics could offer insight into 
mechanisms driving the PANDER induced physiological response.  
Proteomic Evaluation of the PANKO Mouse 
A logical next step for the heuristic elucidation of mechanisms 
altered due to PANDER signaling would be the proteomic 
evaluation of the PANKO mouse liver. This analysis would have a 
multifaceted function. One would be to further detail 
mechanistic changes due to circulating PANDER levels, as the 
PANKO model displays protective traits in relation to glucose 
homeostasis and insulin sensitivity [20]. Another would be the 
ability to compare proteomic datasets for the determination of 
synergistic or deleterious effects of PANDER singling.  
Pander as a Therapeutic Target For T2D 
Type 2 diabetes is characterized by the metabolic triad of 
hyperglycemia, hyperinsulinemia, and hypertriglyceridemia. 
Patients with T2D do have higher circulating levels of PANDER, 
suggesting the possibility of PANDER serving as a potential 
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therapeutic target for the treatment of the disease. One study 
showed that siRNA mediated PANDER knockdown ameliorating hepatic 
steatosis, fasting hyperglycemia, and insulin resistance [255]. 
This finding suggests that a specific PANDER antagonist could be 
developed thereby decreasing hepatic glucose production and 
importing insulin sensitivity in those with T2D.   
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Appendix II: Additional Data 
Protein names and relative fold changes of proteins 
significantly differentially expressed after 1 week HFD: 
Gene names 
Relative 
fold 
change 
Plcg1 0.381435 
Stau1 2.13963 
Apex2 0.596065 
Arhgap1 0.6407519 
Asph 1.765875 
Surf1 1.947278 
Fsip2 0.5817244 
Mup13 4.154806 
Slc4a4 0.4878055 
Nfia 0.3760479 
Baiap2 2.685986 
Chchd2;2410018M08
Rik 1.662387 
Abcc3 1.666087 
Pdzd8 185.6285 
Cgn 1.671586 
Flnc 0.6711034 
Sf1 0.6160217 
Snrpa 1.472404 
Fip1l1 1.510243 
Cfh;Cfhr2 1.605301 
Insig2 0.4657243 
Dnm1l 7.330233 
Arhgef1 1.921077 
Xpo7 1.471547 
Ttc39c 2.378669 
Fga 1.459792 
Evl 0.6587418 
Agxt2l1 0.3559563 
Larp4 2.530345 
Itsn1 1.512999 
Tns1 2.110816 
Glod4 3.646272 
Sep7 0.2648042 
Kif13b 0.4754396 
Rnf213 2.136759 
Numa1 0.3630045 
Zc3h4 1.994663 
Cald1 2.691145 
Mars 2.357934 
Ighg2c 2.061309 
Gstm1 0.6636925 
Ube2m 1.728833 
Hnrnpd 3.509085 
Erc1 2.825798 
Agl 1.547399 
Eif1;Gm6900;Eif1b 0.6144141 
Aox1 0.4023474 
Sec23ip 3.53337 
Akr1c19 0.5993993 
Hnrnpa1;Gm7729 1.817484 
Ate1 1.553319 
Cyp3a25 0.6520976 
Man2b1 0.5492947 
Sod3 1.526737 
Dhx15 0.5897455 
Kpna6 0.6547235 
Bhmt 1.827684 
Slk 2.25369 
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Tpmt 1.877633 
Pdlim1 2.977529 
Ugdh 0.6157275 
Pdk4 1.579193 
Pfdn2 1.461094 
Zfr 1.951703 
Clpp 0.6554446 
Cyp8b1 1.518638 
Tpp1 0.2757733 
Ighg1 1.836913 
Apoa4 0.6535253 
Spta1 1.693892 
Apoa2 0.5342332 
Scd1 0.6351788 
Enpep 0.6631159 
Sptan1 0.4039574 
Gba 0.6727477 
Gstp1;Gstp2 0.6149422 
Rpl13a;Rpl13a-ps1 1.537478 
Gstm3 0.461477 
Gna11 14.8535 
Pnp 0.6740907 
Glb1 0.5712821 
Gsta4 0.4628519 
Gjb1 0.6035815 
Mug1 1.64811 
Mug2 0.4408822 
Grn 0.5431889 
Msr1 1.755044 
Aimp1 1.847534 
Saa4 2.044003 
Stat1 1.465669 
Stat3 10.21981 
Plin2 0.5798625 
Prox1 0.471484 
Pctp 0.6361815 
Rab2a 1.463263 
Rad23b 10.9129 
Ddx6 0.66936 
Idi1 1.480901 
Acot8 0.6652374 
Bcl2l13 1.800706 
Pcbp1 1.476236 
Ube2n 0.2722801 
Arf4 1.597499 
Rps4x 2.105162 
Hpcal1 1.830205 
Ybx1 11.61314 
Ppp2ca 2.252791 
Pfkfb1 1.7803 
Stam 0.6600952 
Tceb1 0.6251504 
Csrp1 2.755449 
Ctsc 0.6354332 
Apoa1 1.565434 
Eif5b 1.646062 
Clu 2.009331 
Stt3b 1.456945 
Mrps23 1.566648 
Zc3h15 1.456376 
Pcnp 0.3443391 
Gm4951 5.038405 
Dtx3l 1.810269 
Thrap3 2.810547 
Crk 1.781839 
Cttn 0.6044632 
Myl6;Myl6b 33.21538 
Caprin1 1.743813 
Cyp7b1 1.749647 
Gstt2 0.6283621 
Hp 0.4440044 
Hsph1 0.6508555 
Itih3 0.5484354 
Dag1 0.5455048 
Ifit1 1.454958 
Cyp3a11;Cyp3a41a 0.6628979 
Retsat 0.5154113 
Gbf1 0.2244995 
Tpm4 0.2171946 
Cltb 0.6214236 
Dusp23 0.5087084 
Zc3h11a 1.472332 
Abcf1 1.49008 
Fam21 0.4245494 
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Paqr9 1.987115 
Tex2 0.06754684 
Rpl17;Gm6133 1.510082 
Ccdc25 1.510886 
Mtdh 0.5452358 
Ubap2l 0.3041546 
Eif4b 0.6744534 
C8b 1.505575 
Tiprl 1.642785 
Mrps27 1.971511 
Qars 4.113383 
Scfd1 2.896938 
Rmdn2 1.661653 
Acot4 0.584224 
Ttpa 0.5680761 
Pgm3 1.65222 
Etf1 0.3460988 
Usp47 0.5203276 
Yars2 0.6502735 
Dnajb12 8.397686 
Parp9 1.626375 
Ufl1 2.44807 
Nemf 1.498199 
Ccar1 0.5146776 
Fgb 1.659373 
Lyrm4 0.3323779 
Optn 1.615594 
Afmid 0.6307501 
Tat 0.5066439 
Eif3l 0.4607333 
Vmn1r81 0.1258778 
Nags 0.2912511 
Clptm1 0.6022055 
Alas1 0.5096336 
Cyp4f15 1.479559 
Mavs 0.6691536 
Fgg 1.50806 
Rnpep 1.966123 
Fam114a2 1.507987 
Ppp2r5d 3.076226 
Hnmt 1.605739 
Cyp2c70 1.46422 
Setd3 0.3494835 
Sec16b 1.50422 
Hnrpll 0.2606823 
Psip1 2.914569 
Adi1 1.489059 
Arfgap2 0.5713199 
Vwa5a 1.790802 
Tmed9 0.655109 
Cdk5rap3 0.386995 
Nudt7 1.665034 
Atp5l 0.5987753 
Denr 1.799277 
Smc3 0.6080589 
Pin4 1.71839 
Sugt1 2.482455 
Dhrs7 5.154897 
Gars 1.877612 
Ephx1 0.6002197 
Atad1 48.77322 
Acad8 0.6030048 
Pipox 0.6343673 
Itpa 1.486199 
Spcs1 1.697268 
Csad 0.4896066 
Ehhadh 0.6723068 
Ethe1 0.602212 
Aspdh 1.46729 
Ranbp2 0.5426502 
Tm9sf3 1.695559 
Palmd 1.463614 
Eny2 2.878258 
Nudt5 0.5914416 
Cd2ap 2.309652 
Acsl4 0.6408588 
Sult1b1 1.587632 
Iigp1 1.69999 
Srr 4.523575 
Sqrdl 2.550393 
Pmm2 0.1122382 
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Protein names and relative fold changes of proteins 
significantly differentially expressed after 2 weeks HFD: 
Gene names 
Relative 
fold 
change 
Asph 1.520191 
Surf1 0.4012588 
Mup13 1.581039 
Cgn 0.5362627 
Flnc 3.149808 
Ttc39c 1.62239 
Fga 1.466956 
Glod4 1.759611 
Kif13b 0.424042 
Zc3h4 0.6162452 
Cald1 0.5453088 
Gstm1 0.5925368 
Eif1;Gm6900;Eif1b 1.58489 
Akr1c19 0.5359498 
Man2b1 2.267688 
Bhmt 1.672241 
Ugdh 0.5079002 
Pfdn2 1.384016 
Tpp1 0.5881704 
Spta1 0.55989 
Scd1 2.203455 
Gna11 24.69589 
Idi1 0.5049234 
Ube2n 0.480821 
Ctsc 0.5073419 
Pcnp 2.218574 
Dtx3l 1.47564 
Cttn 0.3413381 
Myl6;Myl6b 3.457103 
Cyp7b1 1.800089 
Hp 1.384247 
Itih3 2.043431 
Cyp3a11;Cyp3a41a 0.3255548 
Retsat 1.464846 
Abcf1 1.480091 
Fam21 0.578999 
Ccdc25 1.724578 
Mtdh 0.4663262 
Eif4b 0.4870172 
Qars 1.395311 
Scfd1 0.5498611 
Rmdn2 1.365477 
Pgm3 1.47092 
Etf1 0.4714662 
Yars2 0.6874558 
Ufl1 2.201306 
Fgb 1.633457 
Tat 0.650875 
Fgg 1.42869 
Hnrpll 4.519113 
Atp5l 1.662135 
Ephx1 0.4425046 
Itpa 1.375381 
Csad 0.2105905 
Eny2 1.920668 
Nudt5 0.491861 
Acsl4 0.5509092 
Sult1b1 0.5092717 
Sep9 2.282336 
Nt5c 0.116789 
Pir 0.6824492 
Fubp3 1.450907 
Acss2 0.6096534 
Ttn 9.025482 
Dhtkd1 1.420972 
Btk 0.4266294 
Hbb-b1 1.661538 
Cobll1 1.626633 
Hspg2 2.105071 
Mylk 1.407685 
Crat 2.068318 
Col14a1 1.511459 
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Mup14 1.370881 
Cfb;Gm20547;C2 0.6077403 
Sumo3;Sumo2 0.5910952 
Sgpl1 10.71338 
Pxmp2 1.677597 
Cp 1.384627 
Tnxb 1.902963 
Sptb 1.551577 
Dsp 0.2959642 
Muc5b 1.495581 
Psmd13 0.672456 
C6 1.619012 
Plekhg4 1.524661 
Tacc2 1.968936 
Dlg1 0.6135224 
Acbd5 0.3715609 
Ide 1.92109 
Pxn 0.6413723 
Lamc1 1.568641 
Aox3 1.401558 
Psme2 0.5131395 
Gstm6 0.6540459 
Ces1e 0.644677 
Adssl1 0.5385465 
Larp1 2.585628 
Akap1 1.457723 
Cyp4a14 0.674463 
Gpx4 0.648078 
Ctss 0.6636455 
Cops4 1.430214 
Cyp1a2 1.410124 
Igh-3 2.021223 
Igh-6 0.6262731 
Hbb-y 1.776248 
Krt1 0.6105009 
Fabp4 1.634037 
Slc4a1 1.582153 
Me1 0.4723189 
Alb 1.372216 
Polr2a 1.454335 
Anxa1 1.412104 
Ctsb 0.5513661 
Gstm1 0.3707425 
Gsn 1.550389 
Ca1 1.407239 
Bpgm 1.544704 
Ugt2b5;Ugt2b17;Ugt
2b37 0.5904676 
Plg 1.383596 
Eno3 14.10223 
Serpina1b 1.375557 
Ces1c 0.6498297 
Hsd3b3 1.378858 
Plaa 0.6599321 
Bgn 1.847009 
Atxn10 1.382918 
Dpp4 0.4031897 
Ahsg 1.444836 
Fkbp4 2.370085 
Des 4.12829 
Ap1m1 0.688768 
Cpox 1.561087 
Inmt 0.6518477 
Gfpt1 2.159464 
Pfkm 6.371564 
Cbr1 0.598063 
Ndufs6 0.4115654 
Slc16a1 1.616706 
Rpl37a 0.5679144 
Rpl30 0.5995435 
Acta1;Actc1;Acta2;
Actg2 6.720537 
Psmb7 0.6828474 
Urod 0.6084508 
Cct4 1.737043 
Serpina1e 1.428035 
Egfr 1.414254 
Apoh 1.639902 
Fabp5 0.5283146 
Serpina6 2.084544 
Cd36 1.558558 
Entpd5 0.6890399 
Mcu 1.626438 
Sult1d1 2.032893 
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Cyp2c67 0.6805737 
Mup20 1.453761 
Acaca 1.375513 
Gm2a 0.6027935 
Hars;Hars2 1.59032 
Prdx2 1.37062 
Mrps31 0.605942 
Pon3 1.364828 
Dbnl 1.993963 
Selenbp2 1.853543 
Sqstm1 1.46075 
Isg15 1.64129 
St8sia1 1.415362 
Vcl 1.418062 
Xpnpep1 1.602915 
Rps27 1.551266 
Acsm5 0.6864626 
Acp6 0.5317355 
Prkaa2 5.052769 
Mzt1 2.010334 
Tmx3 0.3868667 
Tor1aip2 0.6197904 
Ggt5 1.740589 
Vwa8 1.416566 
Pcdh1 0.4104605 
Pdlim5 1.647413 
Taco1 2.925275 
Matr3 0.6450172 
Ces2a 0.4863703 
Blmh 2.101796 
Gspt1;Gspt2 1.67325 
Eif3c 1.530812 
Cmbl 0.1375855 
Rbpms2 0.2626331 
Akr1c20 3.32357 
Upb1 0.6069337 
Hsd17b13 0.6831186 
Hip1 2.054385 
Lpcat3 0.5275787 
Hba-a1;Hba 1.503392 
Csde1 1.544548 
Ces1f 0.656278 
Lrp1 1.374426 
Scpep1 0.6664485 
Fdps 0.5978547 
Steap4 0.5600349 
Mvd 1.796615 
Ufsp2 1.98497 
Gstt3 0.6324927 
Cisd2 0.6790795 
Acot13 0.6882023 
Ndufb3 1.61353 
Ndufb7 1.573898 
Ergic2 0.5723651 
Cenpv 1.466036 
Serbp1 1.631676 
Spcs2 0.4282517 
Mrpl45 1.715147 
Sarnp 1.38444 
Fkbp11 0.5593412 
Chordc1 2.656504 
Idh3a 2.040065 
Fam210b 1.611108 
Atg7 1.675447 
Gng12 0.5303684 
Keg1 0.6222575 
Pik3ap1 0.5828943 
Dpys 0.6844273 
Cars 5.388743 
Dkc1 2.289682 
Galk1 2.099247 
Naga 0.6842728 
Ecsit 0.6707909 
Hsd17b6 0.642907 
Nsdhl 0.6587443 
Coro1b 0.4238915 
Ctsz 0.5692298 
Npc2 0.5191967 
Uba2 0.6191235 
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Protein names and relative fold changes of proteins 
significantly differentially expressed after 5 weeks HFD: 
Gene names 
Relative 
fold 
change 
Fga 0.5565329 
Eif1;Gm6900;Eif1b 4.64922 
Akr1c19 0.6455268 
Bhmt 1.586102 
Ugdh 0.5426302 
Spta1 0.618498 
Scd1 0.6004217 
Idi1 0.6038125 
Myl6;Myl6b 2.029287 
Hp 0.4751627 
Itih3 0.4012391 
Cyp3a11;Cyp3a41a 0.5873733 
Retsat 0.2899573 
Abcf1 0.07953208 
Mtdh 2.600151 
Rmdn2 0.6646559 
Pgm3 1.379967 
Etf1 0.6319894 
Csad 2.012395 
Nt5c 0.04433255 
Sumo3;Sumo2 0.4332882 
Pxmp2 1.540206 
Dsp 0.5830574 
Acbd5 2.108819 
Pxn 2.059725 
Cyp4a14 1.77883 
Gpx4 1.422816 
Hbb-y 1.591732 
Gstm1 0.5883532 
Ca1 0.2088533 
Ugt2b5;Ugt2b17;Ug
t2b37 0.6505102 
Ces1c 1.631755 
Cpox 1.557151 
Cbr1 0.6257932 
Ndufs6 0.5562072 
Fabp5 0.4782128 
Entpd5 0.6561843 
Selenbp2 1.941571 
Isg15 1.789426 
Vwa8 1.617307 
Pcdh1 1.408123 
Blmh 0.1114469 
Steap4 1.739158 
Cisd2 0.6215038 
Serbp1 2.631808 
Sarnp 0.4003085 
Chordc1 2.724179 
Naga 0.6494528 
Plcg1 2.640055 
Stau1 1.407103 
Evl 1.88667 
Agxt2l1 0.2791096 
Tns1 2.291259 
Dhx15 0.6287116 
Cyp8b1 1.916416 
Apoa4 2.079067 
Enpep 0.6379438 
Stat3 0.6360878 
Plin2 1.810392 
Rad23b 0.6331703 
Pcbp1 1.650051 
Pfkfb1 1.570299 
Tceb1 0.3995706 
Apoa1 1.590551 
Gm4951 1.739777 
Crk 1.944579 
Ifit1 1.40704 
Paqr9 1.456485 
Ttpa 0.100786 
Nemf 2.038141 
Clptm1 1.765388 
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Mavs 1.40735 
Setd3 0.4788162 
Sec16b 1.547328 
Psip1 2.974812 
Dhrs7 0.5088156 
Palmd 18.86196 
Sec24a 1.989405 
Hsd17b10 1.586534 
Ubr4 1.423306 
Mlx 0.5862924 
Itih4 0.1996279 
Ccdc163 0.3035374 
Macf1 5.142352 
Gyk;Gk;Gykl1 1.532338 
Tjp1 0.129243 
Kng1 0.5652297 
Mgll 2.896255 
Cops6 1.41358 
C4bp;C4bpa 0.4352296 
Txndc5 0.6601502 
Vmn2r18 1.521806 
Mvp 0.4631629 
Cul5 1.656223 
Atxn2 1.403364 
Myh11 3.087201 
Prps1;Prps1l3 1.522675 
Hnrnpl 6.022238 
Carkd 0.612823 
Slc27a2 1.408109 
Cops5 0.6439772 
Psma3 0.516611 
Snx3 2.363112 
Sp3 11.15369 
Mtx2 1.528359 
Soat2 0.5679289 
Ttr 0.6546721 
Apoe 1.843146 
H2afv;H2afz 1.396456 
Eif4a2 1.460119 
Cfl1 0.5515693 
Tgm2 0.6603783 
Arsa 0.5973958 
Cnbp 1.708198 
Tango2 1.91618 
Rab8a 0.5894765 
Nudt2 2.029465 
Nploc4 0.3513883 
Cops2 1.507085 
Arf2;Arf1;Arf3 17.16401 
Abat 1.428664 
Arf6 1.664782 
Rpl32 1.762477 
Tubb4b;Tubb4a 1.475187 
Slc9a3r1 1.538232 
Erh 0.6501374 
Casp7 1.493398 
Cyp2e1 1.680852 
Pepd 0.4708975 
Acss3 1.723395 
Brd4 0.6229033 
Irgm1 1.558377 
Hsd3b5 1.642486 
Tgtp;Tgtp1 2.886168 
Tfrc 1.926037 
Ugt1a6 0.5312187 
Ecm29;AI314180 1.614732 
Spcs3 0.195443 
Usmg5 1.483233 
Ldhd 1.429092 
Cdc42bpb 1.535184 
Plxna4 0.6180173 
Pdk1 1.568133 
Sep9 1.535167 
Eif2a 0.2418695 
Eea1 1.501697 
Scfd2 0.6488068 
Hmgcs1 0.4085626 
Abca6 0.2605887 
Sf3a1 1.488119 
Hexim1 1.634173 
Hpgd 2.072552 
Prodh2 1.391638 
Idh3b 1.582234 
Ppa2 1.405769 
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Cyp4a12a;Cyp4a12b 1.47192 
Gckr 1.559857 
Cyp2c50 1.528956 
Rtn4ip1 1.47229 
Cds2 0.6181253 
Prpf8 0.2757098 
Btf3l4 0.4282234 
Txndc12 0.4925236 
Emc2 0.6134063 
Xpot 2.838478 
Smc1a 0.4501086 
Pbld2 1.393424 
Nsfl1c 0.4396557 
Aldh1b1 0.5518795 
Tomm70a 1.595674 
Ccdc47 0.1405633 
Cyc1 1.548082 
Iyd 0.3596738 
Hsd17b11 1.424516 
Ehd4 1.492226 
Lima1 2.381341 
Cse1l 1.463295 
Ddx21 1.503807 
Cog8 0.5566417 
Pdk2 0.5369678 
Bag3 0.6163701 
Edf1 1.447348 
Txnrd1 0.645256 
Tbl2 1.853377 
Hebp1 1.406322 
Myo1c 1.502757 
Vapa 1.378392 
Slc25a20 1.53385 
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Protein names and relative fold changes of proteins 
significantly differentially expressed after 9 weeks HFD: 
Gene names 
Relative 
fold change 
Ugdh 0.5891099 
Spta1 0.5784131 
Idi1 0.3123715 
Myl6;Myl6b 1.866926 
Itih3 0.574432 
Retsat 0.08500097 
Rmdn2 1.887924 
Dsp 0.3020843 
Acbd5 2.229617 
Pxn 0.3890634 
Hbb-y 1.556997 
Ces1c 1.568841 
Ndufs6 1.9469 
Fabp5 0.480027 
Selenbp2 0.5083526 
Blmh 0.303142 
Chordc1 0.2528934 
Tns1 0.2825769 
Apoa4 0.3981675 
Stat3 2.688463 
Paqr9 1.724019 
Nemf 0.5315067 
Psip1 3.046514 
Macf1 2.167337 
Vmn2r18 2.949214 
Myh11 0.3472071 
Hnrnpl 5.94249 
Nudt2 1.774392 
Arf2;Arf1;Arf3 2.098171 
Ldhd 0.4680342 
Cdc42bpb 2.235204 
Eif2a 1.988483 
Hmgcs1 1.654925 
Hpgd 5.033892 
Cyp2c50 1.599537 
Iyd 0.4577687 
Lima1 1.919864 
Ddx21 0.5620486 
Pdk2 1.587814 
Edf1 1.661237 
Mup13 0.2916172 
Kif13b 2.068748 
Cald1 4.156598 
Gna11 4.018547 
Cyp7b1 0.5710642 
Tat 0.2069451 
Hnrpll 3.986255 
Sult1b1 1.7032 
Sep9 0.5072663 
Cobll1 0.4869169 
Plekhg4 0.4872091 
Ide 2.734689 
Krt1 0.04630987 
Slc4a1 0.5679211 
Me1 1.536843 
Serpina1e 0.499966 
Serpina6 0.1048201 
Mzt1 0.4120255 
Matr3 0.4479917 
Dkc1 0.2974608 
Ctsz 0.5764206 
Uba2 29.40795 
Slc4a4 0.2905559 
Numa1 0.04206754 
Pdlim1 2.270483 
Pdk4 0.4979565 
Gstp1;Gstp2 0.517442 
Mug2 0.2840395 
Saa4 2.415868 
Bcl2l13 1.607058 
Ybx1 7.352725 
Stam 0.5341896 
Csrp1 2.19096 
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Stt3b 1.864374 
Zc3h15 0.5954136 
Dag1 1.814263 
Hnmt 1.539679 
Acad8 0.5923195 
Iigp1 1.929469 
Cyp4a10 0.5185038 
Rbmx;Rbmxl1 1.637656 
Gpd2 1.523714 
Tpd52l2 0.5863031 
Gpcpd1 0.1907386 
Dusp3 1.629201 
Aldh3a2;Aldh3a1 1.522434 
Eif2b3 3.538503 
Ank1 0.5590422 
9030624J02Rik 0.4259851 
Sorbs2 0.5788537 
Ier3ip1;Hdhd2 1.579509 
Ces2g 1.960606 
Luc7l2 0.5384802 
Grsf1 1.536767 
Acacb 8.891789 
Pklr 1.663551 
Utrn 1.806213 
Lyplal1 3.197311 
Sult1a1 1.610899 
Gbe1 1.610307 
Sympk 15.9032 
Lamtor5 2.337684 
Son 0.5651766 
Aamp 3.437081 
Atp6v0a1 1.933604 
Faah 5.074807 
Timm44 0.4295759 
Copb2 1.616613 
Snca 0.451253 
Acot1 0.5924052 
Nnmt 0.5163231 
C4b 1.658415 
 
0.1829913 
S100a10 0.5979404 
H1f0 0.4980908 
Gstm2 0.5002655 
Fasn 1.818273 
Vtn 0.5427374 
Ldlr 1.703822 
Fkbp2 0.4326515 
Rab11b;Rab11a;Ra
b25 2.25317 
Tbca 0.5228305 
Tdo2 0.4152339 
Inpp1 1.625695 
Csrp3 2.599492 
Fabp2 1.787468 
Nucb1 2.729924 
Gch1 0.5900288 
Hp1bp3 0.3276092 
Slco2b1 1.616068 
Galns 0.4148191 
Gm4952 1.643673 
Mocs1 2.072997 
Gcdh 1.551488 
Gpam 1.88744 
Ddx5 0.3415053 
Atrx 0.5959773 
Pdcd4 1.934485 
Mrc1 2.233552 
Trim28 0.4374858 
Gstt1 2.0547 
Dync1li2 2.541237 
 
1.692045 
Sestd1 1.559453 
Mogs 0.5716146 
Vac14 1.642213 
Tmem214 0.4690467 
Clmn 2.260602 
Fam160b1 0.2771389 
Fam25c 0.5851889 
Sltm 0.4088566 
Ugt3a2 0.2512125 
Agpat2 1.742233 
Gale 1.839434 
Kars 2.222318 
Ces1 1.671457 
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Acaa1b 1.524465 
Pla2g15 0.5986165 
Acy3 1.53319 
Tbrg4 0.4697535 
Nono 3.288072 
Aass 0.5112808 
Arpc5 1.781187 
Nubpl 5.048543 
L3hypdh 2.759283 
Nhp2l1 0.5768063 
Oxsm 1.694731 
Selo 1.538901 
Baiap2l1 0.2501519 
Crot 1.577842 
Pygl 1.534469 
Msrb1 1.993234 
Adh4 1.873812 
Fbxo6 0.4945161 
Pex14 1.77883 
Gbp2 0.2456626 
Strap 0.3241378 
Hnrnpc 1.601239 
 
